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Losing Muscle Mass: an Inevitable Consequence of Aging? 
Mrs. Jacobs is a 76-year old lady living independently. She loves to practice gardening and 
cooking using vegetables from her own garden. Once a week she takes care of her 
grandchildren and they play games together. Although she can still perform all activities of 
daily living herself she hired someone to support her with the housekeeping. She feels a bit 
sad that she cannot join her friends anymore on their weekly walks because she is getting 
too slow to keep up. Mrs. Jacobsʼ neighbour, Mr. Blom, visits Mrs. Jacobs for a cup of 
coffee. He tells her that he is a bit worried about her because he hasnʼt seen her work in 
her beloved garden for the last few weeks. Mrs. Jacobs tells him that lately she seems to 
have lost strength in her hands and she has difficulties getting up from a chair. Mr. Blom 
wonders whether she should go see a doctor to discuss her symptoms. But Mrs. Jacobs 
brushes his worries aside and does not see the need to visit a doctor, “those things are 
part of the aging process, arenʼt they?” 
The human body is composed of more than 600 skeletal muscles, accounting for about 
40% of body weight.1,  2 In the early years of life muscle mass and function increase. This 
growth and strengthening of muscles continues for up to about 30 years, after which 
muscle mass and function slowly start to decrease (Figure 1).3, 4 In 1989, Rosenberg came 
up with the term sarcopenia to describe the loss of muscle mass.5 Sarcopenia is derived 
from the Greek words ‘sarx’ (flesh) and ‘penia’ (loss).6 Sarcopenia occurs in 1-52% of the 
community-dwelling older adults, depending on definition, age group, measurement tool, 
and cut-off points used.7, 8 Older adults with sarcopenia have a higher risk of disability, loss 
of independence, decreased quality of life, and an increased mortality risk.9-11 Sarcopenia 
has been recognized as a geriatric syndrome and fits within the list of geriatric giants 
(frequently occurring geriatric syndromes) such as immobility and instability.12, 13 Early 
identification of sarcopenia followed by an appropriate intervention, such as exercise 
combined with nutritional advice, has the potential to delay or even reverse the loss of 
muscle mass and function.14 This thesis focuses on the prevalence of sarcopenia, 
characteristics of sarcopenic older adults, and health- and economic related outcomes. 
This first chapter introduces the topic, aims, and outline of the thesis. 
1. Mechanisms of Sarcopenia 
Human skeletal muscles are composed of two types of muscle fibers.2 Type I muscle fibres 
are called slow-twitch muscle fibres and are used for endurance exercise.2 Type II fast-
twitch muscle fibres are able to supply great strength of contraction required for jumping for 
instance.2 As a person ages, the number of muscle fibres decreases and the size of the 
remaining muscle fibres reduces (atrophy).15 In older adults atrophy of type II fibres is seen 
most frequently.15 The exact causes of this process are multifactorial but not yet fully 
understood.16 Potential mechanisms that could explain the loss of muscle mass with aging 
are decreased activity of hormones that stimulate muscle synthesis (e.g. IGF-1, growth 
hormone, testosterone), increased activity of inflammatory factors that promote catabolism 
(e.g. TNF-Į, interleukin 6), and denervation of muscles.16-19 Furthermore, bed rest, 
disease, and lifestyle factors such as physical inactivity and an insufficient diet (e.g. low 
protein intake, vitamin D deficiency) may contribute to the loss of muscle mass.17, 18
Studies show that the decline in muscle strength is even steeper than the decline in 
muscle mass.20-22 Muscle strength declines not only because of a reduction in muscle 
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quantity but also due to decreased muscle quality (defined as strength corrected for size). 
Several mechanisms affecting muscle strength and quality are known, including 
impairments in neural (central) activation, changes in muscle protein structure and 
function, and fat infiltration.23 The latter, describing fat cells squeezing in between muscle 
cells, has been associated with both reduced muscle strength and impaired mobility.24-27
Figure 1 Life course model of sarcopenia based on the World Health Organization model  
of functional capacity3 (reproduced with permission of the J Nutr Health Aging) 
2. Prevalence of Sarcopenia
The definition and cut-off points chosen to identify older adults with sarcopenia highly 
influence the prevalence of sarcopenia.28 In the last few years several researchers have 
tried to agree on a single definition of sarcopenia with appropriate cut-off points for low 
muscle mass.29-31 Originally, sarcopenia was defined as low muscle mass. For clinicians, 
the pharmaceutical industry, and regulatory agencies, this definition was not satisfying as 
muscle strength and function might be more clinically relevant (i.e. stronger predictors of 
adverse outcomes).32, 33 Muscle strength does not depend solely on muscle mass and an 
increase in muscle mass does not necessarily lead to increased muscle strength and vice 
versa.32 Therefore, international working groups presented consensus definitions on 
sarcopenia which in addition to low muscle mass include poor muscle function,34
weakness,35 limited mobility,36 or poor muscle strength and performance.37 Prevalence 
rates of sarcopenia vary highly, e.g. 3-52% (low muscle mass)38 and 1-29% (low muscle 
mass with poor muscle strength and/or performance)39 in community-dwelling older adults. 
In long-term care institutions (e.g. nursing homes, care homes for disabled adults) reported 
prevalence rates range from 14-33%.39 These ranges can be partly explained by age 
group (higher prevalence at higher ages), cut-off points for low muscle mass and function, 
and the chosen measurement tool. Although a growing number of studies on the 
prevalence of sarcopenia in community-dwelling and nursing home populations are 
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published, studies in older adults receiving home care or living in an assisted or residential 
living facility (not being a nursing home) are scarce. Older adults in these settings might be 
at an early stage of dependency, which would make insight in the prevalence of 
sarcopenia and characteristics (like functional status) of this population valuable as it might 
facilitate early intervention against sarcopenia. 
3. Sarcopenia-Related Health Burden 
The main responsibility of skeletal muscles is to support standing balance and locomotion, 
which are needed for undertaking activities of daily living. A decline in skeletal muscle 
quantity and quality may result in mobility limitations, difficulties performing activities of 
daily living, and an increased risk of falls.40-43 The aforementioned physical limitations may 
affect quality of life and increase institutionalization, which in turn could lead to anxiety and 
increased risk of dependency.41, 44 In addition, mortality rates for sarcopenic older adults 
have been reported to be 1.5 times higher than for non-sarcopenic older adults.41, 45 The 
higher risk of mortality is mainly predicted by a decreased muscle strength.46
3.1 Physical Frailty 
Sarcopenia has been designated as key pathway between physical frailty and disability or 
as key component of physical frailty.47-50 Frailty is a clinical state of increased vulnerability 
of an older person to a stressor.51 Frail older adults have a higher risk of falls and 
hospitalization, and their risk of mortality increases threefold compared to non-frail older 
adults.52 The Frailty Phenotype is one of the most well-known and often used definitions of 
frailty.53 The Frailty Phenotype consists of five criteria, (1) unintentional weight loss, (2) 
self-reported exhaustion, (3) weakness (poor grip strength), (4) slow walking speed, and 
(5) low physical activity. If three or more of these criteria are present the person is 
identified as frail.53 Although a variety of components shape the concepts of physical frailty 
and sarcopenia (e.g. weight loss, exhaustion, low physical activity versus low muscle 
mass), they share a core condition: impaired physical function.54 Therefore, several 
experts in the field have suggested combining frailty and sarcopenia to increase 
awareness among a broader public and to facilitate identification and treatment of both 
sarcopenia and frailty.10, 49, 55 Although it is clear that sarcopenia and frailty share common 
characteristics, studies reporting hard numbers on the overlap of the two conditions are 
limited. 
4. Economic Burden of Sarcopenia 
In the Netherlands about 18% (3 million; year 2015) of the population is 65 years or 
older.56 This percentage is expected to increase to more than 25% in the year 2035.57
Without intervention the ageing population will lead to an increased (and thus expensive) 
need for care in the future.58 Most older adults prefer to stay at home, in order to preserve 
their social network and because they are familiar with their environment.59 Nevertheless, 
institutionalization is not always preventable. About 20% of the older adults receive home 
care and 5-10% of the older adults are living in a residential care home or nursing  
home.60, 61 The main reasons for institutionalization are cognitive impairment and/or 
disability, and associated lack of support, and assistance in daily living.59
Sarcopenia has been associated with institutionalization and increased health care 
costs due to its link with physical disability, falls, and comorbidities such as osteoporosis, 
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diabetes, and chronic kidney disease.44, 62 In the United States sarcopenia alone was 
estimated to account for about 1.5% ($18.5 billions) of the direct total health care 
expenditures.62 In that study costs were indirectly calculated. As far known there are no 
studies investigating the economic burden of sarcopenia using direct measures to estimate 
costs and there are no European studies on the economic burden of sarcopenia. 
5. Counteracting Sarcopenia 
Ageing inevitably leads to a loss of muscle mass and function; however, the rate of muscle 
loss is modifiable. Several researchers studied opportunities to prevent, delay or reverse 
the process of sarcopenia. Current recommendations to reverse or delay the progression 
of sarcopenia include resistance exercise and protein supplementation.14, 63 Drug treatment 
is also being studied with regard to counteracting sarcopenia.  
5.1 Exercise 
Older adults tend to be less physically active than younger adults.64 Disuse of skeletal 
muscles contributes to loss of those muscles: ‘‘use it or lose it’’.65 Exercise-induced muscle 
contraction leads to hypertrophy (increase in volume) of muscle fibres, causing increased 
muscle mass and strength.15 Resistance exercise (Text Box 1) is the most promising 
intervention against sarcopenia. A meta-analysis of 47 studies on the effect of resistance 
exercise on muscle strength showed that older adults were able to gain up to 30% extra 
muscle strength.66 Greater improvement of muscle strength occurred with higher intensity 
training.66
Although the effect of (resistance) exercise on improvements in muscle mass and function 
is clear, studies on the effect of general physical activity on sarcopenia show inconsistent 
results.67 Murphy et al.68 showed that older adults with moderate physical activity were 
more likely to transition out of pre-sarcopenia. The LIFE-P study, a randomized-controlled 
trial with one year follow-up, investigated the effect of modest increases in physical activity 
on muscle strength in older adults with moderate functional limitations.69 Participants of the 
LIFE-P study received aerobic, strength, flexibility, and balance training, which turned out 
to prevent loss of muscle strength and improved physical performance.69, 70 However, other 
studies did not find an association between physical activity and sarcopenia.71, 72
It should be noted that older adults may take longer to reach the same level of 
improvement than younger adults and individual variation exists in the adaptive response 
to exercise training.64 In other words, in some older adults exercise may lead to great 
Text Box 1 Definitions by the American College of Sports Medicine:58
x Exercise: planned, structured, and repetitive movement to improve or maintain one 
or more components of physical fitness. Exercise may include: 
o Aerobic exercise: exercises in which the body’s large muscles move in a 
rhythmic manner for sustained periods 
o Resistance exercise: exercise that causes muscles to work or hold against 
an applied force or weight 
x Physical activity: body movement that is produced by the contraction of skeletal 
muscles and that increases energy expenditure
502188-L-sub01-bw-Mijnarends
GENERAL INTRODUCTION 
13
increases in muscle mass and function while in other older adults the effects of exercise 
may be minimal.64, 65, 73 However, in general, physical activity/exercise has a positive effect 
on muscle mass and function and is thus seen as an important remedy in the struggle 
against sarcopenia.74, 75 Besides the positive effects of exercise on muscle mass and 
function exercise has additional benefits, such as improved health, reduced risk for chronic 
diseases, and increased average life expectancy in older adults.64, 76, 77
5.2 Nutrition 
Without energy muscles don’t work. Muscles need energy and nutrients for contraction, 
metabolism, and maintenance.78 Nutrient intake and dietary supplementation of amino 
acids and/or proteins stimulate protein synthesis and inhibit protein breakdown of skeletal 
muscles.79 As a result inadequate dietary intake may lead to weight loss (including loss of 
muscle mass), muscle fatigue, and weakness.78 Older adults are at risk of inadequate 
dietary intake, as they are more likely to experience e.g. loss of appetite (anorexia of 
aging/anorexia because of disease), problems with chewing or swallowing, altered 
hormonal responses, slower gastric emptying, pain, and depression.78 Hence, a nutritional 
intervention may have the potential to reduce the risk of (malnutrition-related) sarcopenia. 
Several studies have investigated the effects of protein, vitamin D, antioxidants, 
polyunsaturated fatty acids, magnesium, and fruit and vegetables consumption on muscle 
mass, strength, and performance. The findings show that so far the role of nutrition 
(supplementation) in counteracting sarcopenia remains equivocal, which could be partly 
attributed to a lack of large, well-designed studies on nutrition across healthcare  
settings.13, 79
Current nutritional recommendations for the prevention of sarcopenia stated by the 
Society for Sarcopenia, Cachexia and Wasting Disease include a protein intake between 
1.0 and 1.5 g per kg body weight per day, and supplementation with vitamin D and a 
leucine enriched amino acid supplement.80 The effect of a nutritional intervention might be 
stronger in the presence of a (resistance) exercise component as exercise stimulates 
muscle protein synthesis.81-83 The Society for Sarcopenia, Cachexia and Wasting Disease 
therefore added 20-30 minutes per week of resistance and aerobic exercise to their 
nutritional recommendations for the management of sarcopenia.80
5.3 Drug Treatment 
Up to now, (resistance) exercise combined with a nutritional intervention has been found 
most effective for the prevention and management of sarcopenia. However, applying such 
an intervention in (sarcopenic) older adults can be challenging.84 In case resistance 
exercise is not feasible, pharmacological agents may be of support in reducing functional 
decline.84 Some examples of pharmacological agents that have been tested in sarcopenia 
research are testosterone, growth hormone, creatine, and angiotensin-converting enzyme 
(ACE) inhibitors.84, 85 Although pharmacological agents might be beneficial in treating 
sarcopenia, more research is needed to get insight in which agents are most appropriate. 
6. Identifying Older Adults with Sarcopenia  
Early identification of older adults with sarcopenia would be of great clinical relevance as it 
could reduce the substantial health and economic burden caused by sarcopenia. 
Especially in light of the current changes in the Dutch health care system, in which 
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residential living facilities will disappear and older adults will have to be empowered to live 
independently as long as possible (aging in place), identification and management of 
sarcopenia is of importance. At the start of this thesis, as far known no systematic review 
on the psychometric properties of tools to measure sarcopenia in community-dwelling older 
adults was available. Identification of a set of valid, reliable, and feasible tools may support 
proper identification of sarcopenia in community-dwelling older adults. 
To facilitate case finding of sarcopenic older adults the European Working Group of 
Sarcopenia in Older People (EWGSOP) provided an algorithm for identifying adults with 
sarcopenia (Figure 2).37 Several studies have been performed using this algorithm.7 The 
EWGSOP algorithm provides a clear view on which muscle parameters to include (muscle 
mass, grip strength, gait speed) in the assessment of sarcopenia. However, cut-off points 
for low muscle mass and assessment methods may differ.7, 37
Figure 2 Algorithm for sarcopenia case finding as presented by the  
European Working Group on Sarcopenia in Older People37
Sarcopenia can be diagnosed via questionnaire or performance based measures. One 
questionnaire to diagnose sarcopenia is the SARC-F. It consists of the components 
strength, assistance with walking, rise from a chair, climb stairs, and falls.86 The advantage 
of this questionnaire is that sarcopenia can be rapidly diagnosed. Subjects may however 
over- or underestimate their physical capabilities. Most research into sarcopenia therefore 
makes use of performance-based measures. Several performance-based measures for 
muscle mass, strength, and physical performance are explained below.
Older adult  65 years 
Normal grip  
strength 
Normal gait speed  
> 0.8 m/s 
Sarcopenia No sarcopenia 
Slow gait speed  
 0.8 m/s
Low muscle 
mass 
Measure grip strength 
Low grip 
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Women < 20 kg 
Men < 30 kg 
Measure muscle mass 
Measure gait speed 
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muscle mass 
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6.1 Muscle Mass 
Muscle mass can be assessed by magnetic resonance imaging (MRI), computed 
tomography (CT), a 4-compartment model, ultrasonography, dual-energy X-ray (DXA), 
creatinine excretion, bio-electrical impedance analysis (BIA) or calf circumference.87 MRI, 
CT, and creatinine excretion are seen as gold standards to assess muscle mass, however, 
not always feasible due to their high costs or high radiation exposure.87, 88 BIA  is  a  
technique to measure muscle mass which is, in contrast to MRI, CT or DXA, feasible for 
application in a home-setting or by community medical services, relatively inexpensive, 
and does not expose the subject to radiation.89 Several population specific equations to 
estimate muscle mass by BIA have been proposed.90 However, BIA should be interpreted 
with caution in subjects with an altered hydration status or with an extreme (low or high) 
BMI.89 In addition to the availability of several techniques to assess muscle mass, which 
hampers comparison between studies, cut-off points for low muscle mass are not well-
defined.37 Cut-off points for low muscle mass have be based on 1) a muscle mass lower 
than two standard deviations from a (healthy adult) reference population, 2) on the lowest 
sex-specific 20th percentile of the sample under study or 3) on previously established 
associated health-risks such as disability.8, 87, 91 The EWGSOP prefers using a healthy 
young adult population as a reference population.37 The Foundation for the National 
Institutes of Health Biomarkers Consortium Sarcopenia Project defined low lean mass 
using DXA.35 They suggested cut-off points for appendicular lean mass adjusted for body 
mass index, based on the ability of the cut-off points to distinguish between presence or 
absence of weakness.35, 92
6.2 Muscle Strength 
The measurement of grip strength seems better defined, although for this muscle 
parameter differences in assessment protocols and cut-off points do persist.93 Most studies 
using the EWGSOP algorithm measure grip strength by a handheld dynamometer.7 For 
grip strength the EWGSOP provided cut-off points of < 30 kg for men and < 20 kg for 
women and BMI specific cut-off points.37 The Foundation for the National Institutes of 
Health Biomarkers Consortium Sarcopenia Project defined weakness as grip strength < 26 
kg for men and < 16 kg for women.35 While handheld dynamometry is a simple method to 
evaluate grip strength other techniques to assess muscle strength are available, such as 
an isokinetic dynamometer, vigorimeter, or leg press.94
6.3 Physical Performance 
To assess physical performance the EWGSOP recommends usual gait speed. Gait speed 
is often assessed over a 4 or 6 meter track or by a 6-minute walk test.95 Some researchers 
assess fast gait speed of their subjects, most researchers assess usual gait speed.96 Most 
studies using the EWGSOP algorithm apply cut-off points for slow gait speed of  0.8 m/s, 
which is predictive of reduced overall survival and disability.35, 37, 96 Another cut-off point for 
gait speed has been proposed by the International Working Group, consisting of 
researchers from America, Asia, and Europe.32 They recommend  1.0 m/s as cut-off point 
for slow gait speed.36 This cut-off point was found to be predictive of poor outcomes, such 
as mobility disability, hospitalization, and mortality.96-98
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7. Aims and Outline of the Thesis 
In this introduction several gaps in knowledge have been presented, namely: a) No 
systematic review on the psychometric properties of tools to measure sarcopenia in 
community-dwelling older adults has been performed, b) Sarcopenia prevalence studies in 
older adults receiving home care or living in an assisted or residential living facility are 
scarce, c) Studies reporting hard numbers on the overlap between sarcopenia and frailty 
are limited, d) There are no studies investigating the economic burden of sarcopenia using 
direct measures to estimate costs, and e) The effect of general physical activity on the 
incidence of sarcopenia is unclear. Therefore, the overall aim of this thesis is to get more 
insight into the prevalence of sarcopenia and identify characteristics, health and economic 
outcomes of community-dwelling older adults with sarcopenia. To achieve this, the cross-
sectional Maastricht Sarcopenia Study was set up and a secondary data analysis was 
performed with data from the population-based Age, Gene/Environment, Susceptibility-
Reykjavik Study. A short summary of the MaSS and AGES-Reykjavik Study is presented 
below.  
Chapters 3 to 5 of this thesis report on data from the Maastricht Sarcopenia Study 
(MaSS). This study included 247 community-dwelling older adults 1) without additional 
care, 2) living at home or in an assisted living facility with professional home care, or 3) 
living in a residential living facility. All participants were living in Maastricht, the 
Netherlands. Data was collected during a single 1-2 hour home visit, including 
measurements of height, weight, muscle mass, muscle strength, physical performance, 
comorbidities, cognitive function, physical activity, nutritional status (by a food frequency 
questionnaire and blood samples), frailty, functional status, and health care utilization.  
Chapter 6 reports on a secondary data-analysis, using data from the population-
based Age, Gene/Environment, Susceptibility-Reykjavik Study (AGES-Reykjavik Study). 
The AGES-Reykjavik Study is a large cohort study with 5-year follow-up.99 The baseline 
examinations (n = 5,764) took place between 2002 and 2006 and the follow-up 
examinations took place between 2007 and 2011 (n = 3,316). The examinations consisted 
of several clinic visits and included numerous measurements on vascular, neurocognitive, 
and musculoskeletal health and questionnaires on physical, psychological, and social 
health.99
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7.1 Outline 
Below a short outline is given of the content of this thesis. This outline is also illustrated in 
Figure 3. 
Chapter 1: General introduction of the thesis 
Chapter 2: Describes the results of a systematic review on the validity and reliability of 
tools to measure muscle mass, strength, and physical performance 
Chapter 3: Explores the prevalence of sarcopenia and characteristics of sarcopenic 
community-dwelling older adults, a) without additional care, b) living at home 
or in an assisted living facility with professional home care, and c) living in a 
residential living facility. 
Chapter 4: Examines the relation between sarcopenia and frailty and the concurrent 
validity of two frailty tools (Fried criteria and FRAIL scale) 
Chapter 5: Reports on the health (disability in activities of daily living, quality of life), and 
economic burden of sarcopenia in community-dwelling older adults 
Chapter 6: Studies the relation between physical activity and the incidence of sarcopenia 
Chapter 7: General discussion, which reflects on the studies presented in this thesis 
Chapter 8: Focuses on the societal value of the studies in this thesis 
------------------------------------------------------------------------------------------------------------------------ 
Figure 3 Flowchart of thesis outline
Systematic review on the validity and reliability of tools  
to measure muscle mass and function (Chapter 2)
Expert consultation and pilot study  
(not presented in thesis) 
Define tools 
Feasibility 
testing 
Study
Sarcopenia
Prevalence 
(Chapter 3)
Causes
Low physical activity 
(Chapter 6)
Malnutrition (not 
presented in thesis)
Adverse outcomes
Frailty (Chapter 4)
Disability in activities of daily 
living, decreased quality of 
life, costs (Chapter 5)
Cross-sectional Maastricht  
Sarcopenia Study 
Population-based AGES-
Reykjavik Study 
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ABSTRACT 
Background: This study critically appraises the measurement properties of tools to 
measure muscle mass, strength and physical performance in community-dwelling older 
people. This study can support the selection of a valid and reliable set of tools that is 
feasible for future screening and identification of sarcopenia.  
Methods: The databases Pubmed, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), and Cochrane were systematically searched (January 11, 2012). 
Studies were included if they investigated the measurement properties or feasibility, or 
both, of tools to measure muscle mass, strength, and physical performance in community-
dwelling older people aged  60 years. The consensus-based standards for the selection 
of health status measurement instruments (COSMIN) checklist was used for quality 
appraisal of the studies. 
Results: Sixty-two publications were deemed eligible, including tools for muscle mass (n = 
16), muscle strength (n = 15), and physical performance (n = 31). Magnetic resonance 
imaging, computed tomography, and a 4-compartment model were used as gold standards 
for muscle mass assessment. Other frequently used measures of muscle mass are dual-
energy x-ray and the bioelectrical impedance (BIA); however, reliability data of the BIA are 
lacking. Hand-held dynamometry and gait speed or a short physical performance battery 
provide a valid and reliable measurement of muscle strength and physical performance, 
respectively.  
Conclusions: It can be concluded that several tools are available for valid and reliable 
measurements of muscle mass, strength and performance in clinical settings. For a home 
setting BIA, handheld dynamometry and gait speed or a short physical performance 
battery are the most valid, reliable, and feasible. The combination of selected instruments 
and its use for the screening and identification of sarcopenia in community-dwelling older 
people need further evaluation. 
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1. Introduction 
The term sarcopenia was first introduced by Rosenberg1 in 1989 and literally means 
poverty (or deficiency) of flesh. The relevance of sarcopenia as a geriatric syndrome is 
indicated by the statement that “no decline with age is more dramatic or potentially more 
functionally significant than the decline in lean body mass”.1 Over the last 6 years, several 
initiatives have been undertaken to find consensus on a proper definition of sarcopenia.2
Diagnosing sarcopenia by measuring only muscle mass appeared to be insufficient. 
Therefore, in 2009, two consensus definitions were proposed, adding loss of muscle 
function (International Working Group on Sarcopenia) or muscle strength and physical 
performance (European Working Group on Sarcopenia in Older People) to its definition.2 In 
2010, another working group formulated sarcopenia as a reduced muscle mass with 
limited mobility.3 Depending on the definition used, prevalence rate estimates of 
sarcopenia in community-dwelling older people > 60 years can vary between 3 and 52%.4,5
With adequate screening for sarcopenia among community-dwelling older people, 
those with an increased risk for adverse outcomes, such as physical disability, and 
increased risk for falls, loss of independence, and death6-9 may be identified at an earlier 
stage. After this initial screening, diagnosis could take place in a clinical setting. Early 
identification of sarcopenia would be of great clinical relevance because the loss of muscle 
mass and strength with aging can be largely reversed by proper exercise and nutritional 
intervention.8 The European Working Group on Sarcopenia in Older People introduced an 
algorithm for the identification of older people with sarcopenia based on their definition.10
For identification of sarcopenia in a research setting, several tools were stated to measure 
muscle mass, strength, and physical performance. However, those tools are not 
specifically focused on screening among community-dwelling older people, for whom case 
finding should be performed. Thus, exploring the measurement properties (validity and 
reliability) of tools feasible for measurements of muscle mass, strength, and performance 
is an important step for the future development of a set of tools to screen for or diagnose 
sarcopenia in a valid and reliable way among community-dwelling older people. 
To the best of our knowledge, no systematic review on the measurement properties 
of tools to measure muscle mass, strength, and physical performance in community-
dwelling older people has previously been published. The objective of this systematic 
literature review is to critically appraise the measurement properties of tools to measure 
muscle mass, strength, and physical performance. Moreover, the feasibility of such tools in 
community-dwelling older people will be evaluated. The identification of a set of most valid 
and reliable tools may support the future development of a screening tool for sarcopenia in 
community-dwelling older people. 
2. Methods 
Online databases PubMed, Cumulative Index to Nursing and Allied Health Literature, and 
Cochrane were systematically searched in title and abstract. The search was limited to 
publications in English and Dutch. Articles were searched up to January 11, 2012. Search 
terms were selected from literature and expert consultation, taking into account the three 
parameters of sarcopenia, that is, muscle mass, strength and performance, as mentioned 
in the consensus definition of the European Working Group.10 Backward citation tracking 
was performed to identify additional relevant articles.  
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The final selection of search terms was: (1) construct of interest - muscle mass, fat free 
mass, skeletal muscle, muscle strength, lower limb strength, upper limb strength, lower 
extremity strength, upper extremity strength, grip strength, hand grip strength, elbow 
flexion strength, ankle strength, knee strength, maximal strength, physical performance, 
functional performance, muscle quality, muscle function, gait speed, walking speed; (2) 
target population - elderly, older adults, older people, older persons, sarcopeni*, 
community-dwelling, assisted living; (3) type of measurement instrument - tool*, 
instrument*, technique*, measure*, assess*, evaluat*, test; and (4) measurement 
properties - reliab*, valid*, feasib*, consistenc*, accura*, agreement, precision, 
psychometric propert*. Asterisks indicate search for words with alternative ending, e.g. 
reliable, reliability etcetera. 
2.1 Study Eligibility Criteria 
The following inclusion criteria were used for the selection of relevant studies: The study 
had to evaluate the validity, reliability, and/or feasibility of a tool to measure muscle mass, 
strength, physical performance, or sarcopenia; focus on community-dwelling older people 
or people in assisted living facilities at age  60 years; and provide a description of the 
method used to measure muscle mass, strength, physical performance, or sarcopenia. 
Studies were excluded if they studied a specific patient population (e.g., patients with 
Parkinson disease) or if they measured only activities of daily living (e.g., Late Life 
Function and Disability Instrument), because those scales are focused on functional
activities rather than on physical performance.  
2.2 Study Appraisal and Synthesis Methods 
The search hits were inserted in EndNote X2 and duplicates were removed. All titles and 
abstracts were independently screened by two authors (D.M. and S.t.B.) and scored as 
“relevant” or “not relevant” based on the inclusion and exclusion criteria mentioned earlier. 
The reviewers discussed their opinions to reach consensus if they disagreed about the 
inclusion of a study. A third reviewer (J.M.M. or Y.L.) was asked to participate in the final 
decision if disagreement persisted. Subsequently, full texts were assessed for inclusion by 
one reviewer (D.M.), according to the eligibility criteria mentioned earlier. After that, the 
methodological quality of the studies was assessed by the consensus-based standards for 
the selection of health status measurement instruments (COSMIN) checklist.11 The 
COSMIN checklist evaluates the methodologic quality of studies on measurement 
properties among others, content validity (evidence that the content of a test corresponds 
to the content of the construct it was designed to cover), construct validity (the degree to 
which the scores of a tool are consistent with hypotheses or are related to other variables 
and other tools measuring the same construct), and concurrent validity (evidence that 
scores from a tool correspond with the gold standard or concurrent external tools 
conceptually related to the measured construct). Criteria encompass, for example, 
handling of missing items, sample size, and appropriateness of statistical methods. A 
methodologic quality score (poor, fair, good, or excellent) per box was obtained by taking 
the lowest rating of any item in a box (“worse score counts”). One reviewer (D.M.) 
assessed the quality of all articles, and a second reviewer (D.S.) randomly assessed one 
third of the articles to validate the outcomes of the first reviewer. Studies with a poor quality 
score were excluded for this review; no weighting was applied to the studies rating fair, 
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good, or excellent quality. The final selection of articles was checked by an expert in the 
field of sarcopenia (A.J.C.) who verified that relevant articles were included. 
A tool is scored “+” when having a high reliability [intraclass correlation coefficient or 
weighted Kappa  0.70 or Pearson correlation (r)  0.80; high construct validity when 
correlation between constructs  0.50, or high concurrent validity when Pearson/Spearman 
correlation or area under the curve  0.70].12
3. Results 
An overview of the process of study selection and reasons for exclusion is shown in Figure 
1. After title, abstract, and full-text screening, 135 studies were found eligible and assessed 
for quality. Of these 135 studies, 49 were appraised for quality by a second reviewer 
(D.S.); disagreement between the reviewers existed over four, because of lack of clarity of 
appropriate statistical methods (n = 2), choice of measurement property (n = 1), or 
interpretation of study results (n = 1). In a consensus meeting, the two reviewers discussed 
their opinions, after which agreement was reached. 
A final selection of 62 studies was included in this review, classified as having fair (n
= 61) or good (n = 1) quality. An overview of the characteristics of the individual studies is 
presented in Supplementary Data files. Table 1 provides an overview of the assessed 
measurement properties of the included studies. The tools are described in the following 
sections according to the parameter: muscle mass (n = 16), strength (n = 15), and 
performance (n = 31).  
Table 1 Measurement Properties Assessed in the Included Studies (by the COSMIN Checklist) 
Measurement Property Muscle 
Mass 
Muscle 
Strength 
Physical 
Performance 
P F G P* F G P* F G 
Box A Internal consistency30,35 - - - - - - 2 - -
Box B Reliability18,21-23,25-31,34,35,38,40,41,44-47,49-53,56,58,68-71 - - - - 14 - - 17 - 
Box C Measurement error25,26,68 - - - 1 1 - - 1 - 
Box D Content validity58 - - - - - - - 1 - 
Box F Hypothesis testing18-20,23,29,30,32-36,38,39,41-45,47,48,51,52,54,55,58,68,71,72 - - - - 8 - 3 16 1 
Box H Criterion validity13-17,20,21,24,37,41,51,53,57,69,73-83 - 16 - - 5 - - 4 - 
Box I Responsiveness13,50 - 1 - - - - - 1 - 
COSMIN, consensus-based standards for the selection of health status measurement instruments; F, fair; G, 
good; P, poor. No studies were scored with excellent (E). *For some studies more than one box was assessed; in 
case one box was assessed ‘poor’ quality but the other with ‘fair’ or ‘good’ the study was included in the final 
study selection, only taking into account data from the fair/good box. 
3.1 Validity, Reliability and Feasibility 
The validity and reliability of 10 different tools to assess muscle mass were reported (Table 
2). The included studies evaluated mainly the concurrent validity, only one study assessed 
responsiveness,13 and no studies evaluated the reliability of the tools. As listed in Table 2, 
magnetic resonance imaging (MRI), computed tomography (CT), and a 4-compartment (4-
C) model were used as gold standards for assessment of muscle mass. The only study 
describing responsiveness showed that ultrasonography was able to detect changes in 
muscle mass before and after training.  
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Figure 1 PRISMA (Preferred Reporting Items for Systematic Reviews and  
Meta-Analyses) flowchart showing selection procedure of articles 
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Dual-energy X-ray (DXA) was found to be highly correlated with MRI, CT, and the 4-C 
model. Bioelectrical impedance (BIA) was found to have high concurrent validity; however, 
significant differences in estimation of mean fat-free mass between BIA and DXA were 
found.14 Furthermore, it was stated that its validity is questionable due to significant 
differences in the estimation of muscle mass by BIA compared with DXA, and reliability 
data are lacking. Calf circumference15 and skin-fold thickness16 both showed low 
correlations with DXA. Feasibility criteria discussed were exposure to radiation and costs.17
Table 2 Measurement Properties of Muscle Mass Tools in Community-Dwelling Older Persons 
Instrument Reliability Validity* Portable and 
Executable in a 
Home Setting? 
Outcome Concurrent Comparator 
Instrument 
BIA 
Single frequency 
14,16,73,75-77,80
Multifrequency73,74, 78
r > 0.79,  
R2 = 0.70,
LOA 12 kg** 
+ TBW, 4-C model, 
DXA 
Yes 
ICC > 0.95 
ICC > 0.69 
+
-
DXA whole body 
DXA Segmental 
BOD POD74 LOA -11.0  
to 2.4 kg**  
? DXA No 
Calf circumference15 r = 0.63 - DXA Yes 
CT13,17,83 r > 0.83,  
R2 = 0.96 
+ Used as gold 
standard vs. DXA 
and 
ultrasonography 
No 
DXA14-17,78-81 r > 0.91 + MRI, CT, 4-C 
model 
No
Equation for LBW79 LOA 0.65 – 
11.65 kg** 
+ DXA Yes 
MRI17 r > 0.91 + Used as gold 
standard vs. DXA 
No
Skin fold thickness16 R2 = 0.62 - DXA Yes 
Ultrasonography13 r > 0.83 + CT Yes 
4-C model76,83 R2 = 0.98,  
r = 0.95 
+ Used as gold 
standard vs. DXA 
and BIA 
No 
+, high concurrent validity (Pearson/Spearman correlation or area under the curve (AUC)  0.70 or 
responsiveness  0.50); (-), low validity (Pearson/Spearman correlation or AUC < 0.70); 4-C model, 4-
compartment model; BIA, bioelectrical impedance; BOD POD, measure of air displacement plethysmography; 
CT, computed tomography; DXA, dual-energy x-ray; ICC, intra-class correlation coefficient; LOA , limits of 
agreement; LBW, lean body weight; MRI, magnetic resonance imaging; TBW, total body water. *Only concurrent 
validity (evidence that scores from a tool correspond with the ‘gold standard’) was assessed in the included 
studies. **LOA could not be interpreted, since no information was provided on the minimally important change. 
Table 3 provides an overview of the tools to measure muscle strength and their validity and 
reliability. In the included studies, reliability, construct, and concurrent validity were 
assessed. The handheld dynamometer (HHD), by which measurements of hand grip, 
ankle, elbow, hip, and knee strength can be made, is valid and reliable.18-26 It showed both 
high interrater and intrarater reliability, and concurrent and construct validity were shown 
by comparison of several types of HHDs with an isokinetic dynamometer,24 a 
vigorimeter,20,23 and sit-to-stand testing.19 Other tools to assess muscle strength like the 
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leg press,27 plate spring gauge,28 and pull down29 showed good reliability. However, no 
validity data were found for these specific tools. Feasibility criteria mentioned were rate of 
injuries, simplicity, time of the measurement, safety, and costs.29 
Table 4 lists the validity and reliability of tools that can be used to measure physical 
performance. Most studies evaluated the intrarater reliability, construct and/or concurrent 
validity. Tools to assess physical performance comprised questionnaires,30, 31 several 
performance-based tools,31-57 and a tool using video animation (the mobility assessment 
tool).58 Some tools measure single performance items, such as gait speed or standing 
balance, whereas other tools include multiple items. The latter was applied in, for example, 
the frequently used short physical performance battery (SPPB), which includes standing 
balance, gait speed, and chair rises (sit-to-stand).31, 37, 40, 50 The mobility assessment tool is 
a tool that uses video clips of several types of performance, which subjects have to score 
as being able to do or not. Reliability and validity for gait speed measurements was 
confirmed in nine studies31, 32, 37, 38, 40, 51, 53, 54, 56 and it was found to have high construct 
validity, shown by correlations with SPPB and stair climb, and predictive validity for 
disability.37,42,53-55 Muscle soreness, safety, ease of administration, acceptability to patients, 
portability, time span, and ability to perform the test were mentioned with regard to 
feasibility.35, 41, 49, 58
4. Discussion 
Many tools are described that measure muscle mass, strength, and physical performance. 
MRI, CT, and a 4-C model were used as gold standards to measure muscle mass. Also, 
DXA, even though it is not the gold standard, was often used as reference method, 
because it is a cheaper and quicker option than the other gold standards for muscle mass. 
However, when comparing an instrument with a reference instrument that is not a gold 
standard, it is unknown to which degree the correlation between instruments is influenced 
by measurement errors of the reference instrument. A remarkable finding was the lack of 
studies examining the reliability of tools to measure muscle mass in older people. Reeves 
et al,59 excluded from this review because of a small sample size, looked at the reliability of 
ultrasonography and its validity compared with MRI, and found good reliability and validity 
for ultrasonography. This adds to the evidence for high concurrent validity and 
responsiveness of ultrasound measurements found in this review.13
The leg press and HHD used on both upper and lower extremities are valid and 
reliable tools to measure muscle strength. The HHD is frequently used; however, Roberts 
et al60 concluded in their review that protocols to measure grip strength by HHD differ, 
which makes comparison between studies difficult. Stark et al61 reviewed the reliability and 
validity of HHD in young and older people, and also found that the various studies revealed 
a lack of homogeneity in methodology for the application of HHD, which underlines the 
need for using a standard protocol. They concluded that HHD cannot fully replace 
isokinetic measurements, but considering the costs of isokinetic devices and the 
impracticality, HHD is a good alternative. However, using hand grip strength as a predictor 
of overall strength seems unjustified in the healthy older adult.62 It can be argued that lower 
extremity strength might be even more relevant than upper extremity strength, because 
lower extremity strength is important for functional activities.62
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Many instruments have been applied to measure (aspects of) physical performance. Gait 
speed is a useful tool to assess physical performance given its high reliability and 
concurrent validity. Participants with SPPB scores  10 at baseline had significantly higher 
odds of mobility disability at 3-year follow-up.63 Cooper et al’s64 review concluded that 
walking speed, chair rises, and standing balance (components of the SPPB) were all 
associated with mortality. Those studies add to the clinical importance of the frequently 
used physical performance tools, namely, gait speed and the SPPB. 
4.1 Feasibility  
For quick screening of muscle mass, strength, and physical performance among 
community-dwelling older people, it would be beneficial if tools are feasible to apply in a 
general practitioner practice or in a home setting. With regard to muscle mass, many tools 
are available in clinical practice, but no well-validated and reliable tools are available for 
measurements of muscle mass in a home setting. BIA and the use of anthropometrics 
(such as calf circumference and skin-fold thickness measurements) were all found to be 
feasible for a home setting because the required equipment is portable. From those, BIA 
showed better evidence for validity, yet its validity is highly dependent on age, sex, and 
cultural influences,14 because, for example, oedema, diuretics and prosthesis hamper BIA 
measurements. Furthermore, it is likely that the use of different reference populations and 
cut-off points for muscle mass have large effects on the outcome.8, 65, 66 In a review on field 
and laboratory techniques to assess muscle mass, it is stated that 3-C and 4-C methods 
may be required and are usually recommended in older people, but BIA is put forward as 
the best option for field measurements.67 Ultrasound is a promising alternative to the BIA; 
however, for ultrasound to become a feasible and reliable alternative for BIA, work is 
warranted.  
4.2 Critical Appraisal of Methodology 
With regard to the methodology of this review, some aspects should be addressed. Most 
studies scored “fair” because they did not describe how missing items were handled. 
Studies were excluded when they had a sample size of less than 30, which may have 
narrowed our results. In addition, a correlation of 0.69 is classified as low validity, whereas 
a correlation of 0.71 is classified as high, despite the marginal difference. For muscle 
strength and performance, gold standards are not available, which hampers assessment of 
proper concurrent validity. It should be taken into account that for some tools, only one 
study on validity and reliability was available. 
4.3 Conclusions and Implications of Key Findings  
For a valid and reliable screening or diagnosis of sarcopenia, firstly one has to agree on 
the combination of the parameters by which sarcopenia is measured. In this article, the 
European Working Group on Sarcopenia in Older People criteria were chosen, including 
muscle mass, muscle strength, and physical performance. Gold standards used for the 
assessment of muscle mass were MRI, CT, and a 4-C model. A valid and reliable tool for 
muscle strength is the HHD; the SPPB and gait speed have good measurement properties 
with regard to the assessment of physical performance.  
To measure muscle mass, strength and physical performance in a general 
practitioner practice or home setting, BIA, HHD and gait speed over a short distance or the 
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SPPB can be used, since those measures are transportable and executable in those 
specific settings. However, because the validity of BIA is not optimal, it is debatable to 
measure only muscle strength and physical performance for a first screening, and when 
scores on these parameters are below normal, further assessment of muscle mass by, for 
example, DXA, as a more valid alternative for the measurement of muscle mass, could be 
used. The use of a combination of tools to measure muscle mass, strength, and physical 
performance for the screening and diagnosis of sarcopenia in community-dwelling older 
people, as well as predictive value, need further evaluation. 
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ABSTRACT 
Background: Sarcopenia negatively affects mobility and quality of life. Few studies exist 
on sarcopenia prevalence in older people receiving home care or living in an assisted or 
residential living facility. The objective of this study was to estimate the prevalence of 
sarcopenia in 1) those living independently at home without additional care, 2) those living 
at home or in an assisted living facility with professional home care, and 3) those living in a 
residential living facility with additional professional nursing care and/or meal service, and 
to characterize older people with sarcopenia.  
Methods: The cross-sectional Maastricht Sarcopenia Study was undertaken in people 
65 years. Sarcopenia was assessed according to the European Working Group on 
Sarcopenia in Older People algorithm, using skeletal muscle mass index (SMI; bioelectrical 
impedance), muscle strength (handheld dynamometer) and gait speed (as part of the short 
Physical Performance Battery – SPPB). Subjects were characterized for functional status 
(Groningen Activity Restriction Scale – GARS), number of comorbidities (Charlson 
Comorbidity Index), and cognitive status (Mini-Mental State Examination – MMSE). 
Differences in prevalence between the three groups and characteristics of sarcopenic 
versus non-sarcopenic older people were compared using Student’s t-tests or Chi-square 
tests. Logistic regression was performed to assess the association of sarcopenia with 
functional status, number of comorbidities and cognitive status, controlling for age, sex and 
body mass index.  
Results: 227 participants were included in the analyses, 157 without care, 41 living at 
home or in an assisted living facility with home care, and 29 living in a residential living 
facility. Sarcopenia was significantly more prevalent in people living in a residential living 
facility (58.6%) compared to those receiving home care (41.5%) and those living at home 
without care (12.1%). Most sarcopenic older people had low SMI in combination with poor 
grip strength. People with sarcopenia had a significantly (P < 0.05) lower functional status, 
more comorbidities and a slightly lower cognitive function. After correcting for age, sex and 
BMI, sarcopenia was significantly associated with impaired functional status (OR 2.11, 
95% CI: 1.43-3.12), but not with the number of comorbidities and cognitive status.  
Conclusions: Sarcopenia was more prevalent in older people with a care need, i.e. with 
home care or living in a residential living facility. The impaired functional status associated 
with sarcopenia underlines the need for early diagnosis and treatment of sarcopenia, to 
stimulate longer independence and prevent disability. 
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1. Introduction 
Sarcopenia, the age-related decline in muscle mass and function, negatively affects 
mobility and quality of life and is associated with increased nursing home admission in 
community-dwelling older people.1 Early identification of sarcopenia in older people is of 
clinical importance to enable early intervention. Interventions to improve muscle mass and 
function, such as exercise or nutrition, have the potential to delay the development of 
mobility difficulties related to sarcopenia.2
To facilitate early identification of sarcopenia in older people, the European Working 
Group on Sarcopenia in Older People (EWGSOP) developed an algorithm.1 This algorithm 
defines sarcopenia as low muscle mass with poor strength and/or performance. In the past 
years, several studies were performed to assess the prevalence of sarcopenia according 
to the EWGSOP criteria, in both the community and nursing home settings.3 Studies in 
community-dwelling older people using the EWGSOP definition have reported prevalence 
rates of sarcopenia between 1% and 29%.3 The huge variation between those studies, 
though using the same definition, can be partly explained by differences in group 
characteristics such as varying age groups,4 the use of different techniques to assess 
muscle mass, such as bio-electrical impedance (BIA) or dual-energy X-ray and various cut-
off points to define low muscle mass.5-8
As one could expect, studies in participants with a need for care, like hospital patients 
or people in long-term care institutions, report on a higher prevalence of sarcopenia than 
studies in community-dwelling older people.3, 9, 10 Although several studies have assessed 
the prevalence rates of sarcopenia in the community and nursing homes,3 studies on the 
prevalence of sarcopenia in older people receiving other forms of care, e.g. professional 
home care or residential living facilities, are scarce.11, 12 Especially people receiving home 
care or living in residential living facilities might be a good target population for an 
intervention to delay or prevent sarcopenia, as these people might be at an early stage of 
dependency. 
Sarcopenia and/or its individual components (muscle mass, strength, performance) 
has been associated with functional status, the ability to perform activities of daily living 
(ADL).10, 13-20 Gait speed seemed the strongest predictor of disability in both sexes,15, 18, 19
but also associations were found between disability and grip strength16, 18, 19 and between 
disability and low skeletal muscle mass.18, 19 The association between low skeletal muscle 
mass and disability seems stronger in the presence of comorbidities.21 Next to impairments 
in functional status and the presence of comorbidities, sarcopenic individuals are more 
likely to have an impaired cognitive function.22
As studies on the prevalence of sarcopenia in older people receiving professional 
home care or living in a residential living facility are scarce, and these people might be at 
an early stage of dependency, insight in the prevalence of sarcopenia and characteristics 
(like functional status) of this population is valuable. Therefore this study aimed to estimate 
the prevalence of sarcopenia, using the EWGSOP algorithm, in 1) those living 
independently at home without additional care, 2) those living at home or in an assisted 
living facility with professional home care, and 3) those living in a residential living facility 
with additional professional nursing care and/or meal service. Moreover this study aimed to 
characterize older people with sarcopenia in terms of functional status, comorbidities, and 
cognitive status.  
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2. Methods 
2.1 Design and Setting
The cross sectional Maastricht Sarcopenia Study (MaSS) was undertaken in: 1) older 
people living independently at home without additional care, and 2) people living at home 
or in an assisted living facility with professional home care, and 3) older people living in a 
residential living facility with additional professional nursing care and/or meal service, in 
Maastricht, The Netherlands.  
2.2 Sample 
Eligibility criteria encompassed: people  65 years with an understanding of the Dutch 
language, who gave written informed consent. Persons with an implantable cardiac 
defibrillator/pacemaker, persons in a wheelchair or bedridden, and those suffering from 
severe active rheumatoid arthritis, post stroke status with evident lingering symptoms, 
diseases of the nervous system, acute angina pectoris or dementia were excluded, 
because they would not have been able to perform the physical tests safely.23 A power 
calculation was made for the main outcomes of the MaSS study (difference in nutritional 
status in sarcopenic older people compared to non-sarcopenic older people; not reported 
here). The required sample size was calculated by means of G*Power 3.1, a power 
analysis program that is commonly used in social sciences.24 The significance level was 
set to Į = 0.05, the power (1-ȕ) to = 0.80 and the estimated prevalence at 12.5%, as being 
within the prevalence reported in other studies.25, 26 This resulted in a required sample size 
(taking into account 10% drop out by coincidence) of 252. This sample size provides 
sufficient power to compare characteristics between sarcopenic versus non-sarcopenic 
participants. 
2.3 Recruitment
Participants were recruited between May 2013 and March 2014. The municipality of 
Maastricht randomly extracted 2448 addresses of people  65 years. An information letter, 
informed consent form and stamped response envelope were sent to the selected 
addresses. After receiving the signed consent form, one of the researchers (D.M./E.L.) 
made a phone call to check for eligibility and a home visit was planned. To create 
awareness of the study, an interview was given to a local newspaper and a flyer with 
general information about the study was spread in all pharmacies and assisted and 
residential living facilities in Maastricht. 
2.4 Data Collection 
Data was collected during a single 1-2 hour home visit. A pilot study was performed to test 
the feasibility of this method of data collection.27 Standardized protocols were used to 
ensure conformity of data collection. Home visits were always performed in the morning 
because participants had to be in fasting state for the muscle mass measurement.  
2.5 Measures
The prevalence of sarcopenia was assessed using the algorithm of the EWGSOP.1
According to this algorithm participants were categorized as sarcopenic when they had a 
low muscle mass and poor muscle strength and/or physical performance. The measures 
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used for muscle mass, strength and performance were evaluated as valid and feasible for 
the measurement of sarcopenia in a home setting.28 Muscle mass was assessed by bio-
electrical impedance (BIA AKERN 101, 50 kHz), according to the ESPEN guidelines.29
Muscle mass was calculated using the Janssen et al.6 equation: skeletal muscle mass (kg) 
= [(height2/resistance BIA analysis resistance*0.401) + (gender*3.825) + (age*-0.071)] + 
5.102, where height is in centimetres, resistance in ohms, male gender is coded 1, female 
0 and age in years. This equation was developed in a population of 18-86 year olds and is 
applicable in a Caucasian population,6 like the Dutch population. Cut-off points for low 
muscle mass were based on the calculated skeletal muscle index (SMI); 1) in men SMI 
8.50 kg/m2 and in women  5.75 kg/m2, also called severe sarcopenia and 2) SMI 8.51-
10.75 kg/m2 (men) and 5.76-6.75 kg/m2 (women) also called moderate sarcopenia.30
Muscle strength was assessed by a JAMAR hand-held dynamometer. Participants 
performed one try-out attempt with their arm in 90° angle, followed by three attempts with 
each hand, alternating left and right. Participants were told to take a deep breath, and to 
start squeezing as they exhaled. Researchers encouraged the participants to squeeze as 
hard as possible. The maximum grip strength was used in the analyses, with cut-off points 
for poor muscle strength defined as < 20 kg for women and < 30 kg for men, as suggested 
by the EWGSOP.1 Physical performance was assessed using the short physical 
performance battery (SPPB) with a total score ranging from 0-12.31 The SPPB includes 
normal gait speed over a four meter track (score 0-4), 5x chair stand (score 0-4) and a 
balance test (score 0-4); higher scores indicate better performance. For slow gait speed a 
cut-off point of  0.8 m/s was used, as proposed by the EWGSOP.1 Furthermore, 
characteristics of participants were collected through a questionnaire that included age, 
sex, ethnicity, living situation i.e. type of care, comorbidities by the Charlson Comorbidity 
Index,32 functional status assessed by the validated Groningen Activity Restriction Scale 
(GARS)33 and cognitive function by the Mini-Mental State Examination (MMSE).34 Height 
(stadiometer type SECA 213) and weight (scale type SECA 877) were also measured with 
clothes, but without shoes, and BMI calculated as weight/height2. The BIAs, JAMARs and 
scales were regularly calibrated, every three weeks (BIA and JAMAR) and every three 
months (scales) respectively. 
2.6 Data Analysis
SPSS version 21 (SPSS Inc, Chicago, IL) was used for statistical analyses. Means (±SD) 
were used to summarize continuous variables. Chi-square test was used to compare the 
prevalence of sarcopenia in the three previously defined groups. Insight in the scores on 
individual parameters of the sarcopenia definition (i.e. SMI, grip strength, gait speed) and 
the SPPB was obtained by a descriptive analysis. Student’s t-test (continuous variables) or 
Chi-square test (categorical variables) were used to compare the characteristics of 
sarcopenic versus non-sarcopenic older people. Logistic regression analysis was 
performed to assess the association of sarcopenia (dependent variable) with functional 
status (GARS score), number of comorbidities (Charlson Comorbidity Index) and cognitive 
status (MMSE score), controlling for age, sex and BMI. 
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2.7 Ethical Considerations
The Medical Ethics Committee of the Academic Hospital Maastricht and Maastricht 
University approved the study after which the study was registered at 
http://www.clinicaltrials.gov (NCT01820988).  
3. Results 
A flow diagram of inclusion is shown in Supplementary Data, File 1. In total, 227 
participants had complete data sets and were included in the analyses. Most participants 
were Caucasian (98%), 6 participants were Asian. Analyses were performed with and 
without persons with oedema (n = 35). Excluding participants with oedema did not lead to 
significant differences in sarcopenia prevalence and outcomes between groups, therefore 
the analyses shown below include people with oedema. 
3.1 Prevalence of Sarcopenia  
Of the total sample, 53 participants (23%) were classified as sarcopenic (Supplementary 
Data, File 2). Of those, 12 participants (5%) had severe sarcopenia, while the others (n = 
41, 18%) had moderate sarcopenia. Sarcopenia was more prevalent in residential living 
facilities (58.6%) compared to those receiving home care (at home or in an assisted living 
facility) (41.5%) or those living at home without care (12.1%) (Table 1).  
Of the 174 participants not identified as sarcopenic, 113 (65%) had low SMI, but 
normal gait speed and grip strength (Figure 1, Part A). Of the 53 participants with 
sarcopenia, low SMI in combination with poor grip strength was present in 26 participants 
(49%, Figure 1 – Part B). Of the 53 participants with sarcopenia, 18 participants (34%) had 
low SMI combined with both poor strength and slow gait speed (Figure 1 – Part C), and 
low SMI in combination with slow gait speed was present in 9 participants (17%, Figure 1 – 
Part D). Moreover, 20 of the 174 non-sarcopenic participants (11%) had low grip strength 
and/or slow gait speed, but normal muscle mass (Figure 1, parts E, F, G). Forty-one 
participants (18%) did not have any muscle impairment.  
3.2 Characteristics of Sarcopenic Participants 
Participants with sarcopenia were significantly older (P < 0.001), had on average more 
comorbidities (P = 0.002), were more disabled in ADL (P < 0.001), had a lower cognitive 
function (P = 0.006) and had a lower BMI (P = 0.024) compared to their non-sarcopenic 
peers (Table 1). Sarcopenic participants scored lower on all performance measures, such 
as chair stand, balance score and total SPPB score (Table 1). Logistic regression analysis 
showed that there was a significant association between sarcopenia and functional status 
(OR 2.11, 95% CI: 1.43-3.12), but not with the number of comorbidities and cognitive 
status (Table 2). There was a significant (but small) interaction between age and functional 
status (interaction term OR 0.992, 95% CI: 0.987-0.996), i.e. the association between 
sarcopenia and functional status was stronger at younger age. Men more often had a low 
SMI compared to women, i.e. 106 out of 117 (91%) versus 60 out of 110 (55%) 
respectively (P < 0.001) (Table 1). Women had more often poor grip strength, i.e. 35 out of 
110 (32%) women versus 24 out of 117 men (21%) (P = 0.052).  
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(continued on next page) 
Table 1 Participant Characteristics 
Variable Total  
(n = 227) 
Characteristics of 
Participants with/without 
Sarcopenia 
Characteristics of Participants Based on 
Care Need 
Non-
Sarcopenic  
(n = 174) 
Sarcopenic  
(n = 53) 
No Care  
(n = 157) 
Home Care at 
Home/Assisted 
Living (n = 41) 
Residential 
Living Facility 
(n = 29) 
General characteristics 
Age in years, mean (SD) 74.9 (7.2) 73.3 (6.4) 80.4 (7.1)* 72.1 (4.9) 80.7 (7.1) 82.3 (8.2) 
Age category, n (%) 
65-75 years 135 (59.5) 123 (70.7) 12 (22.6)* 121 (77.1) 7 (17.1) 7 (24.1) 
76-85 years 67 (29.5) 40 (23.0) 27 (50.9)* 35 (22.3) 23 (56.1) 9 (31.0) 
86-95 years 25 (11.0) 11 (6.3) 14 (26.4)* 1 (0.6) 11 (26.8) 13 (44.8) 
Sex, n female (%) 110 (48.5) 85 (48.9) 25 (47.2) 73 (46.5) 22 (53.7) 15 (51.7) 
Comorbidities, n (%) 
Cancer  14 (6.2) 8 (4.6) 6 (11.3) 5 (3.2) 4 (9.8) 5 (17.2) 
Chronic lung disease 45 (19.9) 32 (18.3) 13 (24.5) 21 (13.4) 15 ( 36.6) 8 (27.6) 
Diabetes 26 (11.5) 18 (10.3) 8 (15.1) 8 (5.1) 10 (24.4) 8 (27.6) 
Heart attack/infarct 26 (11.5) 17 (9.8) 9 (17.0) 16 (10.2) 4 (9.8) 6 (20.7) 
Heart failure 22 (9.7) 15 (8.6) 7 (13.2) 11 (7.0) 6 (14.6) 5 (17.2) 
Hypertension 100 (44.1) 71 (40.8) 29 (54.7) 65 (41.4) 18 (43.9) 17 (58.6) 
Gastro-intestinal 
disease 
21 (9.3) 17 (9.8) 4 (7.5) 11 (7.0) 3 (7.3) 7 (24.1) 
Peripheral arterial 
disease 
43 (18.9) 31 (17.8) 12 (22.6) 23 (14.6) 15 (36.6) 5 (17.2) 
Rheumatic disorder 72 (31.7) 54 (31.0) 18 (34.0) 43 (27.4) 18 (43.9) 10 (34.5) 
Stroke**  13 (5.7) 5 (2.9) 8 (15.1)* 5 (3.2) 5 (12.2) 3 (10.3) 
Other**  63 (27.8) 41 (23.6) 21 (41.5)* 41 (26.1) 15 (36.6) 13 (44.8) 
Number of comorbidities, 
mean (SD)  
2.1 (1.8) 1.9 (1.8) 2.7 (1.7)* 1.6 (1.4) 2.9 (2.0) 3.2 (2.1) 
BMI, mean kg/m2 (SD) 27.1 (3.9) 27.5 (4.0) 26.1 (3.3)* 26.9 (3.6) 27.7 (4.5) 27.6 (4.8) 
MMSE score, mean (SD) 28.7 (1.3) 28.9 (1.3) 28.3 (1.4)* 28.9 (1.2) 28.2 (1.6) 28.4 (1.4) 
Level of care, n (%) 
No care  157 (69.1) 138 (79.3) 19 (35.8)* 157 (100.0) 0 (0.0) 0 (0.0) 
Home care at home/ 
assisted living 
41 (18.1) 24 (13.8) 17 (32.1)* 0 (0.0) 41 (100.0) 0 (0.0) 
Residential living 
facility 
29 (12.8) 12 (6.9) 17 (32.1)* 0 (0.0) 0 (0.0) 29 (100.0) 
GARS score, mean (SD) 23.4 (9.0) 21.6 (7.3) 29.4 (11.3)* 20.0 (4.3) 29.5 (10.7) 33.2 (12.9) 
Muscle characteristics 
SMI, mean kg/m2 (SD)
Men (total n = 117) 9.5 (0.9) 9.5 (0.9) 9.3 (0.8) 9.5 (0.8) 9.3 (1.0) 9.6 (0.9) 
Women (total n = 110) 6.8 (1.0) 7.0 (0.9) 6.0 (0.5)* 6.8 (0.8) 6.9 (1.1) 6.7 (1.3) 
Low SMI, sex-specific 
proportion 
Men (total n = 117) 106 out of 117 78 out of 89 28 out of 28* 75 out of 84 18 out of 19 13 out of 14 
Women (total n = 110) 60 out of 110 35 out of 85 25 out of 25* 37 out of 73 13 out of 22 10 out of 15 
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Variable Total  
(n = 227) 
Characteristics of 
Participants with/without 
Sarcopenia 
Characteristics of Participants Based on 
Care Need 
Non-
Sarcopenic  
(n = 174) 
Sarcopenic  
(n = 53) 
No Care  
(n = 157) 
Home Care at 
Home/Assisted 
Living (n = 41) 
Residential 
Living Facility 
(n = 29) 
Muscle mass as % of total 
body weight, mean (SD) 
Men (total n = 117) 35.1 (3.1) 35.4 (3.0) 34.0 (3.1)* 35.2 (3.1) 34.4 (3.2) 35.1 (2.7) 
Women (total n = 110) 25.4 (3.0) 25.6 (2.8) 24.7 (3.4) 25.7 (3.0) 24.9 (2.8) 24.5 (3.0) 
Grip strength, mean kg (SD)
Men 36.2 (8.0) 39.1 (6.4) 26.9 (5.0)* 38.2 (7.5) 31.4 (6.9) 30.1 (6.8) 
Women 21.8 (6.3) 23.8 (5.3) 15.1 (4.5)* 24.0 (5.1) 17.9 (6.3) 17.1 (7.0) 
Poor grip strength, n (sex-
specific %) 
Men (total n = 117) 24 (20.5) 3 (2.6) 21 (17.9)* 10 (11.9) 7 (36.8) 7 (50.0) 
Women (total n = 110) 35 (31.8) 12 (10.9) 23 (20.9)* 11 (15.1) 15 (68.2) 9 (60.0) 
Gait speed, mean m/s (SD) 1.0 (0.3) 1.1 (0.2) 0.8 (0.2)* 1.1 (0.2) 0.9 (0.2) 0.7 (0.2) 
Balance score, mean (SD) 3.6 (0.8) 3.8 (0.6) 3.2 (1.1)* 3.8 (0.5) 3.4 (1.0) 2.9 (1.2) 
Chair stand score, mean 
(SD)
2.6 (1.3) 2.9 (1.4) 1.6 (1.2)* 3.0 (1.0) 1.9 (1.3) 1.3 (1.4) 
Chair stand 5x, mean s 
(SD)a
13.3 (4.4) 12.5 (3.2) 16.7 (6.4)* 12.3 (3.0) 15.2 (4.2) 18.3 (8.9) 
SPPB score, mean (SD) 9.9 (2.4) 10.5 (1.9) 7.8 (2.6)* 10.7 (1.5) 8.7 (2.6) 7.1 (3.1) 
Prevalence of sarcopenia, 
n (%) 
53 (23.3) 0 (0.0) 53 (100.0) 19 (12.1) 17 (41.5) 17 (58.6) 
Moderate sarcopenia 41 (18.1) 0 (0.0) 41 (77.4) 14 (8.9) 12 (29.3) 15 (51.7) 
Severe sarcopenia 12 (5.3) 0 (0.0) 12 (22.6) 5 (3.2) 5 (12.2) 2 (6.9) 
BMI, body mass index; GARS, Groningen Activity Restriction Scale (total score range 18-72, higher scores 
indicate more restriction in ADL); MMSE, Mini-Mental State Examination; SMI, skeletal muscle index; SPPB, short 
physical performance battery. Low SMI defined as  10.75 kg/m2 (men) and  6.75 kg/m2 (women); Poor grip 
strength < 30 kg men, < 20kg women. *Significant difference between sarcopenic and non-sarcopenic 
participants (P-value < 0.05). Significant differences in age category and level of care were found comparing the 3 
groups. **Stroke without evident lingering symptoms; Other, kidney, liver disease, etc. an = 205, since not all 
participants were able to perform the 5x chair stand.
4. Discussion 
Sarcopenia was more prevalent in older people receiving professional home care or living 
in a residential living facility. This result is in line with previous research in community-
dwelling older people versus a long-term care setting, which showed that the prevalence of 
sarcopenia is higher in people with a need for care.3 Only two publications were found on 
the prevalence of sarcopenia in an assisted living or residential living population. A study 
by Krause12 reported a 54.5% (men) and 36.3% (women) prevalence of sarcopenia in 
people living in the community or an assisted living facility. The higher prevalence found 
compared to our study might be because they did not use the EWGSOP algorithm and 
their sample size was rather small (n = 33). The other publication was a protocol article of 
a study on sarcopenia prevalence in residential care, but this study did not publish results 
yet.11
Our study showed that poor grip strength and slow gait speed were not always 
coincided by low SMI, meaning that also non-sarcopenic older people might have impaired 
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muscle function. Grip strength and gait speed have been shown to be good predictors of 
negative health outcomes like accelerated dependency in ADL, and they are easy to 
measure in clinical geriatric practice.15, 16, 18, 35, 36 Therefore, the first steps in the EWGSOP 
(gait speed and grip strength) are of clinical relevance, also in non-sarcopenic older 
people. 
Figure 1 Prevalence of Muscle Impairments as Percentage of the Total Population  
Part A: people with low SMI, Part B: people with low SMI and poor grip strength, Part C: people with 
low SMI, poor grip strength and slow gait speed, Part D: people with low SMI and slow gait speed, 
Part E: People with only poor grip strength, Part F: People with both poor grip strength and slow gait 
speed, but normal SMI, Part G: people with only slow gait speed. Parts B, C and D are persons with 
sarcopenia according to the EWGSOP definition. Percentages are calculated based on the total 
sample (n = 227). *SMI, skeletal muscle index; m, moderately low SMI, low skeletal muscle index 
8.51-10.75 kg/m2 (men), 5.76-6.75 kg/m2 (women); s, severely low SMI, low skeletal muscle index 
8.50 kg/m2 (men) and  5.75 kg/m2 (women). 
Low SMI was more prevalent in men than in women; however a study by Volpato et al.,4
also using BIA but using slightly different cut-off points, shows that low SMI is more 
prevalent in women. As our results and the study by Volpato et al.4 show, it seems that a 
notable number of people with low SMI are not sarcopenic, because their grip strength and 
gait speed are within the normal range. The number of people found with low SMI is 
influenced by the cut-off points used. In our study, we corrected SMI for height squared. 
Other ways of classifying low SMI are by correcting for body weight, BMI or fat mass.37, 38
Cut-off points are based on < 2SD of a reference population, the lowest 20th percentile or 
Low SMI*
(n = 166; n = 142 moderate, n = 24 severe) 
Slow gait speed (n = 41) 
 0.8 m/s) 
Poor grip strength (n = 59) 
< 20 kg female, < 30 kg male 
G
n = 5 (2.2%) 
A
n = 113 (49.8%) 
(m: 101, s: 12) 
D
n = 9 (4.0%) 
(m: 8, s: 1) 
C
n = 18 (7.9%) 
(m: 11, s: 7) 
F
n = 9 (4.0%) 
E
n = 6 (2.6%) 
B
n = 26 (11.5%)
(m: 22, s: 4) 
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based on e.g. association with physical disability. Differences in cut-off points lead to 
differences in prevalence of low SMI and sarcopenia.37
Besides a difference in sarcopenia prevalence depending on the care need, we 
observed that sarcopenia was associated with an impaired functional status. Body 
composition and muscle performance influence functional status. But whether low muscle 
mass,19 poor muscle strength,15, 20 slow gait speed,15 fat mass,39-41 or a combination of 
these factors is mostly affecting functional status is not fully understood yet. Martien et al.42
showed that older people in an assisted living facility have a better functional status 
(assessed by the modified Physical Performance Test, which includes a range of functional 
items) than nursing home residents. Our study shows that people receiving home care and 
living in a residential living facility score lower on functional status (mean GARS score 30-
33) compared to independently living older people (GARS score 20), but all groups still 
have (some) independence in ADL, as the maximum GARS score (indicating total 
dependency in ADL) is 72. People receiving home care or living in a residential living 
facility were not yet totally care dependent, though sarcopenia was more prevalent in these 
groups compared to independently living older people. Therefore empowerment of this 
group to maintain or improve their physical performance by e.g. (resistance) exercise, is 
thought to contribute to better functional outcomes, such as longer independence in   
ADL.2, 43, 44 Besides, early diagnosis of sarcopenia in independently living older people 
might prevent or delay the onset of sarcopenia. 
Table 2 Association of Sarcopenia with Functional Status, Comorbidities and Cognitive Status 
Variable Unadjusted Model OR (95% CI) Model 1 OR (95% CI) 
Functional status (GARS score) 1.09 (1.05-1.13) 2.11 (1.43-3.12) 
# of comorbidities Not significant Not significant 
Cognitive status (MMSE score) Not significant Not significant 
Age - 1.40 (1.21-1.62) 
Age*Functional status - 0.99 (0.99-1.00) 
Sex - Not significant 
BMI - 0.82 (0.73-0.91) 
GARS, Groningen Activity Restriction Scale; MMSE, Mini-Mental State Examination. 
Although previous studies showed an association between cognitive function22 and the 
number of comorbidities19 with sarcopenia, these were not significantly associated with 
sarcopenia in our model. That we did not find an association with cognitive status might be 
explained by the fact that our study sample had in general a high cognitive status and 
there was only a marginal (potentially not clinically relevant) difference in cognitive status 
between the groups. The number of comorbidities might drop from our model due to the 
stronger association of sarcopenia with functional status.  
A limitation of our study is that only 12% of the invited participants were willing to 
participate. A comparison between those who enrolled in the study and those who rejected 
or did not respond could not be made, since we were not allowed to ask participants their 
reasons for non-participation. Another study in the residential care setting reported that 
67% of the randomized subjects declined participation, stating reasons like a lack of 
interest, a fear of something new, and/or cognitive wellbeing.11 Arguing that our sample is 
likely healthier than the general target population, the ‘real’ prevalence of sarcopenia in the 
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community might be higher than presented. Furthermore the residential care group is 
rather small, therefore the ‘real’ prevalence in that group might deviate from the prevalence 
that we found in our sample. We did not include persons with a diagnosis of dementia, 
because of the expected burden of the home visit. This might limit the generalizability of 
our results. A methodological limitation is the bio-electrical impedance, which was selected 
as a measure for muscle mass for feasibility reasons, but might have overestimated or 
underestimated muscle mass.45 Persons with oedema, which might have interfered with 
the validity of the BIA measurement,23 were included in the analyses. Excluding those 
participants led to a sarcopenia prevalence of 26%. 
In conclusion, this study showed that sarcopenia was more prevalent in older people 
with a care need, i.e. with home care or living in a residential living facility. The impaired 
functional status associated with sarcopenia underlines the need for early diagnosis and 
treatment of sarcopenia, to stimulate longer independence and prevent disability.     
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Supplementary Data Chapter 3 – File 1 
Supplementary Figure 1 Adapted CONSORT flow diagram of inclusion
Assessed for eligibility by phone 
call (n = 282) 
No response (n = 2064); persons not 
willing to participate did not have to send 
back the informed consent 
Independently living 
older adults without 
additional care (n=157) 
Drop outs because of illness (n=9) 
Older adults living at home or in 
an assisted living facility with 
professional home care (n=41) 
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Home visits planned (n = 256) 
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Information letters sent  
(n = 2448)
Informed consents returned  
(n = 384) 
Declined to participate (n = 102) 
Not meeting inclusion criteria (n = 26) 
x Severe arthritis (n = 2) 
x Stroke with evident lingering 
symptoms (n = 2) 
x Disease of the nervous system  
(n = 2) 
x Pacemaker/ICD ( n = 5) 
x Dementia (n = 3) 
x Visually impaired (n = 2) 
x Paralyzed (n = 1) 
x Wheelchair (n = 1) 
x Other (n = 8) 
Home visits performed (n = 247) 
Analysed (n = 227) 
Excluded from analyses (n = 20) 
x Not able to perform grip strength  
(n = 1) 
x MMSE < 24 (n = 9) 
x Not able to perform MMSE (n = 1) 
x Prostheses/implants on both sides 
(n=9)
Older adults living in 
a residential living 
facility (n=29) 
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Supplementary Data Chapter 3 – File 2 
Supplementary Figure 2 Identification of sarcopenia according to the EWGSOP algorithm1
Participant  65 years 
n = 227 (48.5% female)
Normal grip strength  
 20 kg (women) n = 68 
 30 kg (men) n = 86 
Normal gait speed >0.8 m/s 
n = 186 
Sarcopenia n = 53 No sarcopenia n = 154 
Slow gait speed  0.8 m/s, n = 41 
Of which 27 persons had poor grip strength
Low SMI 
6.75 kg/m2 (women) n = 25
 10.75 kg/m2 (men) n = 28
Measure grip strength 
n = 186
Low grip strength  
< 20 kg (women) n = 20
< 30 kg (men) n = 12 
Measure skeletal muscle mass index 
n = 73
Measure gait speed 
n = 227
Normal SMI 
Women n = 17 
Men n = 3 
No sarcopenia n = 20  
Moderate (n = 41): 
8 persons had slow gait 
22 persons had poor grip
11 persons had poor grip 
& slow gait 
Severe (n = 12): 
1 person had slow gait 
4 persons had poor grip 
7 persons had poor grip 
& slow gait 
Of which 101 persons had 
moderately low SMI, 12 
persons had severely low 
SMI 
5 persons had slow gait 
6 persons had poor grip 
9 persons had slow gait 
& poor grip 
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CHAPTER 4 
Instruments to Assess Sarcopenia and Physical 
Frailty in Older People Living in a Community (Care) 
Setting: Similarities and Discrepancies 
This chapter was published as: DM Mijnarends, JMGA Schols, JMM Meijers, FES Tan, S 
Verlaan, YC Luiking, JE Morley, RJG Halfens. J Am Med Dir Assoc 2015;6(4):301-8.
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ABSTRACT 
Objectives: Both sarcopenia and physical frailty are geriatric syndromes causing loss of 
functionality and independence. This study explored the association between sarcopenia 
and physical frailty and the overlap of their criteria in older people living in different 
community (care) settings. Moreover, it investigated the concurrent validity of the FRAIL 
scale to assess physical frailty, by comparison with the widely used Fried criteria. 
Design: Data were retrieved from the cross-sectional Maastricht Sarcopenia Study 
(MaSS).
Setting: The study was undertaken in different community care settings in an urban area 
(Maastricht) in the South of the Netherlands.  
Participants: People were 65 years or older, gave written informed consent, were able to 
understand Dutch language and were not wheelchair bound or bedridden. 
Intervention: Not applicable. 
Measurements: Sarcopenia was identified using the algorithm of the European Working 
Group on Sarcopenia in Older People. Physical frailty was assessed by the Fried criteria 
and by the FRAIL scale. Logistic regression was performed to assess the association 
between sarcopenia and physical frailty measured by the Fried criteria. Spearman 
correlation was performed to assess the concurrent validity of the FRAIL scale compared 
with the Fried criteria.
Results: Data from 227 participants, mean age 74.9 years, was analysed. Sarcopenia was 
identified in 23.3% of the participants, when using the cut-off points for moderate 
sarcopenia. Physical frailty was identified in 8.4% ( 3 Fried criteria) and 9.3% ( 3 FRAIL 
scale criteria) of the study population. Sarcopenia and physical frailty were significantly 
associated (P = 0.022). Frail older people were more likely to be sarcopenic than those 
who were not frail. In older people who were not frail, the risk of having sarcopenia 
increased with age. Next to poor grip strength (78.9%) and slow gait speed (89.5%), poor 
performance in other functional tests was common in frail older people. The two physical 
frailty scales were significantly correlated (r = 0.617, P < 0.001).  
Conclusion: Sarcopenia and physical frailty were associated and partly overlap, 
especially on parameters of impaired physical function. Some evidence for concurrent 
validity between the FRAIL scale and Fried criteria was found. Future research should elicit 
the value of combining sarcopenia and frailty measures in preventing disability and other 
negative health outcomes.
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1. Introduction 
In the past two decades, the concepts and definitions of the geriatric syndromes 
sarcopenia and frailty have been frequently revised. In addition, their application in clinical 
practice for diagnosis and therapy has been challenged.1, 2 This has resulted in prevalence 
rates varying between 0.9% and 50% for sarcopenia3 and between 4.0% and 59.1% for 
frailty4 in the older community-dwelling population. The concept of sarcopenia partly 
overlaps with the concept of physical frailty (Supplementary Data, File 1), and therefore 
they might cover the same population. Sarcopenia was defined by the European Working 
Group on Sarcopenia in Older Persons (EWGSOP) as a loss of muscle mass in 
combination with a loss of muscle strength and/or physical performance.5 Frailty is defined 
as a clinical state of increased vulnerability of an older person to a stressor,6 such as pain 
or a psychologically stressful event. Therefore, a holistic approach of frailty encompasses 
a physical, psychological, and social domain; however, most frailty instruments focus on 
physical frailty only.7 Experts consider sarcopenia as a key component of physical frailty8-10
or as a key pathway between physical frailty and disability.11 However, little is currently 
known about the association between the criteria of sarcopenia and physical frailty.12
Although valid models of (physical) frailty exist in epidemiological research, more 
efficient models need to be developed to detect frailty in clinical practice.9 One of the most 
known and validated operational definitions of physical frailty in older people is the frailty 
phenotype.13, 14 Fried et al.14 defined physical frailty as the presence of three or more of the 
following criteria (Supplementary Data, File 1): (1) unintentional weight loss, (2) self-
reported exhaustion, (3) weakness (grip strength), (4) slow walking speed, and (5) low 
physical activity. Although the criteria are easy to perform, their assessment is not always 
doable in clinical practice because of a lack of resources, such as dynamometers, lack of 
space for a walk test, or lack of time to perform multiple measurements.13 A simple and 
rapid screening test, the FRAIL scale, has recently been developed and validated by 
Morley et al.15 It consists of five simple questions to assess physical frailty, related to (1) 
Fatigue, (2) Resistance, (3) Ambulation, (4) Illnesses, and (5) Loss of Weight. Such a rapid 
test might be more feasible for physicians to assess physical frailty in clinical practice and 
thus might facilitate diagnosis and treatment.  
Unravelling the association of the concepts and criteria of sarcopenia and physical 
frailty is needed to boost the development and implementation of an efficient screening 
tool. This study explored the association between the concepts of sarcopenia (by the 
EWGSOP, including both moderate and severely low skeletal muscle index) and physical 
frailty (by the Fried criteria with  3 positive criteria), and the overlap between their 
indicators in older people living in different community (care) settings. It is hypothesized 
that frail older people are more likely to be sarcopenic than those who are not frail. Our 
secondary aim was to examine the concurrent validity of the FRAIL scale to assess 
physical frailty compared with the Fried criteria. The Fried criteria will be used as 
comparison instrument, because it is widely known, validated, and commonly used.13,14,16,17
2. Methods 
2.1 Design and Setting 
Data were retrieved from the Maastricht Sarcopenia Study (MaSS), which was undertaken 
in older people in different community care settings in an urban area (Maastricht) in the 
502188-L-sub01-bw-Mijnarends
CHAPTER 4 
62
south of the Netherlands. MaSS is a cross-sectional study aiming to characterize 
sarcopenia by measuring the prevalence; associated factors, such as nutritional status, 
physical activity, and health; and economic consequences of sarcopenia. More information 
on study design and recruitment can be found at http://www.clinicaltrials.gov 
(NCT01820988). 
2.2 Participants 
The study was conducted in 247 participants aged 65 years or older in the following 
community settings: independently living without home care, older people receiving home 
care, and older people residing in an assisted or residential living facility. On request, the 
municipality of Maastricht provided a random sample of older people. An information letter 
and informed consent form were sent. Participants were included when they gave written 
informed consent, were able to understand the Dutch language, and were not wheelchair 
bound or bedridden. Participants with an implantable cardiac defibrillator/pacemaker, or 
suffering from a severe heart, joint, or nervous system disease or dementia were excluded, 
because of safety reasons and/or incapability of performing the physical tests. 
2.3 Measures 
Sarcopenia was assessed according to the EWGSOP algorithm, including muscle mass, 
strength, and physical performance.5 Muscle mass was assessed by bioelectrical 
impedance (BIA Akern Srl, Florence, Italy 101, 50 kHz), complying with the European 
Society for Clinical Nutrition and Metabolism Guidelines.18 Skeletal muscle mass was 
calculated using the equation developed by Janssen et al,19 because this equation is 
applicable in an older Caucasian population: skeletal muscle mass (kg) = 
([height2/resistance BIA analysis*0.401] + [gender*3.825] + [age*-0.071]) + 5.102, where 
height is in centimetres, resistance in ohms, male gender is coded 1 and female 0, and 
age in years. Muscle mass was then converted to skeletal muscle index (SMI) by dividing 
muscle mass by height (in m) squared. Muscle strength was assessed by a JAMAR hand-
held dynamometer (Sammons Preston, Inc, Warrenville, IL) to measure grip strength. 
Participants performed one try-out attempt followed by alternately three attempts with their 
left hand and three attempts with their right hand. Physical performance was assessed by 
normal walking speed (m/s) over a 4-meter track. These measures for muscle mass, 
strength, and performance were found to be valid and feasible in community-dwelling older 
people.20,21 Participants were classified as sarcopenic when they had a low muscle mass, 
defined as a low SMI  10.75 kg/m2 (in men) and  6.75 kg/m2 (in women),22 and low 
muscle strength (men < 30 kg; women < 20 kg), and/or low physical performance (walking 
speed  0.8 m/s). The cut-off points for low muscle mass include both moderate and 
severe low muscle mass.22 Other performance measures included balance testing and a 
five times chair stand, as part of the Short Physical Performance Battery (SPPB).23 
Physical frailty was assessed by the previously validated Fried criteria14 and the 
FRAIL scale.15,24 The 5 Fried criteria were assessed as follows: (1) a question about 
unintentional weight loss of more than 4.5 kg in the past year (0 = no, 1 = yes) and (2) a 
question about self-reported exhaustion (0 = rarely or a little of the time, 1 = a moderate 
amount of the time or most of the time). Both questions were available in the Dutch 
language. The third Fried criterion is weakness, measured by a hand-held dynamometer, 
with normal grip strength = 0, low grip strength = 1; cut-off points were stratified by gender 
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and body mass index according to Fried et al14 (Supplementary Data, File 2). The fourth 
criterion, walking speed, was measured by timing the participants’ normal walking speed 
over a 4-m track. Normal walking speed = 0, slow walking speed = 1; cut-off points were 
stratified by gender and height14 (Supplementary Data, File 2). The fifth and last Fried 
criterion is physical activity, measured by the Minnesota Leisure Time Physical Activity 
Questionnaire.25 Normal physical activity = 0, low physical activity = 1; cut-off points for low 
physical activity are less than 383 kcal/week (men) or less than 270 kcal/week (women). 
Participants were considered pre-frail or frail when they scored 1 to 2 or 3 to 5 points, 
respectively. The FRAIL scale15 consists of 5 questions: (1) fatigue (0 = none of the time, a 
little of the time, some of the time; 1 = most of the time, all of the time), (2) resistance 
(difficulty walking up 10 steps; 0 = no, 1 = yes), (3) ambulation (difficulty walking several 
hundred yards; 0 = no, 1 = yes), (4) illnesses (hypertension, diabetes, cancer, chronic lung 
disease, heart attack, congestive heart failure, angina pectoris, asthma, arthritis, stroke, 
and kidney disease; 0 = 0-4 illnesses, 1 = 5-11 illnesses), and (5) loss of weight (current 
weight minus weight 1 year ago; 0 = less than 5% change, 1 = change 5% or more). 
Subjects were considered pre-frail or frail when they scored 1 to 2 or 3 to 5 points on the 
FRAIL scale, respectively. The original FRAIL scale was translated from English to Dutch, 
with permission, by a native Dutch speaker. Backward translation was performed by a 
native English speaker. Afterward, the backward translation was compared with the 
original English version by another native English speaker. No differences were found 
between the original and the backward translated versions.  
Furthermore, characteristics of participants were collected through a questionnaire 
that recorded, among others, age, sex, community (care) setting (community-dwelling 
with/without home care, assisted living, residential living facility), chronic diseases (by the 
FRAIL scale and Charlson Comorbidity Index26), depression, and cognitive function (Mini-
Mental State Examination [MMSE]27). Height and weight were assessed by respectively a 
stadiometer (type SECA 213, Seca, Hamburg, Germany) and scale (type SECA 877). Both 
were measured with clothes, but without shoes, and body mass index (BMI) calculated as 
weight/height2. The validated Groningen Activity Restriction Scale (GARS), consisting of 
18 questions, was used to assess disability in (instrumental) activities of daily living.28
Answer categories range from “fully independently without any difficulty” (1) to “can only do 
it with someone’s help” (4), leading to a total score between 18 and 72. 
2.4 Statistical Analysis 
Data were analysed using SPSS version 21 (SPSS Inc, Chicago, IL). Logistic regression 
was performed to assess the association between the EWGSOP definition of sarcopenia 
and the Fried criteria. The association of sarcopenia (yes/no; dependent variable), the 
dichotomized frailty score (frail yes/no), as well as the total frailty score (score 0-5) derived 
from the physical frailty criteria, were studied in older people living in different community 
(care) settings. Age, sex, and BMI were included in the model as covariates. Chi-square 
tests were performed to assess differences in frail scores (0-5) and pre-frail status in the 
sarcopenic versus non-sarcopenic group. Concurrent validity, the extent to which a 
measure (FRAIL scale) is consistent with a gold standard (Fried criteria) was assessed by 
calculating bivariate (Spearman) correlations.  
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Table 1 Participant Characteristics 
Variable Sarcopenic  
(n = 53) 
Frail  
(Fried criteria) 
Frail  
(FRAIL scale)  
Total  
(n = 227) 
Pre-frail  
(n = 81) 
Frail  
(n = 19) 
Pre-frail  
(n = 57) 
Frail  
(n = 21) 
Age in years, mean (SD) 80.4 (7.1) 77.1 (7.3) 85.5 (8.6) 75.3 (7.4) 83.9 (7.6) 74.9 (7.2) 
Age in categories, n (%) 
65-74 12 (22.6) 33 (40.7) 4 (21.1) 30 (52.6) 4 (19.0) 122 (53.7) 
75-84 23 (43.4) 33 (40.7) 3 (15.8) 18 (31.6) 5 (23.8) 75 (33.0) 
85-95 18 (34.0) 15 (18.5) 12 (63.2) 9 (15.8) 12 (57.1) 30 (13.2) 
Sex, n female (%) 25 (47.2) 43 (53.1) 13 (68.4) 31 (54.4) 14 (66.7) 110 (48.5) 
BMI, mean kg/m2 (SD) 26.1 (3.3) 27.9 (4.6) 28.6 (5.1) 27.4 (4.9) 28.8 (5.4) 27.1 (3.9) 
Comorbidities, mean (SD) 2.7 (1.7) 2.8 (1.9) 3.5 (1.3) 2.7 (1.9) 4.1 (1.7) 2.1 (1.8) 
Most prevalent comorbidities, n (%)  
Chronic lung disease 13 (24.5) 25 (30.8) 6 (31.6) 17 (29.9) 10 (47.6) 45 (19.9) 
Diabetes 8 (15.1) 15 (18.5) 5 (26.3) 9 (15.8) 6 (28.6) 26 (11.5) 
Heart attack/infarct 9 (17.0) 12 (14.8) 3 (15.8) 5 (8.8) 3 (14.3) 26 (11.5) 
Hypertension 29 (54.7) 44 (54.3) 11 (57.9) 28 (49.1) 15 (71.4) 100 (44.1) 
Peripheral arterial disease 12 (22.6) 22 (27.2) 5 (26.3) 15 (26.3) 6 (28.6) 43 (18.9) 
Rheumatic disorder 18 (34.0) 35 (43.2) 9 (47.4) 20 (35.1) 12 (57.7) 72 (31.7) 
Depression, n (%) 5 (9.4) 8 (9.9) 3 (15.8) 9 (15.8) 2 (9.5) 17 (7.5) 
MMSE score, mean (SD) 28.3 (1.4) 28.7 (1.4) 28.7 (1.4) 28.9 (1.3) 27.7 (1.6) 28.7 (1.3) 
Community (care) setting, n (%) 
Independently living 19 (35.9) 44 (54.3) 3 (15.8) 31 (54.4) 3 (14.3) 157 (69.2) 
Home care 11 (20.8) 18 (22.2) 4 (21.1) 13 (22.8) 5 (23.8) 28 (12.3) 
Assisted living 6 (11.3) 6 (7.4) 4 (21.1) 2 (3.5) 4 (19.0) 13 (5.7) 
Residential living facility 17 (32.1) 13 (16.0) 8 (42.1) 11 (19.3) 9 (42.9) 29 (12.8) 
SMI, mean kg/m2 (SD)
Men 9.3 (0.8) 9.5 (1.0) 9.7 (1.3) 9.6 (1.1) 9.3 (1.2) 9.5 (0.9) 
Women 6.0 (0.5) 6.9 (1.2) 6.6 (1.2) 6.8 (1.2) 7.1 (1.3) 6.8 (1.0) 
Low skeletal muscle index, n (%) 53 (100.0) 58 (71.6) 12 (63.2) 40 (70.2) 11 (52.4) 166 (73.1) 
Poor grip strength, n (%) 44 (83.0) 43 (53.1) 15 (78.9) 21 (36.8) 16 (76.2)  59 (26.0) 
Slow gait speed, n (%)  27 (50.9) 21 (25.9) 17 (89.5) 13 (22.8) 20 (95.2) 41 (18.1) 
Gait speed, mean m/s (SD) 0.8 (0.2) 0.9 (0.2) 0.5 (0.2) 0.9 (0.2) 0.5 (0.2) 1.0 (0.3) 
Balance score, mean (SD) 3.2 (1.1) 3.6 (0.7) 2.2 (1.4) 3.6 (0.7) 2.5 (1.5) 3.6 (0.8) 
Chair stand 5x, mean s (SD)* 16.7 (6.4) 14.9 (5.2) 18.0 (5.5) 15.5 (5.9) 19.4 (5.8) 13.3 (4.4) 
SPPB score, mean (SD) 7.8 (2.6) 9.3 (1.9) 4.6 (2.7) 9.4 (1.9) 4.8 (2.7) 9.9 (2.4) 
GARS score, mean (SD) 29.4 (11.3) 25.0 (8.1) 43.5 (10.2) 25.4 (6.9) 44.3 (10.3) 23.4 (9.0) 
Fried criteria, n positive score (%) 
Weight loss 0 (0.0) 4 (4.9) 1 (5.3) 4 (7.0) 1 (4.8) 5 (2.2) 
Exhaustion 12 (22.6) 20(24.7) 13 (68.4) 17 (29.8) 10 (47.6) 33 (14.5) 
Weakness (grip)  43 (81.1) 52 (64.2) 18 (94.7) 21 (36.8) 18 (85.7) 70 (30.8) 
Slow walking speed 20 (37.7) 15 (18.5) 17 (89.5) 7 (12.3) 19 (90.5) 32 (14.1) 
Low physical activity 17 (32.1) 16 (19.8) 17 (89.5) 13 (22.8) 13 (61.9) 33 (14.5) 
FRAIL scale, n positive score (%) 
Fatigue 13 (24.5) 19 (23.5) 11 (57.9) 17 (29.8) 17 (81.0) 34 (15.0) 
Resistance 25 (47.2) 22 (27.2) 18 (94.7) 27 (47.4) 21 (100.0) 48 (21.1) 
Ambulation 18 (34.0) 19 (23.5) 16 (84.2) 16 (28.1) 21 (100.0) 37 (16.3) 
Illnesses 1 (1.9) 1 (1.2) 2 (10.5) 0 (0.0) 3 (14.3) 3 (1.3) 
Loss of weight 7 (13.2) 9 (11.1) 3 (15.8) 15 (26.3) 4 (19.0) 19 (8.4) 
Sarcopenia as defined by the EWGSOP: low muscle mass, cut-off point  10.75 kg/m2 (in men) and  6.75 kg/m2,
and low muscle strength (men < 30 kg; women < 20 kg) and/or low physical performance (walking speed < 0.8 
m/s). Subjects are considered frail by the Fried criteria when they score 3-5 points; idem for the FRAIL scale. 
*n = 205, since not all participants were able to perform the 5x chair stand. 
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No official gold standard for physical frailty exists; the Fried criteria were used as 
comparison instrument because it is widely known, validated, and commonly used. 
Concurrent validity was rated positive when the correlation was 0.70 or higher.29
2.5 Ethical Considerations 
The Medical Ethics Committee of the Academic Hospital Maastricht and Maastricht 
University approved the MaSS study. 
3. Results 
Of the 384 people who returned the informed consent form, 282 people were willing to 
participate, of which 256 participants met the inclusion criteria (Supplementary Data, File 3: 
flow diagram of inclusion). Of those 256 people, 9 participants dropped out due to illness 
and 20 people were excluded from the analyses because of the following: prosthesis on 
both sides that might have influenced muscle mass measurement (n = 9), not able to 
perform the grip strength test (n = 1), or not able to perform the MMSE (n = 1) or MMSE 
score less than 24 (n = 9). The other 227 participants had complete data. The total sample 
included 157 independently living older people, and 70 participants receiving care (n = 28 
home care, n = 13 assisted living, n = 29 residential living).  
The participants’ characteristics are shown in Table 1. Sarcopenia was identified in 53 
participants (23.3%) and physical frailty in 8.4% (n = 19) and 9.3% (n = 21) according to 
the Fried criteria and FRAIL scale, respectively. Of the participants, 35.7% and 25.1% 
were pre-frail according to, respectively, the Fried criteria and FRAIL scale. Most of the 
sarcopenic (64.1%) and frail (84.2% by Fried and 85.7% by the FRAIL scale) older people 
received some form of care services. Both sarcopenic and frail older people have higher 
GARS scores than people without sarcopenia or frailty, indicating more disability in 
activities of daily living. For all functional parameters, the frail group seemed to score lower 
than the pre-frail group and the sarcopenic group.  
Table 2 Sarcopenia Versus Frailty 
Variable Sarcopenic (n = 53) Not Sarcopenic (n = 174) P-value* 
Fried criteria, n (%) < 0.001 
0 points (not frail; n = 127) 3 (5.7) 124 (71.3) 
1-2 points (pre-frail; n = 81) 38 (71.7) 43 (24.7) 
3-5 points (frail; n = 19) 12 (22.6) 7 (4.0) 
FRAIL scale, n (%) < 0.001 
0 points (not frail; n = 149) 22 (41.5) 127 (73.0) 
1-2 points (pre-frail; n = 57) 18 (34.0) 39 (22.4) 
3-5 points (frail; n = 21) 13 (24.5) 8 (4.6) 
Percentages are calculated by dividing the number of (not/pre)frail older people by the number of (not) sarcopenic 
older people. E.g. sarcopenic participants that are not frail = 3/53 = 5.7%. *P-value Chi-square test: comparison 
between not sarcopenic and sarcopenic participants. 
In frail older people (Fried criteria  3), the percentage of low SMI was 63.2%, whereas 
poor grip strength (78.9%) and slow gait speed (89.5%) were even more prevalent. 
Furthermore, frail older people most often had a positive score on the frailty indicators 
weakness or resistance and slow walking speed and ambulation, whereas a positive score 
on weight loss or illnesses was less frequent (Table 1). Sarcopenic and frail older people 
have significantly (all P values < 0.05) lower short physical performance battery (SPPB) 
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and balance scores, slower gait speed, and a longer chair stand time than their peers who 
are not sarcopenic or not frail (Table 1). 
3.1 Overlap between Sarcopenia and Physical Frailty 
Of the sarcopenic older participants (n = 53), 3 participants were not frail (5.7%), 38 
participants were pre-frail (71.7%), and 12 participants (22.6%) were frail according to the 
three positive Fried criteria (Table 2). In participants without sarcopenia (n = 174), most 
were not frail (71.3%), 43 participants were pre-frail (24.7%), and 7 participants were frail 
(4.0%). Of the frail older people (n = 19), 12 participants had sarcopenia, whereas of the 
non-frail older people (n = 127), only three participants had sarcopenia (Table 2). 
Sarcopenia was associated with the dichotomized score (frail yes/no; P = 0.022) and with 
the total score (0-5) of the Fried criteria (P < 0.001).  
Results of the final regression model are shown in Figure 1, revealing that frail 
older people have a 60% risk of having sarcopenia. In older people who were not frail, the 
risk of having sarcopenia increased with age. Additionally, looking at the individual criteria 
of sarcopenia, 12 (7.2%) of 166 individuals with low muscle mass, 15 (25.4%) of 59 
individuals with poor grip strength, and 17 (41.5%) of 41 individuals with slow gait speed 
were classified as physically frail. 
3.2 Concurrent Validity of the FRAIL Scale Versus the Fried Criteria 
Thirteen participants were classified as physically frail by both scales, 14 participants were 
classified as physically frail by one scale but not by the other (Figure 2). The Spearman 
correlation between the scales using a dichotomized outcome (frail yes/no) was r = 0.617, 
P < 0.001. The correlation between both scales using the total score (0-5), was r = 0.601, 
P < 0.001.
Figure 1 Overlap between sarcopenia (EWGSOP criteria) and frailty 
Sarcopenia 
n = 4 
n = 5
n = 5 
n = 36 
n = 8 
n = 3 n = 2
Frail according to 
the FRAIL scale 
Frail according to 
the Fried criteria 
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4. Discussion 
This study showed that sarcopenia and physical frailty, identified in older people living in 
different community (care) settings, were significantly associated. Frail older people had a 
higher risk of having sarcopenia than older people who were not frail. In frail older people, 
next to the criteria poor grip strength and slow gait speed, which are determinants for both 
frailty and sarcopenia, poor performance in other functional tests was common. 
Furthermore, some evidence was found supporting concurrent validity between the FRAIL 
scale and the Fried criteria. A notable finding is that both scales identified an almost similar 
number of frail people, but partly different individuals.  
Physical frailty and sarcopenia share to some extent the same criteria, such as loss of 
strength and decreased physical performance. Based on the data from our study, it seems 
that most sarcopenic individuals are pre-frail or frail, whereas most of the non-sarcopenic 
individuals are not (pre)-frail. The overlap that we found might be influenced by the 
measurement method (BIA, cut-off points low SMI) and definition of sarcopenia30-32 (e.g., 
the EWGSOP criteria have different cut-off points for muscle mass and strength compared 
with the recently published Foundation for the National Institutes of Health criteria, which 
define sarcopenia based on muscle mass corrected for BMI and poor grip strength).33
Using uncorrected cut-off points for SMI could have led to an overestimation of sarcopenia 
status. On the other hand, the overlap with sarcopenia is larger when pre-frail individuals 
are also taken into account. Frail older people were more disabled in activities of daily 
living; however, looking at frail older people without disability was not possible because of 
the small sample size. Furthermore, the pre-frail group was bigger than the frail group, 
which should be kept in mind when interpreting the percentage overlap with sarcopenia. 
Figure 2 Association of frailty (yes/no) by the Fried criteria in terms of risk is based on the logistic 
model logit (p) = -8.68 + 12.03 * Fried + 0.16*Age + 0.13 * Age*Fried – 0.17*BMI. Sex was not 
significant and therefore not included in the final model. BMI was set at 27.1 (mean of total sample). 
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The concurrent occurrence of frailty and sarcopenia is likely to increase due to the aging 
population.34 Frisoli et al35 found that almost 53% of the frail older people were also 
sarcopenic, whereas 42% of the older people who were not frail had sarcopenia. Our study 
confirms their results (i.e., frail older people have a higher risk of sarcopenia compared 
with the older people who were not frail). For the older people who were not frail, the risk of 
having sarcopenia was age-dependent. This means that frail older people aged 60 to 70 
years have a higher risk of sarcopenia of about 60%, compared with a risk of 
approximately 10% in people who are not frail. However, at ages 80 to 90 years, the risk of 
having sarcopenia does not differ between frail and non-frail older people, and is about 
60% in both groups. This might be explained by the fact that, although overlap is found 
between the concepts of sarcopenia and frailty, the concepts are not equivalent (e.g., at 
older ages muscle loss might become more severe, leading to a diagnosis of sarcopenia in 
older people who are not frail). Looking at the individual criteria of sarcopenia and frailty, it 
seems that especially parameters of physical function, such as poor strength and slow gait 
speed, overlap. Recent studies36,37 show that grip strength and gait speed might be 
promising measures for those who want to use sarcopenia as a paradigm for frailty. Our 
results show that poor grip strength and slow gait speed are highly prevalent in frail older 
people. Screening for sarcopenia might therewith also identify a considerable number of 
people with (a risk of) frailty. Moreover, both sarcopenic and frail groups have low SPPB, 
balance, and chair stand scores.  
In our study, we found a low number of frail older people with weight loss. Other 
studies found slightly higher percentages of weight loss, namely 8.5%38 and 9.3% in men, 
and 17.2% in women,39 whereas Subra et al37 and Tavassoli et al40 found much higher 
rates of weight loss (24.4%-32.9%) in patients screened for frailty by their general 
practitioner. This might be explained by other characteristics of their study population, such 
as a higher mean age, a larger number of people receiving care (household support; 66%) 
and inclusion of people with low MMSE scores. Also, the methodology for determining 
weight loss (i.e., by actually measuring or via a questionnaire), as well as the time period 
for such weight loss (e.g., several months up to 1 year) might lead to variation. 
The physical frailty scales used in this study were both previously validated,14,15,23,41,42
and found to be feasible to assess physical frailty in community-dwelling older people in 
different care settings. Although both scales identified almost the same number of 
physically frail older people, partly different individuals were identified, as also is indicated 
by a moderate correlation between the scales. The reason for this might be because only 
the FRAIL scale includes a question about illnesses, whereas only the Fried criteria include 
a physical activity criterion. Another reason could be that the FRAIL scale consists only of 
questions, whereas the Fried criteria also include performance-based measures. When 
responding to questions, older people might over- or underestimate their own abilities. 
Furthermore, the absence of a gold standard impedes evidence-based statements over 
what frailty is exactly and what its consequences are; this hampers the comparison of 
studies using different tools. In a recent study by Rodríguez-Mañas et al,2 several experts 
tried to reach consensus regarding a frailty definition. They reached agreement on the 
main dimensions of frailty (physical performance, including gait speed and mobility, 
nutritional status, mental health, cognition), but not yet on its operational definition. Cooper 
et al43 state that evidence-based knowledge on assessment techniques for sarcopenia and 
frailty is missing (e.g., no accepted end points for intervention trials targeting at sarcopenia 
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and frailty exist). Operational definitions for frailty seem to focus on the consequences of 
sarcopenia.44 Cesari et al45 proposed that the assessment of sarcopenia and frailty should 
be refined by putting more focus on physical function impairment, as a precursor of 
disability. Recently, Cruz Jentoft and Michel11 suggested that diagnostic criteria for 
sarcopenia may be used to measure physical frailty in research and practice, as 
sarcopenia might be easier to operationalize than physical frailty for clinical prevention, 
diagnosis, and treatment. This seems logical, as many of the adverse outcomes of frailty 
are probably mediated by sarcopenia.11 Recently, several experts reached consensus over 
the importance of screening all older people for frailty when visiting a health care 
provider.46,47 In the Netherlands, this idea is currently being reconsidered due to the 
substantial number of false positives that are detected.48 It should be recognized that at 
present we lack intervention studies demonstrating that interventions for frailty improve 
health outcomes.6 Adding sarcopenia-related measures to frailty screening, or focusing on 
physical function45 might enhance the identification of the number of people at high risk of 
negative adverse outcomes. There is a reasonable amount of data suggesting that 
exercise and/or protein supplementation enhances physical function and, therefore, might 
prevent disability in people with sarcopenia.45, 49, 50
Preventing sarcopenia and frailty seems most beneficial in community settings in 
which people do not receive care yet. Screening seems most important in settings in which 
people receive care, like home care, assisted living facilities, and residential living facilities, 
as our results indicate that in those settings the prevalence of sarcopenia and frailty seems 
highest. Screening might be extended to acute care settings, nursing homes, and 
hospitals, because in those settings sarcopenia was identified in at least 1 of 3    
patients.51-53
Some limitations of this study should be addressed. Because of the cross-sectional 
nature of this study, no firm conclusions with regard to cause and consequences can be 
drawn. The overlap found between sarcopenia and frailty is related to the chosen 
definitions and cut-off points for sarcopenia and frailty. Bioelectrical impedance was used 
to assess muscle mass, which is not a gold standard and might have led to an over- or 
underrepresentation of people with low muscle mass. Also, 15% responded to the 
invitation to participate. No information was collected about the group not willing to 
participate, because they did not have to send back the informed consent form. Therefore, 
a healthier group might have been included because people in better physical condition 
might be more inclined to participate compared with people with a poorer physical 
condition. As the sample of frail older people is rather small, the corresponding 
percentages should be interpreted with caution. The correlation found between the two 
frailty scales is a lower bound, because the underlying (true) correlation is attenuated 
because these measurement instruments are not perfectly measuring the latent trait 
physical frailty. In other words, the Fried criteria are not officially a “gold” standard. No 
correction for this attenuation could be made because no data are available about the 
reliability of the Fried criteria.54
In conclusion, sarcopenia and physical frailty were associated and partly overlap, 
especially on parameters of impaired physical function. Some evidence for concurrent 
validity between the FRAIL scale and Fried criteria was found. Future research should elicit 
the value of combining sarcopenia and frailty measures in preventing disability and other 
negative health outcomes. 
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Supplementary Data Chapter 4 – File 1 
Supplementary Table 1 Concepts of Physical Frailty and Sarcopenia 
Criteria Sarcopenia5 Fried Criteria14 FRAIL Scale15
Muscle mass Physical examination No No 
Muscle strength/weakness/resistance Physical examination Physical examination Questionnaire 
Physical performance (e.g. walk test) Physical examination Physical examination Questionnaire 
Physical activity level No* Questionnaire No 
Weight loss No* Question  or  physical 
examination 
Questionnaire 
Self-reported exhaustion No Questionnaire No 
Fatigue No No Questionnaire 
Illnesses No* No Questionnaire 
*Those factors are not included in sarcopenia assessment but are involved in the onset and progression of 
sarcopenia.5
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Supplementary Data Chapter 4 – File 2 
Cut-off Points for Grip Strength and Walking Speed 
Cut-off points for grip strength criterion for frailty, stratified by gender and body mass index 
according to Fried et al.14
Low grip strength if:  
Males 
BMI  24 kg/m2 and grip strength  29 kg
BMI  24.1-26 kg/m2 and grip strength  30 kg  
BMI  26.1-28 kg/m2 and grip strength  30 kg  
BMI > 28 kg/m2 and grip strength  32 kg
Females 
BMI  23 kg/m2 and grip strength  17 kg
BMI  23.1-26 kg/m2 and grip strength  17.3 kg  
BMI  26.1-29 kg/m2 and grip strength  18 kg  
BMI > 29 kg/m2 and grip strength  21 kg
Cut-off points for walking speed, stratified by gender and height according to Fried et al.14
Slow walking speed if:  
Males 
Height  173 cm and walking speed  0.65 m/s  
Height > 173 cm and walking speed  0.76 m/s 
Females 
Height  159 cm and walking speed  0.65 m/s 
Height > 159 cm and walking speed  0.76 m/s 
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Supplementary Data Chapter 4 – File 3 
Supplementary Figure 1 Adapted CONSORT flow diagram of inclusion 
Assessed for eligibility  
by phone call  
(n = 282) 
No response (n = 2064); persons not 
willing to participate did not have to send 
back the informed consent
Independently living 
older adults without 
additional care (n = 157) 
Drop outs because of illness (n = 9) 
Older adults living at home with professional home 
care (n = 28), older adults living in an assisted living 
facility (n = 13) or residential living facility (n = 29)
El
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Home visits planned  
(n = 256) 
En
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lm
en
t
Information letters sent  
(n = 2448) 
Informed consents returned  
(n = 384) 
Declined to participate (n = 102) 
Not meeting inclusion criteria (n = 26) 
x Severe arthritis (n = 2) 
x Stroke with evident lingering 
symptoms (n = 2) 
x Disease of nervous system (n = 2) 
x Pacemaker/ICD (n = 5) 
x Dementia (n = 3) 
x Visually impaired (n = 2) 
x Paralyzed (n = 1) 
x Wheelchair (n = 1) 
x Other (n = 8) 
Home visits performed  
(n = 247)
Analysed  
(n = 227) 
Excluded from analyses (n = 20) 
x Not able to perform grip strength  
(n = 1) 
x MMSE < 24 (n = 9) 
x Not able to perform MMSE (n = 1) 
x Prostheses/implants on both sides  
(n = 9) 
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Burden-Of-Illness of Dutch Community-Dwelling  
Older Adults with Sarcopenia: Health Related 
Outcomes and Costs
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502188-L-sub01-bw-Mijnarends
CHAPTER 5 
80
ABSTRACT 
Objective: To explore the burden-of-illness of Dutch community-dwelling older adults with 
sarcopenia, in terms of disability in activities of daily living (ADL), quality of life (QoL) and 
costs from a societal perspective. 
Methods: The Maastricht Sarcopenia Study (MaSS) was performed in adults  65 y, 
receiving 1) no care, 2) home care/assisted living facility, or 3) care in a residential living 
facility. Sarcopenia was defined according to the European Working Group on Sarcopenia 
algorithm. Disability in ADL was measured with the Groningen Activity Restriction Scale 
(GARS); QoL with the EQ-5D-5L. Subjects were questioned about their health care use 
and health-related costs (societal perspective). Data are presented for sarcopenic and 
(age and sex matched) non-sarcopenic subjects. Bootstrapping was performed to estimate 
95% CI around the mean costs. Several subgroup (age, sex, living situation, comorbidities) 
and sensitivity analyses were performed. 
Results: Sarcopenic subjects (n = 53) scored significantly worse on health-related 
outcomes compared with non-sarcopenic subjects (n = 174; GARS 29±11.3 vs. 22±7.3, P 
< 0.001, QoL 0.78±0.2 vs. 0.86±0.2, P = 0.001). This difference was, except for the 
subscale ADL, no longer significant when compared with age and sex matched non-
sarcopenic subjects (GARS 27±10.6, P = 0.097, QoL 0.81±0.2, P = 0.362). Mean health 
care costs of sarcopenic subjects (€ 4325, 95% CI: € 3198-€ 5471) were significantly 
higher than those of non-sarcopenics (€ 1533, 95% CI: € 1153-€ 1912), and higher, i.e.     
€ 1557 per three months (though not significant) compared with age and sex matched non-
sarcopenics (€ 2768, 95% CI: € 1914-€ 3743). Living situation (residential care) was a 
main driver of costs.  
Conclusions: Community-dwelling sarcopenic older adults had a higher health and 
economic burden than non-sarcopenic older adults. This was importantly driven by the 
living situation – keeping older adults independent and out of care-dependent settings may 
contribute to a reduction of health care costs.  
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1. Introduction 
Sarcopenia, the loss of muscle mass and function, is associated with poor health 
outcomes, such as a lower quality of life (QoL) and an increased risk of disability in 
activities of daily living (ADL), institutionalization and mortality.1-5 In 2010, the European 
Working Group on Sarcopenia in Older People (EWGSOP) suggested an algorithm to 
identify sarcopenia, based on low muscle mass in combination with poor strength or 
performance.6 Using this algorithm, about 1-29% of the community-dwelling older adults 
and 14-33% of older adults living in a long-term care institution have sarcopenia.7
In addition to being associated with negative health outcomes, sarcopenia could lead 
to a potential economic burden due to the related costs of disability, falls, 
institutionalization and comorbidities.8,9 Despite the fact that knowing the costs of a 
disease is important for policy makers,10, 11 only one study was found estimating the costs 
of sarcopenia in non-institutionalized adults aged  60 y.8 This study defined sarcopenia as 
low muscle mass, and found that sarcopenia alone accounted for about 1.5% ($18.5 
billions) of the direct total health care expenditures in the United States.8 This equals about 
an extra $900 (about € 677) per (sarcopenic) person per year. In that study, costs were 
indirectly calculated, using relative risk estimates of sarcopenia-related physical disability, 
previously reported costs of disability (from two national surveys conducted in 1980-1995) 
and previously reported prevalence rates of sarcopenia.8, 12 They did not compare 
sarcopenic with (matched) non-sarcopenic older adults, and to the best of our knowledge 
there are no studies that have measured actual health care costs in sarcopenic older 
adults in a European setting.  
With an ageing population and the current pressure on health care systems and 
government budgets, it is relevant to get insight in the burden of sarcopenia in terms of 
health-related outcomes and costs. Early identification and management of sarcopenia (by 
e.g. resistance exercise combined with nutritional supplementation13) could reduce the 
impact of sarcopenia on both the individual (health related outcomes) as well as the 
society (costs of health care). Evidence for a substantial burden of disease strengthens the 
need for interventions and may support policy decisions with regard to prevention, 
diagnosis and treatment.10, 11
The overall aim of this paper is to explore the burden-of-illness of Dutch community-
dwelling older adults with sarcopenia, in terms of disability in ADL, quality of life, and costs, 
from a societal perspective. Older adults with sarcopenia were identified using the 
EWGSOP algorithm.6
2. Methods 
This manuscript follows the Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) and the Dutch guideline for costing research.14, 15
2.1 Target Population and Subgroups 
The Maastricht Sarcopenia Study (MaSS) was performed in community-dwelling adults 
aged  65 years. Community-dwelling older adults were included when they were living: 
x Independently at home without additional care;  
x At home or in an assisted living facility with professional home care;  
x In a residential living facility.  
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In group 3 meal service, household and personal support were included as standard care, 
contrary to nursing homes where medical and paramedical care are also offered.16 The 
base case sample existed of all subjects with complete data. Subgroups were made for 
age (65-80 years/80+ years), sex (male/female), living situation (no care/home care & 
assisted living/residential living) and number of comorbidities (no comorbidities/1-3 
comorbidities/3+ comorbidities), as these variables were expected to influence the costs. 
Subjects with oedema were included in the base case, although oedema might influence 
the measurement of muscle mass. As the reliability of the answers on the questionnaires 
might be affected in people with poor cognitive function, these subjects were excluded in 
the base case. To assess the impact of including subjects with oedema and excluding 
subjects with low cognitive function, these subjects were included and excluded, 
respectively, in the sensitivity analyses. Furthermore, as some other researchers use low 
muscle mass as sole criterion for sarcopenia, we also explored the costs of subjects with 
low versus normal muscle mass.  
2.2 Study Perspective and Time Horizon 
A societal perspective was chosen, meaning that all health-related costs for society were 
included, no matter who paid for it.17 In this study, a time horizon of three months was 
chosen. To prevent recall bias, the measurement period is ideally no longer than three 
months, although patients might remember specific forms of health care for a longer 
period.14 To further improve the completeness of the data, subjects were asked to check 
their agenda or calendar for appointments with a health care provider in the previous three 
months. 
2.3 Sarcopenia Measures 
Sarcopenia was assessed according to the algorithm of the European Working Group on 
Sarcopenia in Older People (EWGSOP).6 Muscle mass was assessed by bioelectrical 
impedance analysis (BIA Akern Srl, Florence, Italy 101, 50 kHz), muscle strength by a 
JAMAR handheld dynamometer (Sammons Preston, Inc, Warrenville, IL) and physical 
performance by normal gait speed over four meters, as described in a previous paper.18
These measures were found to be valid and feasible for identifying sarcopenia in a home-
setting.19 Cut-off points for low skeletal muscle index (SMI) were  10.75 kg/m2 (in men) 
and  6.75 kg/m2 (in women), reflecting those with moderate and severely low SMI. Cut-off 
points for poor grip strength were < 30 kg for men, < 20 kg for women, and for 
performance low gait speed  0.8 m/s, as derived from the EWGSOP.6 Subjects were 
classified as sarcopenic when they had low muscle mass in combination with poor grip 
strength and/or low physical performance.6
2.4 Health Outcomes Measures 
Disability in ADL was measured by the validated Groningen Activity Restriction Scale 
(GARS).20 This questionnaire consists of 11 questions about ADL and 7 questions about 
instrumental ADL, such as being able to do grocery shopping or prepare a meal.20 Answer 
categories range from “fully independent without any difficulty” (score 1) to “fully 
dependent” (score 4). This leads to a total score between 18 and 72, with higher scores 
indicating more disability in ADL.20
502188-L-sub01-bw-Mijnarends
HEALTH AND ECONOMIC BURDEN OF SARCOPENIA 
83
QoL was assessed by the generic, validated EQ-5D-5L questionnaire.21, 22 The EQ-5D-5L 
questionnaire consists of 5 questions corresponding to the dimensions mobility, self-care, 
usual activities, pain/discomfort and anxiety.23 The dimension scores (1 = no problems at 
all to 5 = extreme problems) are combined into a health state score (e.g. 11111 for a 
patient that has no problems at all on any of the five dimensions) and subsequently 
converted into an index value between 0-1 using a country specific value set.23, 24 
Furthermore, the EQ-5D-5L includes a single question about self-rated overall health, with 
scores ranging from 0 (worst imaginable health state) to 100 (best imaginable health 
state). 21, 23, 25
2.5 Economic Outcome Measure 
Health care utilization was assessed bottom-up, by asking subjects about their health care 
use in the past three months (18 questions). The questionnaire was developed for the 
purpose of this study, taking into consideration the steps in developing a cost 
questionnaire stated by Thorn et al.,26 and was tested for feasibility in a pilot study.27
Questions were asked regarding costs within the health care sector (e.g. visits to a general 
practitioner, hospital, paramedical staff, psychological support) and costs for the 
patient/family (e.g. medication, travelling costs to health facility, purchase of medical aids, 
in-house adjustments, use of foodservice and nutritional supplements, unpaid support by 
family or friends), Supplementary Data, Table 1. A societal perspective also takes into 
account costs of productivity losses, but this was not applicable here, since this study only 
included older adults who had passed the retirement age of 65 years.  
2.5.1 Estimating Costs  
The Dutch costing guideline was used for methodological standardization and to obtain 
cost prices of health care utilization.14 Costs of medication were retrieved from the Drug 
Information System of the National Health Care Institute (http://www.medicijnkosten.nl) and 
the website of the Dutch Healthcare Authority (http://www.nza.nl). Delivery costs for the 
medication (assuming that medication is prescribed at least once per three months) were 
included in the total costs of medication, as recommended by the Dutch costing 
guideline.14 In case the manufacturer of medication was unknown, the lowest price for that 
specific medicine was taken. Market prices were used to estimate costs of vitamin 
supplements. Costs of external food service and in-house adjustments were based on self-
report by the participant. Travel costs were based on the mean distance to a health care 
provider and mean transportation costs per km, as stated in the Dutch costing guideline.14
2.5.2 Currency, Price Date and Conversion 
Unit prices are shown in euros. The year 2014 (end of the data collection) was taken as 
reference year. All unit prices were converted to 2014 using price index data from Statistics 
Netherlands.28 Total costs of health care use (Supplementary Data, Table 3) were obtained 
by multiplying the volumes of health care use (Supplementary Data, Table 1) by the 
corresponding unit prices (Supplementary Data, Table 2).  
2.6 Recruitment and Data Collection  
Enrolment took place from May 2013 until February 2014. The municipality of Maastricht 
randomly selected 2448 addresses of adults older than 65 years, who were invited to 
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participate. Inclusion criteria encompassed: given written informed consent, able to 
understand the Dutch language, not wheelchair bound or bedridden. Subjects with an 
implantable cardiac defibrillator/pacemaker were excluded since the measurement of 
muscle mass by bioelectrical impedance forms a potential hazard in these conditions.29
Subjects with severe heart, joint or nervous system diseases or dementia were excluded, 
due to reasons of safety, burden and ethical accountability. Data of subjects who met the 
inclusion criteria (n = 256) were collected by two trained researchers during a two-hour 
home visit. All questionnaires were administered face-to-face. In addition to the 
sarcopenia, health and economic measures described above, data collection included 
assessment of height, weight, cognitive function,30 and chronic diseases,31 as described 
previously.18
2.7 Statistical Methods 
Data was analysed using SPSS version 22 (SPSS Inc, Chicago, IL). Disability in ADL, QoL 
and cost data are presented for sarcopenic and (age and sex matched) non-sarcopenic 
subjects. A manually, randomly selected age and sex matched non-sarcopenic group was 
created, as health care utilization is age and sex dependent, and these two factors are 
unchangeable.32 Differences between sarcopenic and (age and sex matched) non-
sarcopenic subjects regarding age, sex, BMI, cognitive function, QoL and disability in ADL 
were assessed by Student’s t-test (continuous variables), Chi-square (categorical 
variables) or Mann-Whitney U tests (non-normally distributed continuous variables). Even 
though the cost data turned out to be skewed, arithmetic means are presented, being 
generally the preferred way of reporting cost differences.33 Non-parametric bootstrapping 
with 1000 replications was performed to estimate 95% confidence intervals (CI) around the 
mean costs and to assess significant differences in costs between sarcopenic and non-
sarcopenic subjects and between subgroups. Data are presented as means ± SD or 
means with 95% CI. A P value of < 0.05 was considered significant. 
3. Results 
Of the 256 older adults who agreed to participate in the MaSS study and met the inclusion 
criteria, 9 subjects dropped out due to illness and 20 subjects were excluded from the 
analyses because of missing data for grip strength (n = 1) or cognitive function (n = 1), 
poor cognitive function (n = 8), invalid muscle mass measurement (n = 9) or both (n = 1). 
Therefore, the total analytical sample was 227. 
3.1 Characteristics of the Study Population 
Characteristics of subjects are shown in Table 1. Mean age of the subjects was 74.9±7.2y. 
The prevalence of sarcopenia was 12.1% in community-dwelling, 41.5% in home 
care/assisted living, and 58.6% in residential living subjects. Sarcopenic subjects (n = 53) 
were significantly older, had more comorbidities and were more often living in a residential 
living facility compared with non-sarcopenic subjects (n = 174; Table 1). When comparing 
sarcopenic with age and sex matched non-sarcopenic subjects (n = 53), only BMI differed 
significantly (P = 0.001).  
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Table 1 Characteristics of the Study Sample 
Variable Sarcopenic  
(n = 53) 
Non-Sarcopenic,  
Age and Sex Matched  
(n = 53) 
Non-Sarcopenic  
(n = 174) 
Age in years, mean (SD) 80.4 (7.1) 79.7 (7.0) 73.3 (6.4)*
Sex, n female (%) 25 (47.2) 25 (47.2) 85 (48.9) 
Body mass index, mean kg/m2 (SD) 26.1 (3.3) 28.8 (4.6)* 27.5 (4.0)*
# of comorbidities, mean (SD)  2.7 (1.7) 2.4 (1.9) 1.9 (1.7)*
MMSE score, mean (SD) 28.3 (1.4) 28.3 (1.4) 28.9 (1.3)*
Living situation, n (%) *
No care 19 (35.8) 29 (54.7) 138 (79.3) 
Home care/assisted living 17 (32.1) 16 (30.2) 24 (13.8) 
Residential living facility 17 (32.1) 8 (15.1) 12 (6.9) 
*Significantly (P-value < 0.05) different compared with people with sarcopenia based on Mann-Whitney U test 
(Age, BMI, MMSE, Number of comorbidities) or Chi-square test (Sex, Living situation). 
Table 2 Disability in ADL  
*GARS total score may range from 18-72, subscale ADL may range from 11-44, subscale instrumental ADL 
(IADL) may range from 7-28, higher scores indicate more disability in ADL. Item scores range from “fully 
independent without any difficulty” (score 1) to “fully dependent” (score 4). **Significantly (P-value < 0.05) 
different compared with people with sarcopenia based on Mann-Whitney U test (mean GARS score and subscale 
scores) or Chi-square test (items scores). 
3.2 Burden of Sarcopenia in Terms of Health Outcomes 
The GARS score was significantly (P < 0.001) different between sarcopenic (29.4±11.3) 
versus non-sarcopenic subjects (21.6±7.3). This difference was not significant between 
sarcopenic versus age and sex matched non-sarcopenic subjects (26.6±10.6; p = 0.097), 
except for the subscale basic ADL and the item ‘walk outdoors’ (Table 2). Subjects 
GARS Items  Sarcopenia,  
n = 53 
No Sarcopenia, Age and 
Sex Matched, n = 53 
No Sarcopenia,  
n = 174 
Mean GARS score (SD)*  29.4 (11.3) 26.6 (10.6) 21.6 (7.3)**
Subscale basic ADL 16.6 (5.4) 14.9 (5.5)** 12.6 (3.6)**
Subscale instrumental ADL 12.8 (6.2) 11.7 (5.8) 9.0 (4.0)**
Items basic ADL, mean score (SD) 
Dressing 1.5 (0.7) 1.4 (0.9) 1.2 (0.5)**
Get in/out of bed 1.3 (0.5) 1.2 (0.5) 1.1 (0.3)**
Stand up from a chair 1.4 (0.6) 1.2 (0.4) 1.1 (0.3)**
Wash hands/face 1.0 (0.3) 1.0 (0.1) 1.0 (0.1) 
Wash/dry body 1.5 (0.9) 1.6 (1.1) 1.2 (0.7)**
Get on/off toilet 1.1 (0.4) 1.1 (0.3) 1.0 (0.2)**
Eat and drink 1.1 (0.4) 1.0 (0.0) 1.0 (0.0)**
Get around inside house 1.2 (0.5) 1.1 (0.4) 1.0 (0.2)**
Go up/down stairs 2.2 (1.2) 1.6 (1.0) 1.3 (0.7)**
Walk outdoors 1.6 (1.0) 1.3 (0.8)** 1.1 (0.5)**
Take care of feet/toenails 2.7 (1.3) 2.4 (1.3) 1.6 (1.1)**
Items instrumental ADL, mean score (SD) 
Prepare breakfast/lunch 1.2 (0.7) 1.1 (0.5) 1.0 (0.2)**
Prepare dinner 1.8 (1.3) 1.5 (1.0) 1.2 (0.7)**
Do light cleaning 1.4 (0.9) 1.3 (0.8) 1.1 (0.5)**
Do heavy cleaning 2.5 (1.4) 2.4 (1.3) 1.7 (1.1)**
Wash/iron clothes 2.0 (1.3) 1.7 (1.2) 1.3 (0.8)**
Make beds 2.2 (1.2) 2.1 (1.2) 1.5 (0.9)**
Go shopping 1.7 (1.2) 1.6 (1.1) 1.2 (0.7)**
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indicated that they had most difficulty on the GARS items ‘go up/down stairs’, ‘take care of 
feet/toenails’ and the instrumental GARS items ‘do heavy cleaning’ and ‘make beds’.  
As with the GARS score, the overall EQ-5D-5L utility score was significantly (P < 
0.001) lower in sarcopenic (0.78±0.2) compared with non-sarcopenic subjects (0.86±0.2), 
but not significantly different from the age and sex matched non-sarcopenic subjects 
(0.81±0.2; P = 0.362). In general, subjects reported most problems in the domains mobility 
and pain (Figure 1). Subjects with sarcopenia reported more problems with mobility and 
usual ADL compared with non-sarcopenics (P < 0.05), but not compared with age and sex 
matched non-sarcopenic subjects. Self-rated health of sarcopenic subjects (72±16) tended 
to be lower compared with age and sex matched non-sarcopenic (77±13, P = 0.071) and 
was lower compared with the total sample of non-sarcopenic subjects (80±12, P < 0.001). 
3.3 Burden of Sarcopenia in Terms of Costs  
The volumes of resource use, unit prices and mean total costs per person are shown in 
Supplementary Data, Tables 1-3. As depicted in Figure 2, average costs of health care per 
person per three months were significantly higher in sarcopenic subjects (€ 4325, 95% CI: 
€ 3198-€ 5471), compared with non-sarcopenic subjects (€ 1533, 95% CI: € 1153-€ 1912). 
The mean difference in total costs was € 2792. The age and sex matched non-sarcopenic 
subjects also showed lower costs (€ 2768, 95% CI: € 1914-€ 3743) than sarcopenic 
subjects, though the difference was not significant.  
 Sarcopenic older adults (n=53) 
 Age and sex matched non-sarcopenic older adults (n=53) 
 Non sarcopenic older adults (n=174) 
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The highest proportion of costs was attributable to costs of care in a residential living 
facility, followed by support at home and hospital services. Except for costs of care in a 
residential living facility, no significant cost differences were found for the individual cost 
categories (Figure 2) between sarcopenic and non-sarcopenic subjects. 
3.4 Subgroup and Sensitivity Analyses 
Subgroup analyses showed that subjects with higher age, more comorbidities and more 
care dependency had lower utility scores and higher GARS scores, but not by definition 
lower self-rated health (Tables 3 and 4). Furthermore, though differences were not 
significant, higher age, more comorbidities and more care dependency yielded higher 
costs. There were no significant differences in costs between sarcopenic vs. non-
sarcopenic subjects living in the same setting (Table 4). A remarkable finding in the 
sensitivity analysis is that subjects with solely low SMI, scored better on QoL and disability 
in ADL (Table 3), compared to subjects with a normal SMI. Furthermore, excluding 
subjects with oedema (n = 35) did not lead to significantly lower costs, and including 
subjects with low cognitive function (n = 8) did not lead to significantly higher costs. No 
cost difference was found between subjects with low versus normal SMI.  
4. Discussion 
The aim of this study was to explore the burden-of-illness of Dutch community-dwelling 
older adults with sarcopenia, in terms of disability in ADL, QoL and costs, from a societal 
perspective. In this study, a higher health burden (in terms of disability in ADL and QoL) 
was seen in sarcopenic versus non-sarcopenic subjects. No evidence was found for a 
higher health burden in sarcopenic versus age and sex matched non-sarcopenic subjects, 
except for the subscale basic ADL. The total health care costs of community-dwelling 
sarcopenic subjects (n = 53, mean total costs per person per three months € 4325) were 
about three times higher than the health care costs observed in non-sarcopenic subjects (n 
= 174, € 1533), and 1.5 times higher (although not significantly) compared with the age 
and sex matched non-sarcopenic subjects (n = 53, € 2768). This means that sarcopenic 
subjects had an extra annual health care spending of € 11168 compared with non-
sarcopenic subjects and an extra € 6228 compared with matched controls. Costs of care in 
a residential living facility constituted the highest proportion of costs.  
The GARS scores in our sample are comparable with previous GARS data in a 
community-dwelling population aged 65 and older.34-36 Chan et al.37 found higher disability 
scores, but investigated an older population than ours. Two other studies on disability in 
sarcopenia used different tools (e.g. Katz ADL scale) to assess disability, and also found 
an association between sarcopenia and disability,1, 38 however, one other study did not find 
such an association.9 The study design, definition of sarcopenia and gender of subjects 
can influence the association between sarcopenia and disability,39-41 which may explain the 
difference in observations. It should also be noted that the GARS measures the 
competence of a person in the ADL domains, but not actual performance. Bootsma et al.42
showed that discrepancies exist between the two, i.e. some older adults could perform 
ADL activities, but did not perform them regularly. Therefore, in our study, subjects could 
possibly have overestimated their abilities. This might partly explain why we did not find a 
significantly different GARS score in sarcopenic versus age and sex matched non-
sarcopenic subjects. Moreover, subjects in the age and sex matched group were living in a 
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residential living facility (more disabled compared with total group of non-sarcopenic 
subjects) relatively more often and the sample size of the matched controls might have 
been too small to detect significant differences. 
The mean QoL scores of both sarcopenic and non-sarcopenic subjects were in line 
with previous studies using the EQ-5D in sarcopenia research. Previous studies on the 
association between QoL and (domains of) sarcopenia using the Short-Form 3643-47 and/or 
the EQ-5D37, 43, 48, 49 to assess QoL, reported inconsistent results. Some researchers did 
find a significant association between quality of life and sarcopenia,44 muscle mass,46, 48
hand grip strength,37, 43-47 or physical performance,43-47 others did partly find an association, 
e.g. only in men49 or did find an association using the SF-36, but not when using the EQ-
5D.43 In a review on QoL in sarcopenia and frailty, Rizzoli and colleagues3 underline the 
challenge of attributing QoL merely to sarcopenia, as comorbidities are often present and 
might also have an impact on QoL. 
In our study, we found that sarcopenia accounted for an extra annual health care 
spending of € 11168 compared with non-sarcopenic subjects and an extra (although not 
significant) € 6228 compared with matched controls. Looking at the cost difference per 
person, the health care costs for the total population are expected to be substantial. The 
health care costs of matched controls were expected to be higher than the total group of 
non-sarcopenic subjects, as the matched controls were older, and the oldest subjects were 
more likely to reside in a (relatively expensive) residential living facility and had more 
comorbidities. However, the wide confidence intervals around the costs and the small 
sample size of the matched controls might have hampered detection of significant 
differences between sarcopenic and matched non-sarcopenic subjects. There were no 
significant differences in costs between sarcopenic vs. non-sarcopenic subjects living in 
the same setting. However, sarcopenic older adults might be more prone to be admitted to 
residential care as previous research indicated that sarcopenia is associated with 
institutionalization.1 Therefore it can be argued that correcting for living situation when 
comparing costs of sarcopenic vs. non-sarcopenic older adults is not justified. The cost 
difference between sarcopenic and non-sarcopenic subjects that we found was larger than 
found by Janssen et al., who found about an extra $900 (about € 677) per sarcopenic 
person per year.8 Four reasons could underlie this difference. Firstly, Janssen et al.8
defined sarcopenia as low muscle mass, while we also included muscle strength and/or 
performance. But when using their definition of sarcopenia in our sensitivity analyses, the 
cost difference between sarcopenic and non-sarcopenic subjects was not significant. 
Secondly, they indirectly calculated costs of health care, using relative risk estimates of 
sarcopenia-related physical disability and previously calculated costs of disability8 and it is 
unclear whether costs of a residential living facility were included. The bottom-up approach 
that we used to estimate health care utilization, as well as the high proportion of costs from 
living in a residential living facility, could have led to cost differences between studies. 
Thirdly, Janssen et al.8 calculated costs of sarcopenia based on costs of disability. 
Although disability has been shown to be a large health care burden,50 physical disability is 
not the only driver of costs in older adults with sarcopenia.9 The association of sarcopenia 
with falls, institutionalization and comorbidities, such as osteoporosis, diabetes, and 
chronic kidney disease, could also lead to substantially increased costs.2, 9, 51-56 Fourthly, 
differences in costs might emerge from differences in the healthcare systems of the 
Netherlands and the U.S.  
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4.1 Strengths and Weaknesses 
A strength of this study is its bottom-up approach to identify volumes of health care use by 
measuring actual costs in a cross-sectional study. In addition, standardized unit prices 
based on national guidelines were used, facilitating comparison with other Dutch studies. 
Health outcomes were assessed using sufficiently tested instruments.20, 22 Although no 
existing cost questionnaire was used that would have simplified consistency across 
studies,26 existing questionnaires were consulted during the development of the cost 
questionnaire and the questionnaire was tested for feasibility in a pilot study. Although the 
advantage of a generic quality of life instrument such as the EQ-5D-5L that was used in 
this study is that one can compare the burden of different diseases, it may be argued that a 
sarcopenia-specific QoL instrument (such as the recently developed SarQoL)57 might be of 
added value. Furthermore, the cross-sectional design of the study does not allow cause-
consequence comparison. The time frame of health care utilization was three months, 
which might have been too short to identify all cost sources. Finally, generalizability of the 
results may be limited to some extent due to the fact that the response rate was about 15% 
and a selection bias in participation may have occurred. As illness might be a reason for 
non-participation, and subjects needed to be able to undergo several physical tests during 
a two-hour home visit, our sample might have been healthier than the general Dutch 65+ 
population.  
4.2 Implications and Future Research 
Our results indicate that the health and economic burden of sarcopenia seems mainly 
driven by living situation. Prevention and treatment of sarcopenia, especially community-
dwelling older adults living independently at home, might alleviate its health and economic 
burden, for example by delaying the onset of disability and the need for care and 
institutionalization. However, research is needed to confirm this. To help policy makers and 
health care professionals make a well-informed decision about whether or not to 
implement a strategy to reduce the burden of sarcopenia (e.g. resistance exercise 
combined with nutrition), they should have more information than on the sarcopenia 
burden alone. It can be recommended to also provide information on the costs and savings 
of such a strategy.11
5. Conclusions  
Community-dwelling sarcopenic subjects had a higher health and economic burden than 
non-sarcopenic subjects. This was importantly driven by the living situation. Although 
differences in health and economic outcomes between sarcopenic and age and sex 
matched non-sarcopenic subjects were not significant, the same trend was seen. Keeping 
older adults independent and out of care-dependent settings may contribute to a reduction 
of health care costs. 
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Table 2 Cost Prices of Health Care Services  
(continued on next page) 
Cost Category Price Year 
2014 (in €) 
Sourcea and Original Year 
Health care visit (costs/consult) 
General practitioner  
Consult in practice 30.78 Guideline National Health Care Institute - 2009 
Home visit 47.26 Guideline National Health Care Institute - 2009 
Phone consultation  15.39 Guideline National Health Care Institute - 2009 
GP medical post  103.68 The Dutch Healthcare Authority - 2014 
Consult in hospital/clinic 
Medical specialist  131.08 Guideline National Health Care Institute - 2009 
Night in academic hospital 632.02 Guideline National Health Care Institute - 2009 
Days outpatient treatment 275.89 Guideline National Health Care Institute - 2009 
Daily period in day centre  36.34 The Dutch Healthcare Authority - 2014 
Nurse (nurse specialist, diabetes/lung/ 
stoma nurse) 
33.52 Guideline National Health Care Institute - 2009 
Paramedical staff 
Consult: Dietician 29.68 Guideline National Health Care Institute - 2009 
Consult: Physiotherapist 39.57 Guideline National Health Care Institute - 2009 
Consult: Manual therapist 39.57b Guideline National Health Care Institute - 2009 
Consult: Remedial therapist 38.47 Guideline National Health Care Institute - 2009 
Consult: Occupational therapist 24.18 Guideline National Health Care Institute - 2009 
Consult: Activity therapist 38.47 Guideline National Health Care Institute - 2009 
Consult: Medical fitness 39.57b Guideline National Health Care Institute - 2009 
Consult: Speech therapist 36.27 Guideline National Health Care Institute - 2009 
Consult: Osteopath/chiropractor 33.63c Guideline National Health Care Institute - 2009 
Consult: Podiatrist 33.63c Guideline National Health Care Institute - 2009 
Consult: Acupuncturist 33.63c Guideline National Health Care Institute - 2009 
Psychological support 
Consult: Social work 71.45 Guideline National Health Care Institute - 2009 
Consult: Psychologist 86.28 Guideline National Health Care Institute - 2009 
Consult: Social psychiatric nurse 33.52d Guideline National Health Care Institute - 2009 
Consult: Psychiatrist 113.21 Guideline National Health Care Institute - 2009 
Support at home (costs/hour) 
Paid housekeeping  38.47 Guideline National Health Care Institute - 2009 
Paid personal care  48.36 Guideline National Health Care Institute - 2009 
Paid medical care  71.45 Guideline National Health Care Institute - 2009 
Unpaid support  13.74 Guideline National Health Care Institute - 2009 
Non formal support  13.74e Guideline National Health Care Institute - 2009 
Residential living facility (costs/day) 98.92 Guideline National Health Care Institute - 2009 
Assistive devices/in-house adjustments 
Arch support 146.42 The Drug Information System – 2013  
Orthopaedic shoes 1363.18 The Drug Information System – 2013 
Toilet raiser 48.47 The Drug Information System – 2013 
Rollator 124.21 The Drug Information System – 2009 
Crutches 50.56 The Drug Information System – 2009  
Cane  6.06 Self-report  
Special chair 383.71 The Drug Information System – 2009 
Ankle brace 59.95 Market price 
Antiskid mat 5.05 Self-report – 2013 
Stair handrails 807.81 Self-report – 2013  
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GP, general practitioner; aGuideline National Health Care Institute (CVZ, 2010); National Health Care Institute, 
http://www.medicijnkosten.nl; The Dutch Healthcare Authority (http://www.nza.nl/); The Drug Information System 
of National Health Care Institute (http://www.gipdatabank.nl); bCost price based on cost price physiotherapy; 
cCost price based on mean known cost prices paramedical staff; dCost price based on cost price of consult nurse 
in hospital; eCost price based on cost price of unpaid support. 
Cost Category Price Year 
2014 (in €) 
Sourcea and Original Year 
Food service (price per meal) 
Food delivery (‘Tafeltje-dekje’)  5.77 Self-report – 2013/2014  
Restaurant residential home  17.17 Self-report – 2013/2014 
Nutrition  
Oral nutritional supplements Varies Market price 
Vitamin supplements  Varies Market price 
Vitamin B injection (price/per 500 μg) 0.65 National Health Care Institute – 2013/2014 
Medication-related 
Medication Varies National Health Care Institute – 2013/2014 
Delivery costs (price/medicine)  5.55 Guideline National Health Care Institute – 2009 
Prescription costs (per medicine/ week) 
in residential living facility  
3.03 Guideline National Health Care Institute - 2009 
Travelling to health facility (€/km) 0.20 Guideline National Health Care Institute – 2009 
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Table 3 Total Costs of Health Care Utilization  
(continued on next page) 
Cost Category Total Costs (in €) Per Person (Mean, SD) 
Sarcopenia  
(n = 53) 
No Sarcopenia, Age 
and Sex Matched  
(n = 53) 
No Sarcopenia  
(n = 174) 
Total  
(n = 227) 
Health care visit  
General practitioner  
Consult in practice 51.69 (60.3) 45.30 (48.9) 38.74 (39.9) 41.76 (45.7) 
Home visit 0.89 (6.5) 1.78 (13.0) 0.54 (7.2) 0.62 (7.0) 
Phone consultation  0.29 (2.1) 0.00 (0.0) 0.00 (0.0) 0.07 (1.0) 
GP medical post  13.69 (35.4) 3.91 (19.9) 2.98 (17.4) 5.48 (23.3) 
Subtotal GP 66.56 (77.3) 50.99 (55.05) 42.26 (44.8) 47.94 (54.9) 
Consult in hospital/clinic 
Medical specialist  93.98 (184.3) 106.35 (219.7) 94.9 (176.2) 94.70 (177.7) 
Night in academic hospital 178.87 (853.2) 23.85 (173.6) 43.59 (337.0) 75.17 (507.6) 
Days outpatient treatment 5.21 (37.9) 0.00 (0.0) 1.59 (20.9) 2.4 (25.8) 
Daily period in day centre  0.0 (0.0) 49.37 (359.4) 15.04 (198.4) 11.53 (173.7) 
Nurse 1.26 (6.4) 2.52 (8.9) 0.96 (5.6) 1.03 (5.8) 
Subtotal hospital 279.33 (904.0) 182.10 (463.41) 156.09 (447.8) 184.87 (586.71) 
Paramedical staff 
Consult: Dietician 0.56 (4.1) 1.12 (5.7) 1.36 (8.9) 1.18 (8.05) 
Consult: Physiotherapist/ 
manual therapist 
67.19 (186.0) 79.14 (209.4) 50.94 (167.5) 54.74 (171.8) 
Consult: Remedial therapist 0.00 (0.0) 0.00 (0.0) 1.33 (17.5) 1.02 (15.3) 
Consult: Occupational 
therapist 
2.28 (13.6) 0.00 (0.0) 0.14 (1.8) 0.64 (6.8) 
Consult: Medical fitness 27.62 (144.7) 80.63 (237.3) 55.94 (207.1) 49.33 (194.4) 
Consult: Speech therapist 0.00 (0.0) 0.00 (0.0) 2.50 (33.0) 1.92 (28.9) 
Consult: Osteopath/ 
chiropractor 
0.00 (0.0) 1.90 (13.9) 2.51 (17.7) 1.93 (15.5) 
Consult: Podiatrist 1.27 (6.5) 0.00 (0.0) 0.19 (2.5) 0.44 (3.8) 
Consult: Acupuncturist 0.00 (0.0) 1.26 (9.2) 0.39 (5.1) 0.30 (4.5) 
Subtotal paramedical staff 98.93 (227.2) 164.52 (308.0) 115.31 (261.3) 111.48 (253.4) 
Psychological support 
Consult: Social work 16.18 (117.8) 0.00 (0.0) 2.46 (32.5) 5.67 (63.5) 
Consult: Psychologist 0.00 (0.0) 8.14 (59.3) 7.44 (54.8) 5.70 (48.0) 
Consult: Social psychiatric 
nurse 
0.00 (0.0) 0.00 (0.0) 2.31 (30.5) 1.77 (26.7) 
Consult: Psychiatrist 0.00 (0.0) 4.27 (31.1) 2.60 (20.9) 1.99 (18.3) 
Subtotal psychological support 16.18 (117.8) 12.41 (66.4) 14.82 (72.6) 15.13 (85.0) 
Support at home  
Paid housekeeping  352.76 (596.0) 391.09 (719.4) 177.49 (503.5) 218.41 (530.7) 
Paid personal care  221.35 (964.6) 243.53 (753.0) 95.27 (467.5) 124.71 (619.9) 
Paid medical care  0.00 (0.0) 12.13 (88.3) 8.01 (74.7) 6.14 (65.4) 
Unpaid support  23.12 (63.5) 52.17 (118.0) 30.38 (115.7) 28.69 (105.8) 
Non formal support 18.67 (81.9) 38.89 (133.9) 66.80 (210.6) 55.57 (189.5) 
Subtotal support at home 615.89 (1284.0) 737.81 (1332.4) 377.97 (903.0) 433.52 (1006.9) 
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GP, general practitioner. Exchange rate 2014: 1 EUR = 1.33 USD (European Central Bank, retrieved March 16, 
2015, from https://www.ecb.europa.eu/stats/exchange/eurofxref/html/eurofxref-graph-usd.en.html).
Cost Category Total Costs (in €) Per Person (Mean, SD) 
Sarcopenia  
(n = 53) 
No Sarcopenia, Age 
and Sex Matched  
(n = 53) 
No Sarcopenia  
(n = 174) 
Total  
(n = 227) 
Residential living facility  2855.62 (4195.3) 1343.82 (3217.6) 613.99 (2262.4) 1137.36(2978.5) 
Assistive devices/in-house  
adjustments 
53.16 (220.7) 0.00 (0.0) 1.98 (14.8) 13.93 (108.8) 
Food service  138.0 (651.5) 116.85 (344.4) 50.39 (239.2) 70.84 (377.9) 
Nutrition  5.79 (9.9) 6.02 (12.0) 8.15 (13.3) 7.60 (12.6) 
Medication 189.78 (202.7) 142.06 (145.4) 145.60 (469.2) 155.92 (421.5) 
Travel costs to health facility 5.87 (6.7) 10.90 (29.4) 6.76 (17.4) 6.56 (15.6) 
TOTAL COSTS 4325.1 (4240.8) 2767.5 (3366.9) 1533.3 (2607.3) 2185.1 (3277.6) 
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Physical Activity and Incidence of Sarcopenia:  
The Population-Based AGES-Reykjavik Study 
Submitted as: DM Mijnarends, A Koster, JMGA Schols, JMM Meijers, RJG Halfens, V 
Gudnason, G Eiriksdottir, K Siggeirsdottir, S Sigurdsson, PV Jonsson, O Meirelles, TB 
Harris. 
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ABSTRACT 
Background: The prevalence of sarcopenia increases with age. Physical activity might 
slow the rate of muscle loss and therewith the incidence of sarcopenia.
Objective: To examine the association of physical activity with incident sarcopenia over a 
five year period. 
Design: Data from the population-based Age, Gene/Environment, Susceptibility-Reykjavik 
Study (AGES-Reykjavik Study) were used.  
Setting: People residing in the Reykjavik area at the start of the study. 
Subjects: The study included people aged 66-93 years old.  
Methods: The amount of moderate-vigorous physical activity (MVPA) was assessed by a 
self-reported questionnaire. Sarcopenia was identified using the European Working Group 
on Sarcopenia in Older People (EWGSOP) algorithm. Muscle mass was assessed by 
computed tomography imaging of the thigh, grip strength by a computerized dynamometer 
affixed to a chair and gait speed by a 6-m walk.  
Results: 2,309 participants (mean age 74.9±4.7 years; 58% female) had complete data 
and were included in the analyses. The prevalence of sarcopenia was 7.3% at baseline 
and 16.8% at follow-up. The incidence proportion of sarcopenia over five years was 14.8% 
in the least active individuals and 9.0% in the most active individuals. Compared to 
participants who reported that they never participated in MVPA, those reporting a 
moderate-high amount of MVPA had a significantly lower likelihood of incident sarcopenia 
(OR: 0.64; 95% CI: 0.45-0.91).  
Conclusion: A higher amount of MVPA seems to contribute to counteracting the 
development of sarcopenia. To delay the onset of sarcopenia and its potential adverse 
outcomes, attention should be paid to increasing physical activity levels in older adults. 
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1. Introduction 
Sarcopenia, defined as the loss of muscle mass and function, affects quality of life and 
increases the risk of physical limitations and disability in older adults.1, 2 Depending on the 
definition used, the prevalence of sarcopenia in community-dwelling older adults ranges 
from 1% to 50%, with higher prevalence rates in older age groups.3, 4 Although the loss of 
muscle mass appears to be an inevitable part of the aging process, the rate of muscle loss 
is modifiable.5 For instance, resistance training interventions have shown to be effective in 
reversing losses of skeletal muscle mass and function.6 Aiming to delay the onset of 
disability and progression of chronic diseases and to gain other health benefits, current 
recommendations for physical activity are set at 150 minutes per week for moderate-
intensity aerobic activity and two or more days per week for muscle strengthening 
activities.7,  8 Moderate-intensity activity noticeably accelerates the heart rate and includes 
activities like brisk walking or dancing.7 In industrialized countries physical activity levels in 
older adults are low, with 40-60% of the older adults not meeting the recommendations for 
physical activity.7, 9 Although exercise has been proven to be effective in reversing losses 
of muscle mass,6, 10 studies investigating the effect of general physical activity on the 
prevention of sarcopenia show inconsistent results.11 For example, Ryu and colleagues, 
using data from a cross-sectional Korea National Health and Nutrition Examination Survey, 
report that being physically active is associated with a reduced risk of sarcopenia.12 On the 
contrary, Volpato et al.13 did not find an association between physical activity and 
sarcopenia. Raguso et al.14 performed a 3-year longitudinal study and found that leisure 
time physical activity did not seem to prevent the loss of muscle mass. 
In addition to the issue of inconsistent findings of the effect of general physical activity 
on sarcopenia, only a few studies have examined the incidence of sarcopenia.15-17 The aim 
of this study, then, was to examine the association of physical activity with the incidence of 
sarcopenia over a five year period in a large population-based cohort study of older adults, 
the AGES-Reykjavik Study.18 To identify people with sarcopenia, the algorithm of the 
European Working Group on Sarcopenia in Older People (EWGSOP) was used.19 This 
algorithm includes measurements of muscle mass (computed tomography of the mid-
thigh), isometric muscle strength of the hand (computerized dynamometer) and gait speed 
(6 m walk). 
2. Methods 
2.1 Design and Study Population 
This paper describes a secondary data analysis using data of the Age, Gene/Environment, 
Susceptibility-Reykjavik (AGES-Reykjavik) Study.18 AGES-Reykjavik is a population-based 
study undertaken in survivors of the Reykjavik Study.18, 20, 21 The Reykjavik Study, 
established in 1967 and followed by the Icelandic Heart Association, aimed to 
prospectively study cardiovascular disease in people born between 1907 and 1935 and 
residing in Reykjavik.18, 20, 21 Between 2002 and 2006 the AGES–Reykjavik Study re-
examined 5764 survivors of the original cohort who had participated in the Reykjavik Study 
(T1). The second examination (T2) took place between 2007 and 2011 (n = 3,316). All 
participants signed informed consent. The National Bioethics Committee in Iceland and the 
National Institute on Aging Intramural Institutional Review Board in Bethesda, USA, 
approved the study (approval number VSN-00-063).  
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2.2 Measurements 
The baseline examination consisted of three clinic visits within four to six weeks.18 It 
included, among others, vascular, neurocognitive and musculoskeletal components and 
questionnaires on physical, psychological and social health. An overview of all 
examinations included in the AGES-Reykjavik Study has been previously published.18 For 
this paper, relevant measurements are described below. The included measurements were 
performed at both baseline (T1) and follow-up (T2). 
2.3 Identification of Sarcopenia 
Sarcopenia was identified using the algorithm of the European Working Group on 
Sarcopenia in Older People (EWGSOP).19 According to this algorithm, sarcopenia is 
present in older adults with low muscle mass in combination with poor muscle strength 
and/or performance. Muscle mass was assessed by computed tomography imaging (CT), 
using a four-detector CT system (Sensation, Siemens Medical Systems, Erlangen, 
Germany).22 Average thigh total muscle cross-sectional area (cm2) was obtained from a 
single axial 10-mm-thick section in both legs.23 To our knowledge, this is the first study to 
apply the EWGSOP definition using a CT image-based measure for muscle mass.3 The 
EWGSOP does not provide CT cut-off points for low muscle mass, therefore the lowest 
gender-specific 20th percentile of the thigh total muscle cross sectional area (< 83.2 cm2 in 
females, < 116.5 cm2 in males) was used in the main analyses and the lowest gender-
specific 10th percentile (< 78.2 cm2 in females, < 108.2 cm2 in males) in the sensitivity 
analyses. The 20th percentile method has been used before in sarcopenia research using 
DXA.24, 25 Maximum grip strength of the dominant hand was measured by a computerized 
dynamometer affixed to an adjustable special chair (Good Strength software, Metitur, 
Finland), with the elbow flexed at 90° and armrests adjusted for height so that the 
shoulders were relaxed.26 Participants performed three trials, each lasting four to five 
seconds, and after each exam they rested for half a minute. Participants were provided 
with standardized verbal encouragement throughout the testing protocol. EWGSOP cut-off 
points for poor grip strength are < 20kg (women) and < 30 kg (men).19 Usual walking 
speed (m/s) was assessed over a 6 meter track.27 The EWGSOP cut-off point for slow gait 
speed is  0.8 m/s.19
2.4 Physical Activity Assessment 
Physical activity was assessed by a self-reported questionnaire. Participants were asked, 
among others, how many hours per week they participated in moderate to vigorous 
intensity physical activity (MVPA) in the past 12 months (one question). Provided examples 
of MVPA were badminton, golf, biking, swimming, heavy gardening, weight lifting, 
hiking/mountain climbing, fast walking/heavy housework, rowing, aerobics, jogging and 
running. Pre-defined answer categories were never, rarely, occasionally (weekly but less 
than one hour), moderate (1-3 hours per week) and high (more than 4 hours per week). In 
the final analyses the MVPA categories were combined into 1. Never, 2. Rarely-
occasionally, 3. Moderate-high. 
2.5 Covariates 
Age, sex, education (primary, secondary, college, university), marital status (married/living 
together, widow/widower, divorced, single), smoking status (never, previous, current) and 
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> 5 kg weight loss in the past 12 months were assessed by a questionnaire. BMI was 
calculated by dividing body weight in kg by height in meters squared. The total number of 
comorbidities was obtained by self-report, medication assessment and clinical 
assessment, and included cancer, chronic lung disease, asthma, dementia, diabetes, heart 
attack, congestive heart failure, hypertension, rheumatic disorder and stroke. Depressive 
symptoms were assessed by the validated 15-item Geriatric Depression Scale (GDS).28, 29
The total score of the GDS ranges from zero (no depressive symptoms), to 15 (high 
number of depressive symptoms), with 6 or more depressive symptoms as a cut-off point 
for depression.29 Cognitive function was assessed by the Mini-Mental State Examination, 
with scores ranging from 0-30, where higher scores indicate better cognitive function.30
2.6 Statistical analysis 
To compare baseline characteristics of people with and without sarcopenia, Chi-square 
tests (categorical variables) and Student’s t-tests (continuous variables) were used. 
Multinomial regression was used to examine differences in the amount of MVPA between 
participants with and without sarcopenia at T1. Model 1 was adjusted for age, sex, 
education and marital status. Model 2 further included BMI, smoking status, total number 
of comorbidities, depressive symptoms, weight loss, and cognitive function.  
To assess the association between baseline physical activity and incidence of 
sarcopenia, logistic regression was used. For this analysis, only people without sarcopenia 
at baseline were included (n = 2140). As above, model 1 was adjusted for age, sex, 
education and marital status. Model 2 additionally included BMI, smoking status, total 
number of comorbidities, depressive symptoms, weight loss, and cognitive function.
3. Results 
Between baseline (n = 5,764) and follow-up (mean follow-up 5.2 ± 0.3 years, range 4.2-8.2 
years), 1,039 participants died and 1,409 were lost to follow-up or refused to participate, 
leaving a total sample at follow-up of 3,316 participants (Supplementary Data, Figure 1). Of 
these 3,316 participants, 1,007 were excluded due to missing data on muscle parameters 
(n = 670), physical activity (n = 66) or baseline covariates (n = 271), leaving a total 
analytical sample of 2,309 participants. Characteristics of participants who participated at 
baseline only and characteristics of participants excluded because of missing data are 
shown in Supplementary Data, Table 1. Participants that dropped out between T1 and T2 
were at baseline significantly older, had a lower BMI, more comorbidities, a lower 
educational level, were more often living alone, were less active and were more often 
sarcopenic compared to participants that did not drop out.  
Characteristics of the 2,309 included participants are shown in Table 1. The mean 
age of the participants was 74.9 years at baseline and the majority were female (57.8%), 
which reflects the gender distribution of this age group in the general population. The 
prevalence of sarcopenia was 7.3% (n = 169) at baseline (see sarcopenia identification in 
Supplementary Data, Figure 2) and 16.8% (n = 389) at follow-up. At baseline, significant 
differences between sarcopenic and non-sarcopenic older adults were found for all 
characteristics except smoking status and weight loss. At baseline 38.5% of the 
participants did not engage in MVPA, which was 47.7% at follow-up. 
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3.1 Physical Activity in People with and without Sarcopenia 
Multinomial regression indicated that sarcopenic older adults engaged in significantly less 
MVPA (Table 2). People with sarcopenia at baseline had a lower likelihood (OR = 0.49,
95% CI: 0.32-0.76) of having a moderate-high amount of MVPA compared with 
participants without sarcopenia. People with sarcopenia at baseline also tended to have a 
lower likelihood (OR = 0.89, 95% CI: 0.59-1.34) of engaging rarely-occasionally in MVPA 
compared with participants without sarcopenia, but this was not statistically significant.  
Table 2 Differences in MVPA between People with and without Sarcopenia 
Unadjusted Model 
OR (95% CI) 
Model 1  
OR (95% CI) 
Model 2  
OR (95% CI) 
Rarely-occasionally vs. never (ref) MVPA 0.72 (0.49-1.05) 0.92 (0.61-1.37) 0.89 (0.59-1.34) 
Moderate-high vs. never (ref) MVPA 0.38 (0.25-0.56) 0.53 (0.35-0.81) 0.49 (0.32-0.76) 
Dependent variable is sarcopenia status (0 = no sarcopenia, 1 = sarcopenia). Model 1 is adjusted for age, sex, 
education and marital status. Model 2 further included BMI, smoking status, total number of comorbidities, 
depressive symptoms, weight loss, and cognitive function. MVPA, moderate-vigorous physical activity. 
3.2 Incidence of Sarcopenia 
As shown in Table 3, the incidence proportion of sarcopenia in participants who never 
engaged in MVPA, rarely-occasionally engaged in MVPA and participants with a 
moderate-high amount of MVPA was 14.8% (118 out of 799), 10.4% (55 out of 527) and 
9.0% (74 out of 814), respectively. Participants who reported a moderate-high amount of 
MVPA at baseline had a significantly decreased likelihood of incident sarcopenia 
compared to those who reported never to participate in MVPA (OR: 0.68, 95% CI: 0.49-
0.94; Table 3, Model 1). Additionally, in model 1 older age was significantly associated with 
the incidence of sarcopenia. In model 2, next to older age, lower BMI and worse cognitive 
function were significantly associated with the incidence of sarcopenia. 
Sensitivity analyses using the lowest gender-specific 10th percentile for muscle mass 
showed the same trend, a significant difference was found in the incidence of sarcopenia 
between participants who never participated in MVPA compared with participants with a 
moderate-high amount of MVPA (OR 0.64, 95% CI: 0.45-0.90; not tabulated).
4. Discussion 
This study showed that older adults with sarcopenia engaged significantly less in MVPA 
than their non-sarcopenic peers. Further, the incidence proportion of sarcopenia was 
significantly lower in the highly active participants, compared with the least active 
participants.  
The incidence proportion found in this study (9.0-14.8%) is roughly comparable to the 
incidence proportion found in two other recent studies performed in community-dwelling 
older adults.15, 16 Both studies used the EWGSOP algorithm to define sarcopenia, though 
slightly different cut-off points were applied.15, 16 Kim  et  al.15 found a 4-year sarcopenia 
incidence proportion of 15.8% in a community-dwelling population of older women aged 75 
years and older. Yu et al.16 reported a 4-year incidence proportion of sarcopenia of 7.8% in 
a population of 65 years and older, recruited in three Australian cohort studies. Yu et al.16
also found that lower physical activity levels were associated with a higher incidence of 
sarcopenia, though physical activity was not associated with reversibility of sarcopenia. 
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However, in an intervention study by Liu et al.,31 in which sarcopenia was defined as low 
appendicular lean muscle mass, it was found that a physical activity intervention improved 
physical performance in both sarcopenic as well as non-sarcopenic older adults. Murphy et 
al.32 showed that in the Health ABC study people with more physical activity were less 
likely to transition to sarcopenia. A longitudinal study using objectively measured physical 
activity data, by accelerometer, showed that a greater habitual physical activity delayed the 
loss of lean mass.33 In contrast, in a cross-sectional study by Volpato et al.,13 no 
association was found between physical activity and sarcopenia. This may be explained by 
the method used to assess muscle mass, i.e. bioelectrical impedance, which might have 
led to an overestimation of muscle mass.13 Also, being physically active does not equal 
immunity to sarcopenia, as suggested in a review by Marcell.34 Furthermore, the author 
questions whether in addition to physiologic factors, sarcopenia might be associated with 
social issues preventing older adults from taking up exercise.34
Table 3 Association of Physical Activity with the Sarcopenia Incidence Proportion over a Five Year 
Period 
Sarcopenia 
Incidence (%)
Unadjusted Model 
OR (95% CI) 
Model 1 
OR (95% CI) 
Model 2  
OR (95% CI) 
Amount of MVPA at baseline 
Never (n = 799) 14.8 Ref Ref Ref 
Rarely-occasionally (n = 527)  10.4 0.67 (0.48-0.95) 0.78 (0.54-1.12) 0.79 (0.54-1.14) 
Moderate-high (n = 814)  9.0 0.58 (0.42-0.79) 0.68 (0.49-0.94) 0.64 (0.45-0.91) 
Age 1.21 (1.17-1.25) 1.20 (1.16-1.24) 
Sex 0.99 (0.74-1.33) 1.21 (0.89-1.64) 
Education 1.04 (0.89-1.22) 1.07 (0.90-1.27) 
Marital status 1.06 (0.90-1.25) 1.01 (0.84-1.20) 
BMI 0.85 (0.82-0.89) 
Smoking status 1.22 (0.98-1.53) 
# of comorbidities 1.13 (1.00-1.28) 
Depressive symptoms 1.03 (0.95-1.12) 
Weight loss > 5 kg 1.31 (0.82-2.11) 
Cognitive function 0.90 (0.85-0.96) 
BMI, body mass index; MVPA, moderate-vigorous physical activity; Ref, reference group. Depression symptoms 
as assessed by the Geriatric Depression Scale, with scores ranging from zero (no depressive symptoms), to 15 
(high number of depressive symptoms). Cognitive function was assessed by the MMSE. 
Our study supports the idea that physical activity seems to counteract losses of muscle 
mass, and increasing the level of physical activity might delay the development of 
sarcopenia. In 2011, Pillard et al.35 discussed the idea of prescribing physical activity as a 
countermeasure for sarcopenia. The paper describes several steps that a medical 
practitioner can take to encourage physical activity as a medicine, including how to define 
the physical activity dose.35 Both Shephard et al.33 and the European Society for Clinical 
Nutrition and Metabolism (ESPEN) expert group,36 recommend daily physical activity for 
older adults; 15-20 minutes of at least a moderate intensity. The expert group also advises 
combining physical activity with a diet including 1.0-1.2 g protein/kg body weight/day.36
These are first steps in sarcopenia prevention and control.  
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Some limitations should be addressed. The prevalence of sarcopenia found in this study is 
comparable to other studies using the EWGSOP definition in community-dwelling and 
long-term care populations.3 However, the ‘real’ baseline prevalence of sarcopenia (12.2%, 
n = 4,833) was higher than in the analytical sample, because sarcopenic participants were 
more likely to become lost-to-follow-up. Also, the people that dropped out between the first 
(T1) and second (T2) examination had on average more comorbidities and more than half 
never performed MVPA. Since these factors are both likely to increase the risk of 
developing sarcopenia, the actual incidence of sarcopenia is likely to be higher than shown 
in this study. CT imaging is seen as one of the gold standards to assess muscle mass, 
however no official cut-off points for low muscle mass were available, using other cut-off 
points might affect the outcome.3, 37 Physical activity was assessed by self-report. This 
might have led to an overestimation of physical activity levels.38 Objective measurement of 
physical activity could improve the reliability of physical activity data. However, we do 
believe that self-report gives a fair indication of whether a person is not active at all or 
highly active. During the five year follow-up, no interim evaluation of physical activity and 
other measures was performed. It could be possible that events (such as the development 
of disease or hospitalization) that occurred within these five years have confounded the 
relationship between incident sarcopenia and physical activity. Although physical activity 
and exercise are often used interchangeably, in theory they are different concepts.8 For 
this study, one single question was included with regard to physical activity, including both 
general physical activity as well as exercise; data on reliability and validity of the physical 
activity questionnaire are unknown. Further, no conclusions can be drawn with regard to 
the type of physical activity or exercise that contributed mostly to the incidence of 
sarcopenia. 
To conclude, a moderate-high amount (> 1 hour per week) of MVPA seems to 
contribute to counteracting the losses of muscle mass and function. Attention should be 
paid to increasing physical activity levels in older adults, since this might decrease the 
incidence of sarcopenia and therefore might prevent the onset of poor health outcomes. 
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Supplementary Data Chapter 6 
Supplementary Figure 1 Flow diagram of inclusion AGES-Reykjavik Study 
Excluded from analyses: 
x Missing data on muscle 
mass, strength or 
performance (n = 670) 
x Missing data on 
physical activity  
(n = 66) 
x Missing data on 
covariates (n = 271) 
Random selection of participants n = 9,387 
El
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Participants at baseline 2002-2006 n = 5,764 
En
ro
lm
en
t
Participants Reykjavik study n = 30,795 
Survivors of the Reykjavik study n = 11,549 
Not in Reykjavik n = 133 
Deceased n = 1,259 
No response n = 2,231 
Participants at follow-up 2007-2011 n = 3,316
Analysed: n = 2,309 
No follow-up data available 
due to:
Death n = 1,039 
Refusal n = 1,198 
Lost to follow-up n = 211 
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Supplementary Figure 2 Identification of sarcopenia at baseline using the EWGSOP algorithm19
Participant  65 years 
n = 2,309 (47.8% female)
Normal grip strength  
 20 kg (women) n = 951 
 30 kg (men) n = 843 
Normal gait speed > 0.8 
m/s n = 2,019 
Sarcopenia n = 169 No sarcopenia n = 1,794 
Slow gait speed  0.8 m/s, n = 290 
Of which 103 persons had poor grip 
Low muscle mass 
< 83.2 cm2 (women) n = 125
< 116.5 cm2 (men) n = 44 
Measure grip strength 
n = 2,019
Low grip strength  
< 20 kg (women) n = 164
< 30 kg (men) n = 61 
Measure average thigh total muscle 
cross-sectional area, n = 515
Measure gait speed 
n = 2,309
Normal muscle mass 
Women n = 259 
Men n = 87 
No sarcopenia n = 364  
56 persons had slow gait 
76 persons had poor grip 
37 persons had poor grip 
& slow gait 
Of which 293 persons 
had low muscle mass 
131 persons had slow 
gait, 149 persons had 
poor grip, 66 persons 
had slow gait & poor grip
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Supplementary Table 1 Baseline Characteristics of Participants Who Were Excluded From the 
Analyses 
Variable Participants with Only Baseline 
Data, No Follow-Up Data  
(n = 2,448*) 
Participants Excluded Because 
of Missing Data  
(n = 1,007**) 
Age, mean y (SD) 79.7 (6.0) 75.7 (5.3) 
Women, n (%) 1,392 (56.9) 599 (59.5) 
Education, n (%)  
Primary 583 (28.6) 217 (22.1) 
Secondary 965 (47.4) 502 (51.0) 
College/University 490 (24.0) 265 (26.9) 
Marital status, n (%) 
Married/living together 1,059 (51.9) 604 (61.4) 
Widow or widower 750 (36.8) 261 (26.5) 
Divorced 109 (5.3) 59 (6.0) 
Single 121 (5.9) 60 (6.1) 
BMI, mean kg/m2 (SD) 26.7 (4.7) 27.5 (4.9) 
Comorbidities, mean (SD) 2.3 (1.3) 2.0 (1.2) 
Sarcopenia, n (%) 350 (19.2) 72 (10.2) 
Current amount of MVPA, n (%) 
Never 1,186 (58.5) 400 (41.6) 
Rarely-occasionally 409 (20.2) 233 (24.2) 
Moderate-high 433 (21.4) 329 (33.4) 
Presented percentages are valid percentages. *Participants with only baseline data, no follow-up data: BMI, n = 
2,381 (67 missing); Total # of comorbidities, n = 2,008 (440 missing); Education, n = 2,038 (410 missing); Marital 
status, n = 2,040 (409 missing); Sarcopenia status, n = 1,819 (629 missing); Physical activity, n = 2,028 (420 
missing). These participants with only baseline data scored significantly different (P < 0.05) on all variables 
compared with participants that did have follow-up data. **Participants excluded because of missing data: BMI, n 
= 1,006 (1 missing), Total # of comorbidities, n = 805 (202 missing); Education, n = 984 (23 missing); Marital 
status, n = 984 (23 missing); Sarcopenia status, n = 705 (302 missing); Physical activity, n = 962 (45 missing). 
Participants excluded because of missing data scored significantly different (P < 0.05) on all variables, except 
BMI, compared with participants that were included in the analyses. 
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Sarcopenia is thought to have negative effects on both the individual (health outcomes) as 
well as the society (health care costs). As sarcopenia is a rather ‘new’ concept in the 
research world, many gaps in knowledge exist and screening for sarcopenia is not yet 
embedded in clinical practice. Among the unanswered questions were e.g.: which 
measurement tools are valid, reliable, and feasible to assess sarcopenia in a community-
dwelling population? What is the prevalence of sarcopenia in community-dwelling older 
adults receiving professional home care or living in a residential living facility? To what 
extent does the concept of sarcopenia overlap with frailty? What is the health and 
economic burden of sarcopenia? What is the effect of general physical activity on the 
incidence of sarcopenia? As the current focus of governments is on aging in place, 
increasing our understanding of (the burden of) sarcopenia is relevant. Evidence of a 
substantial burden strengthens the need for interventions and may support policy decisions 
with regard to prevention, diagnosis, and treatment. In addition, solid evidence increases 
political and societal support regarding these interventions, which will be needed for 
successful implementation of prevention, diagnosis or treatment interventions.  
The aim of the research presented in this thesis is to gain more insight in the 
prevalence, characteristics, and health and economic outcomes of community-dwelling 
older adults with sarcopenia. This final chapter firstly summarizes the main findings of the 
studies presented in this thesis. Subsequently, theoretical and methodological 
considerations are discussed and implications for research and practice are given.  
1. Main Findings
1.1 Selecting Tools to Measure Sarcopenia
The European Working Group on Sarcopenia in Older People (EWGSOP) developed an 
algorithm for sarcopenia case finding.1 This algorithm, which includes the parameters 
muscle mass, muscle strength, and physical performance, was taken as a starting point for 
the studies presented in this thesis. The EWGSOP suggested several tools to measure the 
muscle parameters,1 however, no systematic review on the measurement properties of 
those tools was available. Therefore, in the first study presented in this thesis (Chapter 2), 
the measurement properties (i.e. validity, reliability) of tools to measure muscle mass, 
strength, and physical performance in community-dwelling older adults were critically 
appraised.2 For quick assessment of muscle mass, strength, and physical performance 
among community-dwelling older adults it would be beneficial when tools could be applied 
in a general practitioner practice or in a home setting. Therefore, also the feasibility of tools 
in these settings was taken into account.  
A total of 62 studies were included in the systematic review, reporting on a wide array 
of tools that are valid and reliable for measurements of muscle mass (e.g. magnetic 
resonance imaging), strength (e.g. leg press), and performance (e.g. six minute walk test) 
in clinical settings.2 With regard to muscle mass, no well-validated and reliable tools were 
found for measurements of muscle mass in a home-setting. The best feasible alternative 
found was bioelectrical impedance analysis (BIA). Evidence for its validity was found; 
however, age, sex, and cultural influences may affect its validity. Hence these factors 
should be considered when using BIA. Furthermore, it is likely that the use of different 
reference populations and cut-off points for muscle mass have large effects on the 
outcome. For muscle strength, the handheld dynamometer was found to be valid, reliable, 
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and feasible. Aligning protocols to assess grip strength by handheld dynamometry was 
suggested to improve the comparability of study results. In addition, it may be 
recommended assessing lower extremity strength where possible, as lower extremity 
strength is important for functional activities. The Short Physical Performance Battery 
(SPPB) and gait speed showed good measurement properties with regard to the 
assessment of physical performance.2
In conclusion, several tools are available for valid and reliable measurements of 
muscle mass, strength, and performance in clinical settings. BIA, handheld dynamometry 
and gait speed or the SPPB were found to be the most valid, reliable, and feasible in a 
general practitioner practice or in a home-setting. Research is needed on the reliability of 
tools to assess muscle mass in an older population. 
1.2 Prevalence and Adverse Outcomes of Sarcopenia 
For chapters 3 to 5 of this thesis, data from the cross-sectional Maastricht Sarcopenia 
Study (MaSS) was analysed. The MaSS study was performed in community-older adults 
living 1) independently at home without additional care, 2) at home or in an assisted living 
facility with professional home care, and 3) in a residential living facility with additional 
professional nursing care and/or meal service. The total prevalence of sarcopenia found in 
the study sample was 23.3%. This study revealed that sarcopenia was more prevalent in 
subjects living in a residential living facility (58.6%) compared to those receiving home care 
(41.5%) and those living at home without additional care (12.1%).  
Furthermore, sarcopenia was significantly associated with physical frailty.3 Physical 
frailty was assessed by both the Fried frailty criteria and the FRAIL scale.4, 5 Subjects were 
categorized as pre-frail when one or two criteria were scored positive and frail when three 
or more criteria were scored positive. Physical frailty was present in 8.4% (Fried criteria) 
and 9.3% (FRAIL scale) of the subjects.3 As for sarcopenia, there is no full consensus yet 
on which definition of frailty to use. However, when using the Fried or FRAIL scale criteria 
and cut-off points for frailty, a majority of the sarcopenic subjects was pre-frail and almost a 
quarter was frail. Frail older adults had a higher chance of having sarcopenia than people 
without frailty. Two of the five frailty criteria that were most frequently present in frail older 
adults were weakness (poor grip strength) and slow walking speed. This information can 
be useful for clinicians as this study showed that screening older adults on muscle strength 
and/or mobility may identify not only older adults with sarcopenia, but also older adults with 
(a risk of) frailty. The two physical frailty scales, the Fried criteria and the FRAIL scale, 
correlated moderately. This means that the scales cannot be used interchangeably, as 
they identify partly different subjects as frail. 
Sarcopenic subjects had a higher health and economic burden than non-sarcopenic 
subjects. Regarding the health burden it was found that sarcopenic subjects had more 
comorbidities, more disability in activities of daily living and a lower quality of life compared 
with non-sarcopenic subjects. These results indicate that sarcopenia deserves to be 
referred to as geriatric giant. Furthermore, sarcopenia accounted for an extra annual health 
care spending of € 11168 per sarcopenic person compared with non-sarcopenic subjects 
and an extra (although not significant) € 6228 compared with matched controls. The living 
situation (residential care) was a main driver of costs. This first study on the economic 
burden of sarcopenia performed in Europe highlights the need for action.  
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1.3 Physical Activity and Incidence of Sarcopenia
Though many studies reported prevalence rates of sarcopenia, few studies exist on the 
incidence of sarcopenia.6-8 Furthermore, studies on the effect of general physical activity 
on sarcopenia show inconsistent results.9 In chapter 6, the relation between physical 
activity and the incidence of sarcopenia was studied. A secondary data analysis using data 
from the population-based AGES-Reykjavik Study, a large cohort study with five-year 
follow-up, was performed. It was found that sarcopenic participants less frequently 
performed moderate to vigorous physical activity than did non-sarcopenic participants. 
Furthermore, this study shed light on the incidence proportion of sarcopenia over five 
years. This proportion was lower in the most active individuals (9.0%) than in the least 
active individuals (14.8%). Older age, lower BMI, and worse cognitive function were 
associated with higher incidence of sarcopenia. This study showed that in addition to the 
substantial prevalence of sarcopenia, 1 out of 7 inactive older adults developed sarcopenia 
in five years’ time and 1 out of 11 active older adults developed sarcopenia over five years’ 
time. 
2. Theoretical and Methodological Considerations 
Theoretical and methodological considerations are inherent to scientific research. In each 
study presented in this thesis limitations particular to that study were addressed. In this 
section, five overarching theoretical and methodological considerations will be addressed. 
2.1 Defining Sarcopenia 
The coining of the term sarcopenia by Rosenberg in 198910 was the beginning of a 
challenge to find consensus over its definition. Currently several definitions of sarcopenia 
circulate in the scientific arena (Table 1). Originally the term sarcopenia was used to 
describe the age-related loss of muscle mass.10 However, whether sarcopenia is mere the 
age-related loss of muscle mass, or that it should be an umbrella term for the low of 
muscle mass irrespective of its cause (cachexia, physical inactivity, bed rest, malnutrition) 
has been an issue of debate.11 Cruz-Jentoft et al.1 raised the idea of using ‘primary’ 
sarcopenia to describe the merely age-related low muscle mass, and ‘secondary’ 
sarcopenia when one or more other causes, such as malnutrition, physical inactivity or 
disease, are present. A majority of the studies on sarcopenia (including the studies 
presented in this thesis) use sarcopenia as umbrella term, because it is difficult to clearly 
separate the individual aetiology for a low muscle mass.11
Another point of discussion around the definition of sarcopenia is whether including 
mere muscle mass in it definition is satisfactory. Muscle strength and/or physical 
performance have been put forward to extend the concept of sarcopenia as it has been 
shown that these muscle parameters relate to muscle mass and may have more clinical 
relevance than muscle mass alone.21, 22 However, opponents of this extension of the 
concept of sarcopenia state that sarcopenia literally means muscle mass and alternative 
mechanisms may underlie loss of muscle mass and strength.23 Therefore loss of muscle 
strength might better be called dynapenia (dyna = strength, penia = loss).24 Studies looking 
at the agreement between several definitions of sarcopenia have shown that the 
agreement is low.17, 25-27 Bijlsma  et  al.25 showed that only one subject out of the 654 
included subjects was identified as sarcopenic according to all diagnostic criteria. Dam et 
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al.17 showed that (positive) agreements between diagnosis of sarcopenia with the FNIH 
criteria and other criteria ranged between 7-32%. 
In the studies presented in this thesis, the recommendations of the European Working 
Group on Sarcopenia in Older People (EWGSOP)1 to define sarcopenia were followed. 
This means that muscle mass, muscle strength, and physical performance were assessed 
to identify older adults with sarcopenia. As shown in Chapter 3, choosing to include only 
muscle mass in its definition would have led to substantial differences in research results, 
i.e. using muscle mass as sole criterion for sarcopenia leads to a higher prevalence of 
sarcopenia. Many subjects of the MaSS study had low muscle mass, but normal muscle 
strength or performance and were therefore not identified as sarcopenic according to the 
EWGSOP criteria. When the criteria of the International Working Group on Sarcopenia 
would have been used (i.e. low muscle mass with limited mobility), research results would 
also have been different, as in the MaSS study several sarcopenic subjects had low 
muscle mass with poor grip strength, but normal gait speed. As the prevalence of 
sarcopenia depends on its definition, also the association found between sarcopenia and 
health and economic outcomes depends on the chosen definition. These results indicate 
that consensus over a definition is urgently needed to foster developments in the field of 
sarcopenia regarding research and practice.  
Table 1 Definitions and Cut-Off Points for Sarcopenia 
Definition Muscle Mass Muscle Strength Physical Performance 
Baumgartner12 ALM/height2 > 2SD below reference 
population; i.e. 7.26 kg/m2 (m), 5.45 kg/m2
(f) based on anthropometrics 
- -
Delmonico13 ALM/height2 under 20th percentile; i.e. 7.25 
kg/m2 (m), 5.67 kg/m2 (f), based on DXA 
- -
Janssen14 1. Skeletal lean mass/body mass×100% of 
1 or more below reference population, 
based on BIA 
2. Skeletal lean mass/height2 < 10.75 
kg/m2 (m), 6.75 kg/m2 (f), based on BIA 
- -
ESPEN-SIG15 Muscle mass > 2SD below mean of young 
individuals 
- Gait speed < 0.8 m/s or 
reduced physical 
performance on other test 
EWGSOP1 Several cut-off points suggested for DXA 
and BIA 
Grip strength < 
30 kg (m) and 20 
kg (f) or BMI 
specific cut-off 
points 
Gait speed  0.8 m/s 
FNIH16, 17 ALM/BMI < 0.789 (men), < 0.512 (f), 
based on BIA, DXA, CT 
Grip strength < 
26 kg (m) and < 
16 kg (f) 
(Gait speed  0.8 m/s*) 
IWGS18, 19 ALM/height2  7.23 (m),  5.67 (f), based 
on DXA 
- Gait speed < 1 m/s 
SSCWD20 ALM/height2 > 2SD below the mean of 
healthy young adults 
- Gait speed  1 m/s or < 400 
m during 6-min walk 
*The FNIH proposed two possible definitions: one including gait speed and one not including gait speed. 
Two points that have to be sorted out to find consensus over a definition are 1) agreement 
over the most important outcome(s), and 2) information on the power of the definition to 
predict the agreed outcome(s). Cawthon et al.28 studied the associations between 
definitions of sarcopenia (the International Working Group, EWGSOP, FNIH, Baumgartner, 
Newman) and recurrent falls, hip fractures, functional limitations and mortality in older men. 
Regarding the EWGSOP definition, it was found that the definition was associated with 
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recurrent falls, functional limitations and mortality.28 Bianchi et al.29 studied the ability of the 
EWGSOP algorithm to predict disability, hospitalization, and mortality at six and nine years 
follow-up. They found that the EWGSOP algorithm predicted all three adverse outcomes; 
but so did low muscle mass and poor grip strength combined (without gait speed) and 
muscle mass and gait speed combined (without grip strength).29 Although these results are 
promising regarding the predictive validity of the EWGSOP definition, these studies were 
performed in men only28, or assessed muscle mass by BIA29; a confirmation of these 
results in future research using better validated muscle mass measurements would 
strengthen the evidence of its predictive validity.  
2.2 Measuring Sarcopenia  
While the challenge of finding a consensus definition of sarcopenia has not yet been 
solved another challenge awaits: which measurement tools and cut-off points should be 
used to identify older adults with sarcopenia? In the review presented in this thesis 
(Chapter 2), multiple tools to measure muscle mass, muscle strength, and physical 
performance were evaluated. It has been pointed out that the choice of a measurement 
tool depends on the setting of the evaluation, e.g. in clinical practice or in a home-setting. 
Depending on the setting and study population, costs, exposure to radiation, rate of 
injuries, duration of the measurement, muscle soreness, ease of administration, 
acceptability to patients, portability, and ability to perform the test were among the factors 
stated to the influence the feasibility of the measurement.2 In the MaSS study (Chapters 3-
5) sarcopenia was assessed during a home visit. In this way we hoped to reduce 
participation bias by also enabling less healthy older adults (e.g. with mobility difficulties) to 
participate. The disadvantage of assessment in a home-setting is that not all tools are 
feasible in this setting. For example, for muscle mass the BIA was used, which can be 
seen as the most valid device for assessment of muscle mass in a home setting; however, 
it might have overestimated the amount of muscle mass.30 This means that in reality the 
prevalence of sarcopenia might be higher than was found in de MaSS study. In the AGES-
Reykjavik Study (Chapter 6) subjects were invited for several clinic visits, allowing the 
measurement of muscle parameters with more advanced techniques such as computed 
tomography (CT). Especially for muscle mass, assessment in a clinical setting provides 
more valid results; however, for screening purposes this might be unfeasible to apply due 
to the higher costs involved.  
Another consideration regarding the choice of measurement tool is whether to use a 
performance-based tool (such as handheld dynamometry to assess grip strength) and/or a 
questionnaire. In the MaSS study, sarcopenia was assessed using performance based 
tools, while frailty was assessed by both performance based tools and a questionnaire.3
With respect to frailty, the Fried criteria and the FRAIL scale partly identified different 
subjects as frail. This could be explained by the possibility that subjects overestimate their 
abilities in a questionnaire; however, it may also be explained by the fact that the questions 
of the FRAIL scale concerned slightly different topics than the Fried criteria, e.g. illnesses 
is included in the FRAIL scale but not the Fried criteria. Although objective measurement 
might reduce the risk of overestimation of abilities, a questionnaire is quick and 
inexpensive thereby making it practical for screening purposes. An example of a brief 
sarcopenia questionnaire is the SARC-F31 and first results show that the questionnaire is 
internally consistent and valid.32 More research is needed to compare the outcomes of this 
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questionnaire with performance based measurements. A combination of a questionnaire 
(e.g. for screening) and performance based tools (e.g. for in-depth assessment of at risk 
individuals) could also be considered. Moreover, advanceladis in technology, such as 
smartphone-based BIA33 or infrared sensors for unobtrusive in-home measurement of gait 
speed34, might stimulate (self-)assessment of muscle parameters in the future.
Choosing a measurement tool is a trade-off between the ideal world and what is 
feasible. The question is to what extent the extra investments (costs, human resources 
etc.) of muscle parameter assessment in a clinical setting weigh against the extra quality of 
the measurement (validity, reliability, accessibility, etc.) compared to assessment in a 
general practitioners (GP) practice or home-setting. With the current knowledge, gait 
speed and/or grip strength seems to have the best ‘price/quality ratio’ and should, where 
possible, be assessed in a GP practice or at home, after which further assessment in a 
clinical setting may take place when indicated.  
2.3 Cut-off Points 
Where the choice of a measurement tool is mainly guided by the setting of evaluation and 
available resources, the choice of cut-off points should incorporate considerations on study 
population (age, ethnicity etc.) and measurement tool. Firstly, the characteristics of the 
population under study should be taken into account when applying cut-off points. 
Important characteristics are among others age, sex and ethnicity. In the MaSS study 
(Chapters 3-5), the cut-off points for BIA suggested by the EWGSOP were chosen, as 
these cut-off points were tested in an older Caucasian population. Most subjects of the 
MaSS were Caucasian; however, a few subjects were Asian. It has been shown that when 
applying the EWGSOP or the IWG criteria to Asian subjects, slow gait speed and low 
handgrip strength were 2-4 times higher than when using the lowest 20th percentile 
method. However, as Asian cut-off points were not presented by the EWGSOP, the same 
cut-off point was used for all subjects. As there were only few Asian subjects (of whom 
three out of six were sarcopenic) it is unlikely that the results are highly influenced by this.  
Secondly, as shown in Table 1, for all three muscle parameters a variety of cut-off 
points are used in current research. The EWSGOP presents several cut-off points for 
muscle mass assessed by BIA and dual energy X-ray absorptiometry (DXA), which are all 
based on absolute muscle mass (muscle mass divided by height squared). In addition to 
muscle mass, (appendicular) lean mass (i.e. total body mass without fat mass and bone 
mineral mass) and fat free mass (i.e. total body mass without fat mass) are used in 
sarcopenia research.35 Cheung et al.36 found that absolute lean mass was predictive of 
mortality; however, lean mass divided by BMI was an even stronger predictor. Bijlsma et 
al.37 showed that relative muscle mass (total or appendicular lean mass as percentage of 
body mass) was associated with physical performance, while absolute muscle mass was 
not. This should be taken into account when applying these cut-off points. Finding 
consensus over cut-off points will improve comparability of studies. Furthermore, the 
EWGSOP provides cut-off points for BIA and DXA, but not for MRI, CT, and other tools for 
assessing muscle mass. For these other tools one could choose a cut-off point of two 
standard deviation (2SD) below the mean of young adults or the lowest sex-specific 20th
percentile of the study population. However, for the 2SD method, a (young, healthy) 
reference population needs to be available. An issue when using the lowest sex-specific 
20th percentile of the study population, which was used in Chapter 6, is that the cut-off 
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point is derived from the muscle mass of the total study population. That means that no 
matter how high or low the muscle mass of the study sample is, 20% of the subjects will 
always be considered to have low muscle mass. In the absence of generally accepted cut-
off points these ways of selecting a cut-off point are the best available alternatives. 
However, using large cohort studies to establish sex-specific cut-off points that are 
predictive of sarcopenia-related health-risks, such as disability, is of major importance. 
This also counts for cut-off points for muscle strength and physical performance.  
A third point of consideration when choosing a cut-off point applies to the BIA 
measurement. A BIA device sends an electrical current through the body of the subject 
and subsequently displays a resistance and reactance value. These values have to be 
converted into amount of the skeletal muscle mass (or fat-free mass, lean mass). Several 
formulas have been presented to make the conversion to muscle mass. These formulas 
include e.g. resistance, height, sex and age (formula by Janssen et al.38), height, 
resistance, weight and reactance39 or formulas that are device specific (based on unknown 
variables).40 It will be clear that different formulas will yield different outcomes. For 
example, Sipers et al.40 compared the Janssen formula with the Maltron formula and found 
that the prevalence of sarcopenia highly depended on which formula was used. Although 
those differences were acknowledged, it was felt that using the Janssen formula38 in the 
MaSS study was appropriate as it was the only BIA formula provided by the EWGSOP and 
cut-off points for low muscle mass (based on their predictive validity of disability) were 
established.1, 14
2.4 Study Design 
This thesis includes studies using two different study designs, a cross-sectional design 
(chapters 3-5) and a population-based cohort study with five-year follow-up (chapter 6). 
Both designs have advantages and disadvantages. In a cross-sectional design exposure 
and outcome are measured at one time point, thereby providing a snapshot of the outcome 
at a particular time.41. This design is relatively inexpensive and loss to follow up is not of 
concern. This design is often used to assess the prevalence of a health outcome, as the 
sample is usually taken from the whole population.42 A shortcoming of the cross-sectional 
design is that it does not allow for making causal inference. Therefore, associations made 
should be interpreted with caution, as they might be attributed to bias instead of causal 
association.43 Furthermore, as this design provides a snapshot on one time point, it may be 
that outcomes differ when the study is repeated at another point in time.42 In the MaSS 
study several variables may be prone to seasonal influences, like nutritional intake, 
physical activity and quality of life. Data collection of the MaSS study was spread over all 
four seasons (May 2013 – Feb 2014), therewith reducing potential seasonal effects of 
these variables on the outcome. In addition, exploratory analysis showed that sarcopenia 
status (main outcome) and living situation (important driver of costs) did not depend on the 
season in which the home visit was performed. 
In a population-based cohort study subjects are selected on the basis of a shared 
characteristic, such as year of birth, geographic area or occupation. A strength of this type 
of study is that subjects are followed over time, making it possible to assess causality as 
exposure occurs prior to outcome.44 A cohort study is the best way to measure incidence 
and natural history of a disease.45 Disadvantages of a population-based cohort design are 
that they are time consuming, might incur high costs, and the design is prone to high loss 
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to follow-up. In the AGES-Reykjavik Study (Chapter 6) 58% of the initial baseline sample 
participated at follow-up. Subjects that were lost to follow-up significantly differed from 
subjects that did not drop out (selection bias) regarding among others age, level of 
physical activity, and sarcopenia status. Furthermore, the time span between 
measurements was five years, during which no interim evaluation was performed. Events 
that occurred within these five years might have influenced the association found between 
sarcopenia and physical activity. 
2.5 Sample and Selection  
Regarding both the MaSS study and the AGES-Reykjavik study sample bias should be 
kept in mind. Bias can be defined as “a systematic difference between study 
measurements and the true population values”,46 and may refer to 1) selection bias, 2) 
information bias (observer bias, recall bias, etc.) and 3) confounding.43
Firstly, possible selection bias in both study designs will be addressed. Are those 
included in the sample systematically different from the ones not included? If yes, then it is 
a matter of selection bias.46 For the MaSS study, the municipality of Maastricht was asked 
to provide a random sample of older adults living in Maastricht, as selecting subjects via a 
health care provider (which was done for the pilot study) had proven to be difficult. By 
asking the municipality to provide a random sample the likelihood of addressing a 
representative sample was high. Selection bias was therewith partly prevented. Another 
issue affecting the representativeness of the sample is the response rate. It was known 
beforehand that nonresponse is a common issue in large (cross-sectional) studies,42
therefore several strategies were implemented in an attempt to limit nonresponse, for 
example by publishing an articles in a local newspaper and newsletter of care facility, 
informing managers of assisted living and residential living facilities, distributing flyers at 
these facilities and pharmacies, and creating a website. Despite this, only 15% of the 
potential subjects responded. Collecting data about non-responders and telephone 
prompting were not allowed by the Medical Ethics Committee who approved the MaSS 
study. Older adults with a poorer physical condition might be less inclined to participate 
than older adults in better physical condition.3 This means that a healthier group might 
have been included and hence the sample might not have been fully representative. 
Therefore, prudence is called for when generalizing the results to the whole population. In 
addition, the eligibility criteria of the study might have further affected the generalizability of 
the results. Subjects had to be able to endure a two-hour home visit and due to safety 
reasons older adults suffering from severe disease(s) were excluded. It could however be 
argued that when these (severely ill) older adults were included, the prevalence of 
sarcopenia would be higher than currently reported. Furthermore, as stated before, by 
performing home visits we hoped to reach older adults with a poor physical condition as 
well, thereby limiting the chances of jeopardizing the representativeness of the study 
sample. The fact that the sarcopenia prevalence found in the MaSS study is comparable to 
other studies investigating the prevalence of sarcopenia and the similarity of the MaSS 
subjects demographics (age, sex) compared to the total Dutch population may be seen as 
indications that the results are representative. Looking at the AGES-Reykjavik Study, the 
response rate was higher than the MaSS study but still only 35% of the selected 
participants participated at baseline and follow-up, and subjects that were lost to follow-up 
significantly differed from subjects that did not drop out, as stated in the previous section. 
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However, as for the MaSS study, eradicating selection bias would probably have 
strengthened the association found (i.e. between incidence of sarcopenia and physical 
activity) as older adults having a poorer physical condition (having a higher change of 
developing sarcopenia) were more likely to become lost to follow-up.  
Secondly, is there a systematic difference in the measurement of study parameters 
between observers or between study groups?46 If so, then information bias is present 
(including observer bias, recall bias, etc). In both the MaSS study and the AGES-Reykjavik 
Study observer bias was kept as low as possible by developing and discussing standard 
operating procedures. In the MaSS study these procedures were additionally tested by two 
trained data collectors in a pilot study. During the data collection of the pilot study both 
data collectors were present at the home visit, one as assessor and one as observer, to 
ensure conformity of data collection. This procedure was repeated three and six months 
after the data collection had started. Recall bias was not applicable for many variables, as 
the questions or measurements reflected the day of the measurement itself (e.g. ‘how 
would you rate your own health today’). However, exceptions existed, such as for self-
reported physical activity, weight loss and health care utilization. Although subjects might 
remember specific forms of (health care related) information for a long period, the 
measurement period is ideally no longer than three months.47 Most of the relevant 
questions fell within the recall period of three months, with time frames ranging from the 
past week (e.g. frailty questions) to the past year (e.g. weight loss). Where possible, 
questions that were eligible for recall bias were supported by information noted down in the 
subject’s agenda or calendar (MaSS Study) or in patients records (AGES-Reykjavik). 
Thirdly, confounding may occur in the analysis when an association is found between 
two variables, which in reality results from another variable not included in the analysis.46
In the MaSS study, age, sex and BMI were included as covariates in the models (Chapters 
3 and 4) or a matched sample was used (Chapter 5) to reduce this type of bias. In the 
AGES-Reykjavik Study several potential confounders were added to the analytical models 
as well. However, there is still a chance that variables not included in the model, such as 
interim events or physical activity level throughout life, may have influenced the results. 
In both the MaSS and AGES-Reykjavik Study some form of bias may have crept in, 
as fully ruling out bias is very hard. However, several measures were in place to minimize 
bias and therefore the results from these studies are thought to be plausible. 
3. Implications  
This thesis has shown that plenty of valid and reliable measurement tools and cut-off 
points are available to identify older adults with sarcopenia. The need for identification of 
older adults with sarcopenia was supported by the substantial prevalence of sarcopenia 
and its health and economic burden found. Herewith, this thesis adds to the evidence that 
there is a need for prevention, early diagnosis, and intervention with regard to sarcopenia. 
This section elaborates on the research and practical implications that can be made based 
on the studies presented in this thesis and in the light of existing literature. 
3.1 Research  
This thesis has shown that many tools to measure muscle mass, muscle strength, and 
physical performance exist. No information was found on the reliability of tools to assess 
muscle mass in an older population; further research should look into this. Furthermore for 
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multiple tools many cut-off points were available and it was found that protocols for the 
assessment of grip strength differ. It is of first importance to agree on a universally 
accepted definition and attune cut-off points to identify older adults with sarcopenia. To 
obtain appropriate cut-off points for each muscle parameter (muscle mass, muscle 
strength and physical performance) a first option is to establish reference populations. 
When establishing reference populations, several subgroups (age, sex, and ethnicity) 
should be taken into account. It should be noted that this point is currently given attention 
by the Special Interest Group on Sarcopenia, operating within the European Union 
Geriatric Medicine Society, who is putting effort into combining data from several 
sarcopenia studies. A second option is to search for clinically relevant cut-off points for 
each muscle parameter, based on the ability of the cut-off point to predict adverse 
outcomes. This could be done by performing area under the curve analyses using 
longitudinal data, as this type of analysis allows finding an optimal cut-off point to 
distinguish whether a person is at risk of (an) adverse outcome(s) or not. This type of 
analysis was performed by e.g. Alley et al.,48 who investigated clinically relevant cut-off 
points for grip strength. Next to the study of Alley et al.48 plenty of other studies 
investigated the ability of low muscle mass, poor muscle strength and poor physical 
performance, alone or combined, to predict adverse outcomes.29, 36, 49 It can be 
recommended to bundle these studies in a systematic review and, if possible, perform a 
meta-analysis to obtain an overview of the adverse outcomes predicted by each muscle 
parameter/cut-off point. If such a review was performed other muscle parameters might be 
included as well, such as muscle power, which has been shown to be a strong predictor of 
physical performance.50 Based on the results of such a review, and in close collaboration 
with experts in the field, appropriate cut-off points can be decided upon.  
This thesis and previous literature51, 52 show that the prevalence of sarcopenia in both 
the community as well as in care settings (residential care, nursing homes) is considerable. 
Furthermore it has been shown that the incidence of sarcopenia is 6% lower in active older 
adults compared with inactive older adults. Thus, stimulating exercise in older adults will 
likely yield positive rewards regarding sarcopenia prevention and treatment. However, to 
be able to justify an intervention, intervention endpoints should be specified.31, 32 Endpoints 
of interventions targeted at sarcopenia depend on the nature of the intervention (preventive 
or therapeutic) and should incorporate considerations on, amongst others, clinical 
significance, reproducibility, responsiveness, and feasibility.53, 54 Some studies have shed 
light on the influence of a six month resistance exercise intervention combined with 
nutritional support on muscle parameters,55, 56 however, long-term studies on the effects of 
an intervention program on adverse outcomes are scarce.57 Suggested intervention 
endpoints are mobility disability, ADL dependency, recurrent falls, hospitalization or 
mortality as they are clinically relevant. Further research should focus on identifying 
relevant endpoints and meaningful changes in these endpoints; taking into account the 
different settings in which sarcopenia is present (community-dwelling, nursing home, 
hospital). Mortality may be a good endpoint in nursing homes, but may be less valuable as 
endpoint in community-dwelling older adults. A promising initiative regarding intervention 
endpoints is the “Sarcopenia & Physical Frailty in Older People: Multicomponent Treatment 
Strategies (SPRINT-T)” initiative, which will be the first (two year) interventional clinical trial 
in Europe for frail and sarcopenic older adults.58 This study provides a unique opportunity 
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to examine intervention effects in the long run and can further elicit whether combining 
sarcopenia and frailty screening is profitable. 
Finally, this thesis has shown that sarcopenic older adults made more use of health 
care, leading to higher costs, than their non-sarcopenic peers. As a next step regarding to 
the economic burden of sarcopenia it can be recommended to incorporate cost-
effectiveness analysis in the evaluation of intervention programs aimed at the prevention or 
treatment of sarcopenia.  
3.2 Practice 
The results in this thesis show that according to the EWGSOP definition the prevalence 
and incidence of sarcopenia in older adults is substantial. Sarcopenia was shown to be 
associated with physical frailty, disability in activities of daily living, lower quality of life and 
higher costs of care. Despite the mounting evidence on the burden of sarcopenia coming 
from the studies presented in this thesis and other literature59, 60 in current clinical practice 
screening of individuals at risk of sarcopenia does not take place yet. Older adults deserve 
a helping hand in the fight against muscle decay and support to prolong their 
independency. The Dutch Ministry of Welfare, Health and Sport endorses an increase in 
health care problems due to the aging of the population.61 One focus of the Dutch Ministry, 
as well as Ministries in many other European countries is therefore on prevention targeted 
at keeping older adults healthy, independent, and autonomous (also referred to as healthy 
aging, aging in place), and ensure their participation in society.61 Prevention of sarcopenia 
perfectly fits within this mission; however, several challenges have to be overcome to 
implement sarcopenia screening in current prevention programs. 
Absence of a universally accepted definition, lack of clarity about specific treatment 
options, pharmaceutical interest, and public awareness hamper translation of research 
findings into practice.62 The World Health Organization (WHO) could play a role herein, as 
they manage the International Classification of Diseases and Related Health Problems 
(ICD) database.63 This database is “the standard diagnostic tool for epidemiology, health 
management and clinical purposes”.63 ICD codes are used by health care providers, health 
information managers, policymakers, insurers, patient advocacy organizations etcetera, 
and are used for reimbursement, resource allocation, and decision making purposes.63 The 
importance of an ICD code was acknowledged by the Alliance for Aging Research, and 
they have undertaken steps to establish such a diagnosis code for sarcopenia.64 In the 
meantime, it can be recommended to increase awareness about sarcopenia, its 
consequences, and ways to counteract the loss of muscle mass and function among 
health care providers and the public via multiple channels (e.g. television, newspaper, 
specialist journal), and promote inclusion of sarcopenia education in relevant trainings. 
Once an ICD code is available, it is suggested to incorporate prevention of sarcopenia in 
existing health programs aimed at e.g. exercise, healthy diet and fall prevention.  
Then general practitioners, nurse practitioners, physiotherapists, occupational 
therapists, and geriatricians could play a key role in identifying older adults (at risk of) with 
sarcopenia and advice on prevention and treatment. As has been shown in this thesis, the 
prevalence of sarcopenia was higher in older adults receiving home care or living in 
residential care, compared to community-dwelling older adults living independently. 
Therefore, home care services and residential care facilities should also be target of 
awareness raising campaigns. Furthermore, other researchers have suggested combining 
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screening for sarcopenia with frailty65 or osteoporosis66 for respectively screening or 
treatment purposes. Research presented in this thesis has shown that by assessing hand 
grip strength and gait speed, a large amount of the frail older adults were identified. So 
screening for sarcopenia could also contribute to the identification of older adults with 
frailty.  
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The research in this thesis sheds light on the prevalence of sarcopenia and has identified 
various characteristics, health, and economic outcomes of community-dwelling older adults 
with sarcopenia. This chapter will assess the scientific results that have emerged from the 
research in relation to their importance for society. In this chapter respectively the 
relevance of the study results, target groups for dissemination of results, activities (to be) 
undertaken, and future directions will be discussed.  
1. Relevance  
More than 600 skeletal muscles are the driving spirit of the human body.1 Stand straight, 
keep balance, walk, run, bend over, scratch your knee, get dressed, go shopping, carry a 
bag, you name it. Those actions are all possible because of our skeletal muscles. When 
the muscles are healthy and function normally, one might not realize all the tasks that they 
perform. But when muscle mass and function decrease, difficulties may arise in performing 
activities of daily living and as a result quality of life and autonomy may decrease while the 
risk of care dependency and subsequent institutionalization increases.  
Currently, in the Netherlands, older adults with difficulties in performing activities of 
daily living are eligible to receive home care, or may qualify for housing in a residential 
living facility. However, due to governmental regulation residential living facilities will 
dissolve soon and older adults will be more and more empowered to live independently as 
long as possible (also called ‘aging in place’). Nevertheless, this also corresponds to the 
wish of the majority of older adults themselves, who prefer to stay at home as long as 
possible. Aging in place has several advantages for older adults, such as preservation of 
their personal network and environmental landmarks.2 In addition, aging in place is thought 
to reduce the burden of health care services and has therefore attracted attention of most 
western governments. Sarcopenia may threaten the trend towards aging in place, 
considering its association with difficulties performing activities of daily living and 
institutionalization. Insight in the prevalence of sarcopenia, its characteristics, health and 
economic outcomes is of importance to 1) know which community-dwelling older adults are 
at risk of sarcopenia, and 2) to know what are the target areas for a tailored-made 
approach to prevent/treat sarcopenia and contribute to a sustainable, affordable health 
care system. The results of the studies in this thesis provide guidance for a 
psychometrically sound measurement of sarcopenia, and they show that the prevalence 
and incidence of sarcopenia in several subgroups of community-dwelling older adults and 
the associated health care costs are substantial. Moreover they help to understand the link 
between sarcopenia and frailty and confirm the association between sarcopenia and 
disability in activities of daily living.  
2. Target Groups  
Dissemination of research findings to target groups such as older adults, (older) patients, 
health care professionals, policy makers etcetera enables them to benefit optimally from 
the new knowledge. It gives them a hand in exploring possibilities to prevent exposure of 
unnecessary risks and unnecessary healthcare expenditure.3 The results of this thesis are 
of interest to several target groups, as explained below.
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2.1 Older Adults 
Sarcopenia occurs in older adults living in the community, but also hospital patients and 
nursing homes resident are at risk of sarcopenia. Furthermore, younger adults that are 
temporarily immobile due to disease or injury might also face loss of muscle mass. Many of 
them will have never heard of sarcopenia, as the translation of sarcopenia research from 
science to practice has not yet been established. Informing these people (and their 
informal care givers) about the development, causes and consequences of sarcopenia will 
help them to recognize it and become aware that there are ways to delay the onset and 
progression of sarcopenia.  
2.2 Health Care Professionals  
Health care professionals working with people with (a risk of) sarcopenia such as nursing 
staff, home care workers, physiotherapists, general practitioners, nurse practitioners, 
occupational therapists, geriatricians and dieticians, can in the future help to identify older 
adults with (a risk of) sarcopenia. Also, health care professionals working with frail older 
adults, or older adults with osteoporosis should be attentive to sarcopenia. Chapter two of 
this thesis provides relevant information on the validity and reliability of tools that are 
feasible to screen for sarcopenia in older adults. Health care professionals may use these 
tools to identify older adults with (a risk of) sarcopenia. Although so far no consensus 
approach or national guidelines to treat sarcopenia are available, older adults identified 
with low muscle mass and/or function can be advised to start an exercise program or 
participate in a physical activity stimulating activity.4 In addition, fitness centres could play 
a preventive or curative role by providing facilities and a welcoming environment for older 
adults to exercise. They could also function as ‘walk-in’ for support with (self-) monitoring 
of health by older adults. Regarding nursing homes, recent research showed that nursing 
home residents are lying down or are seated for about 90% of the time.5 A mind-set shift 
within nursing staff from ‘take good care and so take over tasks of the resident’ to ‘let 
residents do it themselves where possible’ could contribute to more physical activity in this 
setting. Supplementation of specific nutrients (protein, vitamins, etc.) could be valuable as 
well, especially when combined with an exercise component.6 Furthermore, educating 
older adults about proper nutrition may further empower people to take responsibility for 
their own process of healthy (muscle) aging.  
2.3 Industry 
The studies in this thesis show that especially in residential living facilities the prevalence 
of sarcopenia is substantial. Bearing in mind that for older adults living in these facilities 
resistance exercise might not always be feasible, nutritional supplementation or 
pharmacological agents may be of support in reducing functional decline.7 In 2015, a 
taskforce made up of researchers, leaders from the pharmaceutical and nutritional 
industries, and representatives from non-profit organizations came together to discuss 
issues relating to drugs for frailty and sarcopenia.8 The results of this thesis support the 
option of combining treatment for sarcopenia and frailty, as has been shown that the two 
frailty criteria that were mostly present in frail older adults were weakness (poor grip 
strength) and slow walking speed, therewith showing much ground in common with 
sarcopenia.  
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In addition to the pharmaceutical and nutritional industries, advancements in technology 
are of interest for older adults with sarcopenia. For example, using a smartphone for self-
monitoring of physical activity with direct feedback and goal setting has been shown 
effective in increasing physical activity levels in older adults with chronic obstructive 
pulmonary disease and diabetes.9 This new technology might also be suitable for 
counteracting (the negative consequences of) sarcopenia. 
2.4 Health Insurance Companies 
The results presented in this thesis demonstrate that sarcopenic older adults imply a 
considerable economic burden for health care. Interventions to prevent or delay the onset 
or progression of sarcopenia might lead to health benefits and subsequently reduce health 
care costs. At this moment health insurance companies are on the sideline, as sarcopenia 
is not officially recognized as a geriatric syndrome in Dutch health care. However, in the 
near future sarcopenia will have its own ICD-10 code, and will thereupon be visible for all 
stakeholders in health care. The Dutch Healthcare Authority obliges health care providers 
to register ICD-10 codes indicating the disease(s) of their patients. In the Netherlands 
health care providers do not have to forward the ICD-10 codes to the health insurance 
companies yet. However, the existence of an ICD-10 code will facilitate reimbursement, 
resource allocation, and decision making regarding future drug, nutritional or exercise 
treatment. By stimulating early identification and treatment of sarcopenia, health insurance 
companies could contribute to a reduction of the health and economic burden of 
sarcopenia.  
2.5 Policy Makers 
Dutch municipalities could contribute to awareness raising and counteracting sarcopenia 
as part of their role in aging in place. The municipality has the responsibility to advise and 
inform their inhabitants about possibilities for aging in place.10 On top of that they could 
provide a safe and challenging environment and stimulate the organization of (social) 
activities to improve physical activity.  
3. Activities/Products 
Public awareness is a key feature when trying to translate research into practice.11 Several 
activities were undertaken to inform the target groups about sarcopenia and the study 
results. Before the start of the MaSS study a special website was launched, including 
information on the study procedures, but also links to general information about 
sarcopenia. In addition, an interview on sarcopenia was given to a local newspaper. 
Information about sarcopenia and the MaSS study have been disseminated to pharmacies 
and residential living facilities, and the latter facilities also placed a short summary of the 
results in their newsletters. Participants of the MaSS study received a brief overview of 
their individual scores on muscle strength, physical performance and nutritional status. 
Participants furthermore received a Dutch summary of the final research findings. A short 
preventive message based on the current evidence base was added to this summary. In 
addition the research findings have been presented at several national and international 
geriatric and gerontology conferences. The results of this thesis can furthermore be spread 
to relevant health care provider associations and associations for older adults.  
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Maastricht University offers bachelor students in Health Sciences a course in which 
sarcopenia is discussed. As these students might become future health care providers or 
employees at health insurance companies, informing this group is of importance. The 
particular studies in this thesis might be added to the resources provided to students.  
4. Future Directions 
The research in this thesis has contributed to unravelling the burden of sarcopenia in 
community dwelling older persons, and provides information on tools to identify older 
adults with sarcopenia. Now it is time to put the money where the mouth is. Advancements 
in the field of sarcopenia lag because of the absence of a universally accepted definition 
(including cut-off points) of sarcopenia. With this in mind, coming to a consensus definition 
followed by registration of an ICD-10 code is urgently needed to progress from the stage of 
sarcopenia research and awareness raising to acceptance and adoption of sarcopenia 
screening and treatment by the clinical community. Only then this geriatric giant will 
receive the attention it needs.  
This thesis provides information on tools to identify older adults with sarcopenia, 
which can be used for screening purposes. Initiatives such as the SPRINT-T initiative are 
undertaken to identify proper strategies to counteract sarcopenia.12 After proven effective, 
these interventions can be tested for feasibility in health care practice. Also the acceptance 
of new technologies to stimulate physical activity could be explored, such as bicycles for 2-
4 persons. Cycling is a habit of many Dutch people, and these 2-4 person bicycles enable 
older adults to exercise in a safe way, if needed with an informal care giver or nursing staff 
as driver. However, as it will take some time to explore these opportunities, in the 
meantime disseminating information about sarcopenia to relevant target groups is of 
importance. 
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Summary 
The human body is composed of more than 600 skeletal muscles, accounting for about 
40% of body weight. Skeletal muscles help you to stand straight, keep balance, walk, run, 
get dressed, bend over, go shopping, carry a bag, scratch your knee, and so on. After 
about 30 years of age, muscle mass and function slowly start to decrease. The older you 
get, the more muscle you lose. When muscle mass and function fall below a certain 
threshold, the person in question may experience mobility difficulties, loss of 
independence, a lower quality of life and an increased risk of morbidity and mortality. 
In 1989 Rosenberg coined the term sarcopenia, to describe the loss (Greek: penia) of 
muscle (Greek: sarx). Sarcopenia has been proposed as a new geriatric giant, a frequently 
occurring geriatric syndrome affecting the lives of a growing number of older adults. As 
sarcopenia is a rather ‘new’ concept in the research world, many gaps in knowledge exist 
and screening for sarcopenia is not yet embedded in clinical practice. The purpose of this 
thesis was to increase our understanding of the prevalence, characteristics, and health and 
economic outcomes of community-dwelling older adults with sarcopenia. The data used 
within this thesis was collected as part of the cross-sectional Maastricht Sarcopenia Study 
(MaSS; chapters 3-5) and the population-based Age, Gene/Environment, Susceptibility-
Reykjavik Study (AGES-Reykjavik; chapter 6). This section summarizes all studies 
described in this thesis. 
Chapter 1 gives an introduction about sarcopenia, discussing its mechanisms, current 
knowledge on its burden and ways to identify and counteract sarcopenia. Additionally 
several gaps in knowledge within sarcopenia research are presented. The chapter ends 
with some background information regarding the data sources and the aims and outline of 
the thesis. 
Chapter 2 describes the results of a systematic review on the measurement properties (i.e. 
validity, reliability) and feasibility of tools to measure muscle mass, strength, and physical 
performance in community-dwelling older adults. Muscle mass, strength and physical 
performance were chosen as the European Working Group on Sarcopenia in Older People 
(EWGSOP) recommended to include these three muscle parameters in the identification of 
older adults with sarcopenia. Sixty-two studies were included in the systematic review, 
reporting on a wide array of tools that are valid, reliable and feasible for measurements of 
muscle mass (e.g. magnetic resonance imaging), strength (e.g. leg press), and 
performance (e.g. six minute walk test) in clinical settings. Bioelectrical impedance analysis 
(BIA), handheld dynamometry and gait speed or the short physical performance battery 
(SPPB) were found to be the most valid, reliable, and feasible in a general practitioner 
practice or in a home-setting. However, regarding muscle mass no well-validated and 
reliable tools were found for this setting.  
Chapter 3 reports on the prevalence and characteristics of sarcopenic older adults who 
participated in the MaSS study. This study included 247 community-dwelling older adults 
living in Maastricht. Data was collected during a single 1-2 hour home visit, including 
measurements of height, weight, muscle mass, muscle strength, physical performance, 
comorbidities, cognitive function, physical activity, nutritional status, frailty, functional 
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status, and health care utilization. In the MaSS study, the prevalence of sarcopenia was 
12.1%, 41.5% and 58.6% in respectively older adults living 1) independently at home 
without additional care, 2) at home or in an assisted living facility with professional home 
care, and 3) in a residential living facility. Most sarcopenic older adults had low muscle 
mass in combination with poor grip strength. 
Chapter 4 explores the association between sarcopenia and physical frailty (MaSS data). 
Frail older adults (about 9% of the study population) were more often sarcopenic compared 
to non-frail older adults. In addition, a majority of the sarcopenic subjects was pre-frail and 
almost a quarter was frail. Two of the five frailty criteria that were most frequently present 
in frail older adults were weakness (poor grip strength) and slow walking speed. Therefore, 
screening older adults on muscle strength and/or walking speed may identify both older 
adults with (a risk of) sarcopenia and older adults with (a risk of) frailty. The two physical 
frailty scales, the Fried criteria and the FRAIL scale, correlated moderately, i.e. they 
identify partly different subjects as frail. 
Chapter 5 examines the health and economic burden of older adults with sarcopenia 
(MaSS data). Sarcopenic older adults had more comorbidity, were more disabled in 
activities of daily living and had a lower quality of life compared with non-sarcopenic older 
adults. Furthermore, sarcopenic older adults presented higher costs of care, which were 
mainly attributed to the living situation (residential living facility versus independently living 
and home care).  
Chapter 6 reports on the relation between physical activity and the incidence of sarcopenia 
in participants from the population-based AGES-Reykjavik Study. The AGES-Reykjavik 
Study is a large cohort study with 5-year follow-up. The examinations consisted of several 
clinic visits and included numerous measurements on vascular, neurocognitive, and 
musculoskeletal health and questionnaires on physical, psychological, and social health. A 
secondary data-analysis showed that sarcopenic older adults less frequently performed 
moderate to vigorous physical activity than did non-sarcopenic older adults. Regarding the 
incidence proportion of sarcopenia over five years’ time: 1 out of 7 inactive older adults and 
1 out of 11 active older adults developed sarcopenia. 
Chapter 7 discusses the main findings of the studies presented in this thesis, and reflects 
on the theoretical and methodological considerations. The chapter concludes with 
implications for research and practice.  
Chapter 8 concentrates on the societal value that the (scientific) knowledge that emerged 
from the studies has. 
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Samenvatting 
Het menselijk lichaam bestaat uit meer dan 600 skeletspieren, die samen ongeveer 40% 
van het lichaamsgewicht uitmaken. Skeletspieren stellen je in staat om rechtop te kunnen 
staan, balans te houden, te lopen, rennen, aankleden, buigen, boodschappen doen, een 
tas te dragen, je knie krabben en ga zo maar door. Na het 30ste levensjaar nemen de 
spiermassa en spierfunctie langzaam af. Hoe meer jaren er verstrijken, hoe meer verlies 
van spiermassa er optreedt. Wanneer de spiermassa en functie onder een bepaalde 
drempelwaarde komen, kan de betreffende persoon moeite ervaren met de mobiliteit en 
zelfstandigheid, een lagere kwaliteit van leven ervaren en heeft de persoon een hogere 
kans op ziekte en sterfte. 
In 1989 heeft Rosenberg de term sarcopenie geïntroduceerd om het verlies van 
spiermassa en functie te beschrijven. De term sarcopenie is gebaseerd op de Griekse 
woorden ‘sarx’ (vlees, spier) en ‘penia’ (verlies). Sarcopenie wordt ook wel gezien als een 
nieuwe geriatrische reus, een veelvoorkomend geriatrisch syndroom dat het leven van 
ouderen (negatief) beïnvloed. Sarcopenie is een nog relatief nieuw begrip in de 
onderzoekswereld, en er zijn dan ook nog veel hiaten in de wetenschappelijke kennis 
omtrent sarcopenie. Ook wordt in de klinische praktijk nog niet standaard gescreend op 
sarcopenie. Het doel van dit proefschrift was om meer inzicht te krijgen in de prevalentie, 
kenmerken en gezondheids- en economische uitkomsten van thuiswonende ouderen met 
sarcopenie. Om dit doel te bereiken zijn gegevens verzameld in de cross-sectionele 
Maastrichtse Sarcopenie Studie (MaSS; hoofdstuk 3-5) en is een secundaire data-analyse 
uitgevoerd op data van de Age, Gene/Environment, Susceptibility-Reykjavik Study (AGES-
Reykjavik; hoofdstuk 6).  
Hoofdstuk 1 geeft een introductie over sarcopenie. In dit hoofdstuk komen de 
onderliggende mechanismen, de belasting van sarcopenie voor zowel mens als 
maatschappij en manieren om sarcopenie te identificeren en aan te pakken aan bod. 
Daarnaast wordt ingegaan op de nog ontbrekende kennis rondom sarcopenie. Als laatste 
wordt in dit hoofdstuk een korte toelichting gegeven op de gebruikte databronnen en zijn 
de doelstellingen van het proefschrift beschreven. 
Hoofdstuk 2 beschrijft de resultaten van een systematisch review naar de validiteit, 
betrouwbaarheid en uitvoerbaarheid van verschillende meetinstrumenten om spiermassa, 
spierkracht en fysiek functioneren te meten bij thuiswonende ouderen. Deze componenten 
zijn gekozen op basis van aanbevelingen van de Europese Werkgroep Sarcopenie bij 
Ouderen (EWGSOP). De EWGSOP adviseert deze drie componenten te gebruiken bij het 
identificeren van ouderen met sarcopenie. De 62 geïncludeerde studies rapporteren over 
een grote range aan meetinstrumenten die valide, betrouwbaar en uitvoerbaar zijn in een 
klinische setting. Daarnaast bleken bio-impedantie, een hand-dynamometer en 
loopsnelheid of een korte fysieke functie batterij (SPPB) het meest valide, betrouwbaar en 
uitvoerbaar in een huisartsenpraktijk of thuis. Echter er zitten wel wat haken en ogen aan 
de validiteit van de bio-impedantie meting in een oudere populatie en er zijn geen studies 
gevonden die de betrouwbaarheid van deze meting hebben onderzocht.  
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Hoofdstuk 3 doet verslag van de gevonden prevalentie van sarcopenie en de kenmerken 
van de deelnemers van de MaSS studie. Aan deze studie hebben 247 thuiswonende 
ouderen deelgenomen. De gegevens zijn verzameld door middel van een 1 à 2 uur durend 
huisbezoek, waarin onder andere lengte, gewicht, spiermassa, spierkracht, fysiek 
functioneren, ziekten, cognitieve status, fysieke activiteit, voedingsstatus en zorggebruik 
zijn gemeten. In de MaSS studie was de prevalentie van sarcopenie 12.1%, 41.5% en 
58.6% in respectievelijk 1) thuiswonende ouderen zonder zorg, 2) ouderen met thuiszorg 
of wonend in een aanleunwoning, en 3) ouderen in een verzorgingshuis. De meeste 
sarcopene ouderen hadden een lage spiermassa gecombineerd met lage spierkracht. 
Hoofdstuk 4 verkent de associatie tussen sarcopenie en kwetsbaarheid (MaSS data). 
Kwetsbare ouderen (ongeveer 9%) waren vaker sarcopeen dan niet kwetsbare ouderen. 
Daarnaast voldeed een meerderheid van de sarcopene ouderen aan 1 of 2 criteria voor 
kwetsbaarheid, en was een kwart van de sarcopene ouderen daadwerkelijk kwetsbaar (3 
of meer criteria van kwetsbaarheid aanwezig). Twee van de meest voorkomende criteria 
van kwetsbaarheid waren een lage knijpkracht en lage loopsnelheid. Knijpkracht en 
loopsnelheid kunnen daarom mogelijk gebruikt worden voor het opsporen van zowel 
sarcopene ouderen als kwetsbare ouderen. De twee gebruikte meetinstrumenten voor 
kwetsbaarheid waren matig gecorreleerd, dat wil zeggen dat ze gedeeltelijk dezelfde, maar 
gedeeltelijk andere ouderen aanmerkten als kwetsbaar. 
Hoofdstuk 5 onderzoekt de gezondheids- en economische belasting van sarcopenie voor 
mens en maatschappij (MaSS data). Sarcopene ouderen hadden meer ziekten, waren 
meer beperkt in activiteiten van het dagelijks leven en hadden een lagere kwaliteit van 
leven in vergelijking met niet-sarcopene ouderen. Sarcopene ouderen hadden daarnaast 
hogere zorgkosten, voornamelijk veroorzaakt door hun woonsituatie (verzorgingshuis ten 
opzichte van thuiswonend zonder zorg of thuiszorg). 
Hoofdstuk 6 beschrijft de relatie tussen fysieke activiteit en de incidentie van sarcopenie in 
deelnemers van het AGES-Reykjavik bevolkingsonderzoek. In dit onderzoek zijn 
deelnemers tweemaal gemeten, met een tussenperiode van 5 jaar. De metingen zijn 
verricht gedurende verscheidene bezoeken aan een kliniek, en omvatten onder andere 
vasculaire, neurocognitieve en spieronderzoeken, en vragenlijsten over fysieke, 
psychologische en sociale gezondheid. Een secundaire data-analyse liet zien dat 
sarcopene ouderen minder vaak deelnamen aan matig tot intensieve fysieke activiteit 
vergeleken met niet-sarcopene ouderen. Gedurende de 5 jaar onderzoek ontwikkelde 1 op 
de 7 inactieve ouderen, en 1 op de 11 actieve ouderen sarcopenie. 
Hoofdstuk 7 is de algemene discussie, waarin de belangrijkste resultaten van het 
proefschrift worden samengevat en theoretische en methodologische overwegingen 
worden beschreven. Afsluitend worden implicaties van de resultaten van het proefschrift 
voor zowel onderzoek als praktijk gegeven. 
Hoofdstuk 8 concentreert zich op de maatschappelijke waarde die de opgedane 
wetenschappelijke kennis heeft. 
502188-L-sub01-bw-Mijnarends
502188-L-sub01-bw-Mijnarends
502188-L-sub01-bw-Mijnarends
DANKWOORD 
157
Dankwoord 
Dan ineens is het zover, mijn proefschrift is af! Ik ben erg dankbaar voor alle steun, 
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